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Abstract 
 
Syphilis, caused by Treponema pallidum (T. pallidum), has re-emerged in the UK and 
globally. There are 11 million new cases annually. The WHO stated the urgent need for 
single-dose oral treatments for syphilis to replace penicillin injections. Azithromycin showed 
initial promise, but macrolide resistance-associated mutations are emerging. Response to 
treatment is monitored by serological assays that can take months to indicate treatment 
success, thus a new test for identifying treatment failure rapidly in future clinical trials is 
required. Molecular studies are key in syphilis research, as T. pallidum cannot be sustained in 
culture. The work presented in this thesis aimed to design and validate both a qPCR and a RT-
qPCR to quantify T. pallidum in clinical samples and use these assays to characterise 
treatment responses to standard therapy by determining the rate of T. pallidum clearance from 
blood and ulcer exudates. Finally, using samples from three cross-sectional studies, it aimed 
to establish the prevalence of T. pallidum strains, including those with macrolide resistance in 
London and Colombo, Sri Lanka. 
 
The sensitivity of T. pallidum detection in ulcers was significantly higher than in blood 
samples, the likely result of higher bacterial loads in ulcers. RNA detection during primary 
and latent disease was more sensitive than DNA and higher RNA quantities were detected at 
all stages. Bacteraemic patients most often had secondary disease and HIV-1 infected patients 
had higher bacterial loads in primary chancres. Treatment kinetics following benzathine 
penicillin injection were assessed in four men. The mean half-life for both blood and ulcer T. 
pallidum nucleic acid clearance was found to be short. All patients had serology consistent 
with cure at one month. Two T. pallidum strain types were found in Colombo, neither 
harbouring macrolide resistance. In London, several strain types were identified, the majority 
of which contained genetic determinants of macrolide resistance. 
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Introduction 
 
Following four decades of low prevalence, syphilis is now resurgent in the UK and is posing 
both old and new challenges (1). Old problems include strategies for identifying and treating 
syphilis that are little changed since the 1940s and far from ideal. New obstacles are the 
emergence and rising prevalence of macrolide antibiotic resistance and the interaction 
between syphilis and HIV-1, which raise questions about the most appropriate management of 
the disease. In this introduction, the history and epidemiology of syphilis are explored in 
addition to the biology and pathogenesis of its causative organism. Current testing and 
treatment strategies are considered in the context of HIV-1 co-infection and in the light of 
new molecular techniques. 
 
1.1 The bacterium: classification, origins and epidemiology 
 
1.1.1 Classification 
 
The spirochete bacterial phylum is one of the 40 major bacterial phyla and is sub-divided into 
three families: Spirochetaecae, Brachyspiraecae and Leptospiraecae. All three are thought to 
have a common ancestor and share, amongst other characteristics, an ultracellular structure 
with flagella and innate rifampicin resistance (2). The causative organism of syphilis, 
Treponema pallidum subsp. pallidum (T. pallidum) sits within the family spirochetaecae and 
the genus Treponema includes nine currently recognised members, often called treponemes, 
three of which are highly related to T. pallidum (3). The clinical disease caused by each of 
these three non-syphilis members (Treponema pallidum subsp. pertenue; Treonema pallidum 
subsp. endemicum and Treponema carateum) are summarised in Table 1.1. It is important to 
note that the exclusion of T. carateum from the pallidum subspecies was based only on the 
absence of a laboratory strain to enable its analysis and classification (4).  
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Table 1.1 Characteristics of three members of the genus Treponema  
 
 T. pallidum subsp. 
pertenue 
T. pallidum subsp. 
endemicum 
T. carateum 
    
Disease Yaws Endemic (non-
venereal) syphilis 
Pinta 
Epidemiology Central Africa, South 
America and Indonesia 
Tropical and desert 
climate 
Prevalence of 2 million 
cases worldwide 
North Africa, Near 
East, South Europe 
Desert and temperate 
climates 
Central and South 
America 
Tropical climates 
Pathology Mostly children under 15. 
Spread by close contact. 
Moderately invasive, skin 
and bone lesions 
Moderately invasive. 
Early, latent and late 
stages 
Non-invasive. Local 
dermal lesions. No 
systemic involvement 
 
Table 1.1. The genus Treponema contains three members, in addition to T. pallidum subsp. 
pallidum (the causative organism of syphilis), which cause a distinct clinical disease (5, 6). 
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1.1.2 Historical origins of syphilis 
 
The Milanese state kept detailed mortality records from 1452 and from 1503 began to note a 
new disease: morbus gallicus or the French disease. The disease was diagnosed on the basis 
of clinical observations such as ulcers and skin lesions and was distinct to descriptions of 
leprosy, which was common at that time (7). The French disease, of course, was syphilis 
although its modern description would not be made until 1837 by the (co-incidentally) French 
venereologist Phillipe Ricord and the discovery of its causative organism, Treponema 
pallidum subsp. pallidum (T. pallidum) would wait until Schaudinn and Hofmann’s work in 
1905 (8, 9). Whilst it is generally agreed that the syphilis epidemic was typical of a disease 
entering a non-immune population for the first time, its origin is still contested. A popular 
theory is that the disease was brought to the Italian peninsular with the return of Columbus 
from the New World. There is human skeletal evidence that venereal syphilis was present in 
Haiti prior to Columbus’ arrival in 1492 (10). Moreover, there are descriptions of a disease 
characterised by ‘buboes’, which affected Columbus’ crew and the disease appeared in the 
Milanese records shortly after his return to join the Spanish in the defense of Naples (11). The 
difficulty, however, is proving that venereal syphilis was not already present in Europe at the 
time of Columbus’ return in 1493. The mortality records kept in Milan were not kept in other 
countries, thus earlier cases of the disease elsewhere may have gone un-recorded. Moreover, 
the fossil record contains some evidence to suggest the presence of treponematoses in Europe 
prior to 1492, but distinguishing the bone changes of non-venereal and venereal syphilis or 
even that of other conditions (rickets, Paget’s disease etc) is difficult (12). An alternative 
theory is that modern syphilis evolved from Yaws, which was brought to Europe from Africa 
during the slave trade at around the time of Columbus’ expeditions (13). Whilst the genetic 
distance between these strains appears to be at least several thousand years it is not 
inconceivable that T. pallidum could have adapted very quickly to its host (14). Wherever its 
origin, by the mid-16
th
 century syphilis had reached epidemic proportions in Western Europe, 
its spread fuelled by the great Italian wars and the sexual relationships: consensual, 
transactional and forced, which are typical of conflict and social upheaval.  
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1.1.3 Modern epidemiology 
 
By the 17
th
 century, it was reported that 20% of ‘patients’ in London’s poor houses were 
being treated for syphilis (15), but it was not until the Wasserman reaction (WR), the first 
serological test for syphilis, was described at the start of the 20
th
 century that an accurate 
assessment of the prevalence of the disease was possible (12, 16). By the end of Queen 
Victoria’s reign, 10% of British adults were reportedly infected and further increases during 
the First World War led, in part, to the venereal disease (VD) regulations of 1916 (17). The 
combination of this public health intervention together with the availability of effective 
treatment (Salvarsan (arsphenamine) in 1910 and penicillin in 1943) led to a significant fall in 
the prevalence of the disease and near complete-eradication (18-20). Today, however, syphilis 
has re-emerged as an important sexually transmitted disease. The annual incidence of early 
infection (primary, secondary and early latent) rose from 139 to a peak of 2874 in England 
between 1998 and 2008 and has remained high (2624 in 2010) (1, 21). Male diagnoses 
outnumber female in the order of 9 to 1, which reflects predominantly male-to-male 
transmission. One quarter of men who have sex with men (MSM) with syphilis in the UK are 
also HIV-1 infected, highlighting a close relationship between the epidemics (1). Rates of 
diagnosis have also risen in women (from 136 to 448 between 1999 and 2007) which has led 
to a worrying re-emergence of congenital syphilis, currently thought to be around 20 cases a 
year (22). Globally, syphilis reached an estimated prevalence of 36 million cases in 2005 
(Figure 1.1) (23). In some populations, it has simply remained prevalent yet over-shadowed 
by the burden and importance of the HIV-1 epidemic. In others, there has been a recent large 
rise in the prevalence of the disease. China, for example, has seen a 30% annual rise in cases 
over the last five years resulting from worker migration and the rise of prostitution during 
their economic boom. Chinese MSM are also dis-proportionately affected, and a 
seroprevalence survey in 2008 found 11.9% to be infected with the disease. Another recent 
seroprevalence survey, this time in India’s West Bengal region, found 8.2% of sexually 
transmitted disease (STD) clinic attendees to be syphilis seropositive and in neighbouring Sri 
Lanka diagnoses of early syphilis doubled between 2008 and 2012 (24, 25). Congenital 
syphilis is also a substantial problem worldwide and thought to cause 500,000 fetal and 
neonatal deaths each year (26).  
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Figure 1.1 Global prevalence and incidence of syphilis  
 
 
 
Fig. 1.1. The estimated global prevalence and incidence of syphilis in 2005 according to 
WHO estimates. Cases refer to men and women aged 15-49 and are presented in millions. 
The source data were extracted from (23). 
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1.2 Genome, proteome and metabolism 
 
The T. pallidum genome is contained on a single circular chromosome comprising 1,014kb 
pairs and contains 1,041 open reading frames (representing 92.9% of the total genomic DNA 
(gDNA)) of which 55% codes for known proteins (Figure 1.2) (5, 27, 28). This is one of the 
smallest genomes of all bacteria, similar in size to that of Borellia and Mycoplasma and 
contains no prophage sequences, transposons or restriction-modification genes (29). T. 
pallidum sub-species have a high degree of sequence homology and through DNA 
hybridisation assays, subsp. Pertenue (yaws) and supsp. pallidum (syphilis) treponemes were 
judged so similar that they were re-classified as sub-species (30). However, Sanger 
sequencing and restriction fragment length polymorphism (RFLP) analysis have subsequently 
identified, single nucleotide differences between subsp. pertenue and subsp. pallidum in 
several genes, including the ‘T. pallidum repeat’ (tpr) sub-family genes tprI and tprC (31). 
Most recently, next-generation genome sequencing compared seven T. pallidum strains 
comprising three subsp. pertuenue and four subsp. pallidum strains. Whilst 99.8% homology 
was observed, 97 genes had between one and six base differences, resulting in two or more 
amino acid changes and many of the proteins involved were known or putative virulence 
factors (32). Many pathogenic bacteria share virulence factors via the horizontal transfer of 
genes present on genomic islands. Other strategies include the transfer of plasmids, 
transposons and bacteriophage-mediated gene transfer (33). It is notable that bacteria lacking 
in these mechanisms, like treponemes, are usually well-adapted to life in their host, often 
unable to replicate outside it, and have a smaller genome. One of the purported sequelae of 
such adaptation and reliance on a host is that small genetic changes can have disproportionate 
effects on phenotype (34). This may explain, therefore, how the clinical diseases caused by 
such a genetically homogenous group are so different. Moreover, why continuous culture of 
T. pallidum outside a human or rabbit host remains elusive (35) and why penicillin resistance 
has not emerged, despite its widespread use to treat syphilis since 1943. Further exploration of 
these concepts requires a more detailed look at the 55% of the T. pallidum proteome that is 
homologous with proteins of known function. 
 
T. pallidum is essentially a scavenger, relying on its host to provide energy, temperature 
regulation and most of the essential nutrients it requires. For energy production, T. pallidum 
seems entirely reliant on glycolysis as it lacks enzymes required for both the tricarboxylic 
 18 
acid cycle and an electron transport chain (28). As a result, only two ATP can be produced 
from a molecule of glucose (compared with 38 ATP for E. coli). (28, 36) and partly explains 
the slow (30-33 hours) generation time of T. pallidum both in vitro and in vivo (35, 36). 
Another growth-limiting factor is the precarious relationship T. pallidum has with oxygen. 
The organism is micro-aerophilic, growing optimally in an environment containing 1.5-5% 
oxygen and surviving little beyond 4 hours at atmospheric oxygen levels (35, 37). This 
phenotype is conferred by an absence of the oxygen free-radical scavenging enzymes 
catalsase and superoxide dismutase and is characterised by the inability of T. pallidum to cope 
with oxidative stress (28). Of course, the organism does have some capacity for aerobic life, 
which is supported by an iron-containing enzyme with superoxide dismutase activity similar 
to the neelaredoxin enzymes typically found in thermophilic bacteria (38, 39). T. pallidum 
growth and survival is also dependent on temperature with the optimal environment being just 
below human body temperature at 32-36C (35) and experimental temperatures above 45C 
result in non-viability of the organism (5). This sensitivity was demonstrated in rabbits 
subjected to a unilateral sympathectomy. The animals developed one warm, vasodilated ear 
(29-34C), which remained susceptible to T. pallidum infection and one cool ear (22-27C) 
which could not be infected (40). Similarly in humans, larger numbers of organisms are found 
in the skin lesions of primary and secondary disease and far fewer in blood and deeper tissues, 
presumably because the skin is cooler (41). The absence of genes encoding heat-shock 
proteins makes T. pallidum unable to protect its enzymes from the denaturing effects of high 
temperatures and seems key to this temperature-sensitivity (42). Finally, this temperature 
intolerance was exploited as a syphilis treatment in the pre-penicillin era when patients were 
infected deliberately with malaria in order to produce fever. For the 90% that survived the 
malaria, the resulting high body temperatures led to an improvement in the signs and 
symptoms of their syphilis (4).  
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Figure 1.2. Genetic map  
 
 
 
Fig. 1.2. The 1.14Mb T. pallidum genome is contained on a single circular chromosome. 
Genes of interest are displayed, but do not represent a continuous sequence. Key Blue: Plus 
strand gene; Green: Minus strand gene; Grey: Intergenic region; Red: transfer RNA; Yellow: 
ribosomal RNA 
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1.3 Culture and propagation 
 
T. pallidum is a fastidious organism for which a continuous in vitro culture system has 
remained elusive. The best results to date were obtained with a tissue-culture system and 
serial passage of subcultures that maintained T. pallidum growth for 11 generations and 
resulted in a 2057-fold increase in the number of bacteria over 18 days (43). The conditions 
required to achieve this modest amplification are complex. Firstly, a static monolayer or 
microcarrier bead culture of Sf1Ep cottontail rabbit epithelial cells or RAB9 rabbit fibroblast 
cells is required. Culture medium is a modified BRMM with reduced essential (50%) and 
non-essential (25%) amino acids, which is enriched with superoxide dismutase, catalase, 
CoCl2, co-carboxylase, histidine, mannitol and heat inactivated rabbit testis extract. 
Environmental conditions include three to four percent oxygen, five percent carbon dioxide 
and a temperature of 34-35C (5, 35). In place of in vitro culture, T. pallidum research, 
therefore, relies on in vivo propagation in laboratory animals. Although venereal syphilis 
strains can be propagated in mice, guinea pigs and hamsters, rabbits are the preferred choice 
as the clinical primary and latent infection they develop closely resembles human disease (44, 
45). Rabbits have been used to passage T. pallidum strains for over 100 years, beginning with 
the first isolated strain (Nichols strain) from the CSF of a patient with secondary disease in 
1912 (46). This highly virulent strain has become the archetype for laboratory research, and 
despite a century of propagation in rabbits, remains infectious to humans (47, 48). 
 
1.4 Invasion, evasion and pathogenesis of T. pallidum 
 
T. pallidum is an well-adapted pathogen as what it lacks in capacity for host-free survival, it 
compensates for in virulence. In humans, it has an infectious dose of as few as 10 organisms 
(with an ID50 of 57 organisms); is able to infect almost any tissue type and can persist in its 
host for years (36, 48). In contrast to many bacterial infections, its success is better defined by 
invasion and immune evasion rather than a strong cytotoxic effect. When added to a variety of 
cell cultures or tissues, including rabbit capillaries, muscle and HEP2 cells, treponemes were 
shown to have a cytopathic effect but only when present in extremely large quantities (49, 
50). By contrast, at low number, they are seen to cause little or no changes thus the tissue 
damage seen during clinical infection seems to be predominantly mediated by the host 
inflammatory response. 
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In rabbits, T. pallidum flaA DNA was detected in the plasma within 24 hours of intra-
testicular injection of 10
6
 organisms and then seen to rise steadily until a peak at 10 days (51). 
When organs were harvested from the same animals between 10 and 14 days post-infection, 
DNA was detected in some brains and kidneys and in most livers and spleens. The serum 
blood fraction was less likely to contain T. pallidum DNA than plasma or whole blood, 
although a recent meta-analysis found serum and plasma to be the best clinical samples in 
which to detect the organism (52). Whichever its preferred blood fraction, T. pallidum spread 
is predominantly haematogenous. It adheres readily to endothelial cells causing vasculitis and 
peri-vasculitis and has been shown to pass rapidly through endothelial inter-cellular junctions 
(53, 54). Once disseminated, treponemes are largely subject to immune clearance, however 
persistence in a variety of niches (collagen bundles, erector pili muscles, nerves) has been 
demonstrated and is thought to contribute to immune evasion and latency (55). There is 
evidence that T. pallidum bacteraemia can precede clinical signs and positive serological tests. 
For example, cases of congenital syphilis where the mother was infected in late pregnancy 
and was yet to develop positive serology (56). Moreover, while a recent study using PCR to 
detect T. pallidum in asymptomatic blood donors with positive syphilis serology failed to 
detect any bacteria there are documented cases of transfusion-related spread from individuals 
with incubating sero-negative disease (57). Invasion of the central nervous system is also well 
documented both in rabbits and humans and is considered separately in Chapter 1.6. 
 
In order to invade, T. pallidum must first adhere to the surface of host cells. It binds to a wide 
variety of nucleated cells in a process mediated through proteins of the extra-cellular matrix, 
such as fibronectin, laminin and collagen I (58, 59). Laminin, a multi-domain glycoprotein is 
localised in the basement membrane of endothelial cells and may be important in T. pallidum 
gaining access to the blood (60). Fibronectin is a soluble dimer and appears to cross-link 
treponemes and mammalian cells (58). In the pre-genomic era, syphilitic serum and anti-
fibronectin antibodies were found to prevent the bacteria binding to epithelial cells in culture 
systems (59). Subsequent knowledge of the T. pallidum genome allowed the ‘in silico’ 
identification of potential adherence-associated proteins, three of which were subsequently 
cloned (61, 62). Two of these, tp0155 and tp0483 were identified as fibronectin binding 
proteins and the third tp0751 as a laminin binding protein which has since been demonstrated 
to mediate T. pallidum adherence. The localisation of these binding proteins at the cell surface 
is yet to be fully elucidated, but once T. pallidum are bound to the host cell, the point of 
attachment seems to localise at the tip facing the organism’s direction of travel (63).  
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The motility of T. pallidum is one of the major determinants of its virulence and 5% of the 
organism’s genome has been found to encode motility and chemotactic proteins (28). 
Flagella, located in the periplasmic space (between the cytoplasmic and outer membrane), 
facilitate rotation around a longitudinal axis and result in a corkscrew motion, which can 
propel T. pallidum through viscous extra-cellular matrices at up to 19M/second (64). The 
structure of the flagella, which contains a hook, basal body and filament is similar to that of 
other bacteria, except that the filament is made of four subunits (three class B core molecules 
and an outer class A sheath) in place of a single protein (65). These filaments are coded by the 
genes flaA (sheath) and flaB1, B2 and B3 (core) and are highly antigenic (66). The genes are 
coded in one large operon and knock-out of the first gene it contains (tap1) rendered T. 
denticola immotile (67). The ability of the unique flagellar structure to propel T. pallidum so 
effectively explains much of its invasive capacity and why a significant proportion of its small 
genome and limited metabolic capacity are given over to motility. 
 
The cell surface of T. pallidum lacks the highly antigenic lipopolysaccharide (LPS) that is 
common to most gram negative bacteria and, overall, there are around 100 times fewer 
transmembrane proteins than are found in other spirochetes or E. coli (28, 68, 69). Antibodies 
in syphilitic serum only readily associate with T. pallidum if the outer membrane is degraded, 
following incubation at 4C or treatment with detergent (70, 71). It is thought that proteins 
associated with the cell membrane are anchored predominantly in the cytoplasmic inner 
membrane and that few breach the outer membrane. Thus, only when they become exposed 
can antibody bind (72). Therefore, whilst the lack of outer membrane-associated proteins and 
LPS leads to increased fragility of the bacterium, it equally makes the organism much less 
immunogenic (4). One of the major, and best characterised, T. pallidum membrane-associated 
proteins is the penicillin-binding 47kDa surface lipoprotein (73). Whilst almost certainly 
anchored to the inner membrane, it is also surface-exposed and antibodies directed against it 
during infection have been identified (74-76). The gene sequence (tpp047) coding the protein 
is highly conserved among T. pallidum strains and subspecies, although it has only been 
found in pathogenic subspecies (77, 78). Another much-studied family of T. pallidum surface-
exposed proteins are the tpr proteins. There is evidence that the in surface expression varies 
during the course of infection in a single host in a way that is thought to contribute to immune 
evasion (79-81). 
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1.5 T. pallidum strain-typing and molecular epidemiology 
 
The United States Centres for Disease Control and Prevention (CDC) described the first and 
most commonly used typing system for T. pallidum, which relies on the molecular analysis of 
two genes (82). The first encodes an acidic repeat protein (arp) (tp0433), and contains a 
variable number of 60 base-pair repeats. The number of repeats for a given strain is 
determined by comparing the size of its arp amplicon with that of the Nichols strain arp gene, 
which is known to have 14. The second target, tpr subfamily II, has sequence heterogeneity 
that can be identified by comparing Mse-I restriction digestion patterns of tpr amplicons (each 
of which is given a separate letter) (82). The subtypes identified with this method are named 
according to the number of arp repeats and the tpr digest pattern, for example, 14d. This 
typing method was originally used to identify 12 different subtypes among 63 samples 
collected in the United States, Madagascar and South Africa. A recent meta-analysis revealed 
that 57 subtypes have now been identified using this method from 14 studies in eight 
geographic areas (83). Following its original description, a predominance of the subtype 14d 
was noted, leading some to conclude this was either the original circulating strain or had 
spread widely through linked transmission (83). Some felt, however, that the typing method 
may be relatively insensitive and three additional gene targets have been proposed to further 
sub-classify strains. The first enhancement involved determining the number of guanidine 
nucleotide repeats in the gene rpsA (tp0297) in a method similar to that used to identify the 
number of arp repeats (84). The authors proposed this number should be added to the end of 
the subtype, eg. ‘14d9’. The second method used tp0136 gene sequence analysis to compare 
strains collected in the Czech republic with the macrolide resistant strain SS14, and has not 
been confirmed elsewhere (85). The third modification, now the most widely used, added 
gene sequence analysis of base pairs 131-215 of the tpp0548 gene open reading frame (86). 
The authors assessed three different targets, and found tpp0548 analysis, which was able to 
subdivide 173 samples from 14 CDC types into 25 types, to be the most discriminatory. Each 
tpp0548 sequence identified was assigned a letter which was placed at the end of the CDC 
type, eg. ‘14d/g’.  
 
Using the CDC typing method with or without tpp0548 sequence analysis, several 
descriptions of syphilis epidemics in the USA (86), Scotland (87), South Africa (88, 89), 
China (90), Taiwan (91), Australia (92) and Canada (93) have now been made (Figure 1.3). 
The range of arp repeats identified was between two and 22; tpr patterns a to m and p have 
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been identified in addition tpp0548 sequences ‘c’ to ‘g’ and ‘I’ and finally eight, nine, 10 or 
12 rpsA tandem repeats (83). Whilst certain types, notably ‘14d’ and ‘14f’ predominate, none 
of the epidemics characterised consisted of a single strain and have allowed analysis of 
population strain distribution. In this way, strain types have been associated with race, 
sexuality and macrolide resistance mutations (86, 93, 94).  
 
Recent bioinformatic data derived from the complete genome sequence of nine T. pallidum 
strains has demonstrated the potential for further characterisation of T. pallidum molecular 
subtypes. In addition to arp, tpr and tpp0548, the genes showing the greatest sequence 
variation were tp0138, tp0326 and tp0488. The optimal combination of molecular typing 
targets may be different depending on geographical location (32). In Madagascar, for 
example, all of the tpp0548 sequences analysed were sequence ‘c’, thus the addition of this 
typing target added little to strain characterisation. Moreover, in Scotland all strain types 
identified contained 14 arp repeats, whereas using tpp0548 or tp0326 analysis may have sub-
classified a number of strains (82, 87). Finally, a recent study found an association between 
neuro-syphilis and a tpp0548-enhanced strain type. Of 42 patients infected with type 14d/f, 
50% had neurosyphilis compared with 10 of 41 patients with a non-14d/f type (86, 95). 
Whilst there is no biological basis for this association at present we have already seen how 
small genetic changes between T. pallidum subspecies are thought to account for the variation 
in the clinical disease they cause. It is entirely possible, therefore, that the phenotype 
associated with the tpr/tpp0548 subtype d/f is indeed neurotropic and that in addition to 
molecular epidemiology, T. pallidum strain type analysis may have the power to predict 
clinical phenotypes.  
 
 25 
Figure 1.3 Geographical distribution of T. pallidum subtypes 
 
 
 
 
Fig. 1.3. Global distribution of T. pallidum strain types according to the Centres for Disease 
Control typing method with or without the addition of tpp0548 gene sequence analysis. 
Source data were extracted from (85, 92, 96).  
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1.6 Clinical Disease 
 
Syphilis is a multi-system disease with a variable course, which is divided into primary, 
secondary and latent stages (Figure 1.4). Transmission is both sexual, through direct skin or 
mucosal contact and vertical, as a result of trans-placental passage of T. pallidum during 
pregnancy. The infectious dose required for half of exposed patients to contract the disease is 
57 organisms and approximately 50% of those who contact syphilis (higher in early disease) 
will become infected (36, 97, 98). Sexual transmission is said to be equally possible during 
the primary and secondary phases of infection, while transmission during latency is rare, 
though not impossible (97). Transmission during pregnancy is as high as 80% during early 
disease and then wanes as time since infection increases such that transmission risk is 30% 
during latent disease (99, 100). 
 
Following sexual contact with an infectious partner, T. pallidum breach the skin through 
micro-abrasions and divide at the point of contact, commonly the mouth, genital or perianal 
skin (4). They enter the circulation quickly through blood and lymphatics while continuing to 
divide in the skin over a mean period of 24 days (range 10 to 90 days) before the initial 
papule of primary infection develops (48, 98). This papule then ulcerates and forms the 
chancre of primary disease, which is typically painless, with a firm margin and 0.5 – 2cm in 
diameter. Magnuson’s work demonstrated that the size of the chancre developed by prisoners 
injected with T. pallidum was proportional to the infectious dose (48)
1
. Histological 
examination of the chancre reveals neovascularisation together with spirochetes, 
lymphocytes, macrophages and a variable number of plasma cells (101). Nerves are also 
infiltrated, via the vasa nervorum, which likely explains the absence of pain. 
 
                                                 
1
 NB. The prisoners taking part in this study were described as ‘volunteers’, but the use of 
prisoners in 1956 is likely to fall short of modern ethical standards and is not condoned. 
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Figure 1.4 The stages of syphilis 
 
 
 
Fig 1.4. Syphilis is a multi-system disease which, if left untreated, progresses through early 
(primary and secondary), latent (early and late) and tertiary stages (4, 96). 
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T. pallidum enter the circulation from the first day of infection and continue to do so as the 
chancre heals over a period of 4-6 weeks (4). Interestingly, this does not result in the systemic 
inflammatory response that one generally associates with gram-negative bacteraemia, and is 
probably the result of T. pallidum not expressing LPS (28, 69). Moreover, the slow division 
time of the bacteria means that the symptoms and signs of secondary disease do not typically 
appear until four to 10 weeks after primary disease (100). In most cases, the chancre has 
healed before secondary disease is evident, but 15% (more in HIV-1 infected patients) will 
have concurrent signs of primary and secondary disease (102). The sine qua non of secondary 
disease is a rash, which will be macular-papular in 50-70% of patients with the unusual 
feature that it may affect the palms and soles (102). The histology of the rash is 
granulomatous and is thought to result from sufficient bacterial replication in the skin to 
provoke an immune response, hence the lag between bacterial dissemination and the 
development of clinically evident secondary disease (100). It is of note that, some patients 
never experience a rash, while others develop the rare and dramatic nodular, ulcerative 
cutaneous manifestation known as lues maligna. In addition to rash, a number of other 
manifestations both systemic and local are well documented. These are described in Table 1.2 
and some are pictured in Figure 1.5.  
 
Secondary disease will usually regress spontaneously within three months. The disease then 
enters a latent stage, defined as ‘early’ up to one year after the presumed date of infection and 
late thereafter. This distinction is made as 25% of patients with latent disease followed up in 
the Oslo trial of untreated syphilis relapsed to secondary disease during the first year, and 
while relapses up to 5 years later were possible, they were rare (103). Patients are not 
generally considered infectious through sexual contact during the latent period, although they 
may still be bacteraemic and transmission of the disease from mother-to-child can occur 
(104). While it is important to note that withholding penicillin from patients following 
demonstration of its efficacy in 1943 cannot be condoned the Oslo and Tuskagee studies were 
of importance in determining the long-term outcome of patients with untreated syphilis (103, 
105). Tertiary syphilis (the final stage of the disease) developed in approximately 30% of 
patients who were untreated for between 20 and 40 years, although it is now seldom seen due 
to partial treatment with antibiotics given for other indications (105). The most common 
presentation of tertiary disease was the gumma. These deep-seated destructive nodules in 
bone, skin and, occasionally, other organs affected around 15% of those with tertiary disease 
and are thought to result from a cellular hypersensitivity reaction (100). Cardiovascular 
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involvement caused important morbidity in around 10% of patients as T. pallidum has a 
predilection for the ascending aorta and can provoke aneurysmal change and aortic valve 
regurgitation (106). Neurological involvement can occur at any stage in infection, although it 
peaks at 12-15 months post-infection and is only seen in around a third of patients (107). 
During the tertiary stage, syphilis was recognised as causing meningo-vascular disease 
(proliferative enderarteritis), resulting in strokes at around 5-10 years and much later (20-30 
years) patients developed the ‘classic’ signs of tabes dorsalis (spinal dorsal column damage), 
dementia and neuropathic ‘Charcot’ joints as a result of neuronal loss, demyelination and 
gliosis (107, 103).  
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Table 1.2 Clinical manifestations of secondary syphilis  
 
Systemic  Myalgia 
  Fever 
  Weight Loss 
  Rash: 
o Maculo-papular (50-70%) 
o Papular (12%) 
o Macular (10%) 
o Annular (6-14%) 
o Rarely: framboiseform, lues maligna 
  Generalised Lymphadenopathy (85%)  
  Alopecia (4-11%) 
 
Local  Condylomata lata (10%) Affect moist intertriginous 
areas (peri-anal, vulval, groin, scrotum .  
  Hepatitis 
  Meningo-vascular Neurological involvement: 
o Stroke 
o Ocular disease (uveitis, iritis) 
o Meningitis 
  Renal (immune complex-mediated glomerulonephritis) 
 
Table 1.2. A summary of the clinical manifestations of secondary syphilis (108, 109).  
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 Figure 1.5 Features of secondary syphilis 
 
 
A. Acutely inflamed disseminated lesions 
 
 
B. Pustular lesions on the palm 
 
C. Oral mucosal ulceration 
 
D. Condylomata lata 
 
Fig. 1.5. Photographs of secondary syphilis. (Images courtesy of The Wellcome Trust Image 
Collection). 
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1.7 Diagnosing syphilis and its cure 
 
The diagnosis of syphilis varies according to stage and relies on clinical findings, point of 
care tests and laboratory assays. The organism cannot be cultured, so testing has traditionally 
relied on direct visualisation and serological testing.  
 
The chancre of primary disease and the moist lesions of secondary disease (condylomata lata, 
mucous patches, chancres) contain T. pallidum organisms that can be visualised directly with 
dark ground microscopy (DGM) (104). A sample of serous exudate is collected from the edge 
of a cleaned and abraded ulcer and placed immediately on a microscope slide. The 
treponemes are identified by their characteristic shape and motility and in the hands of a 
skilled operator the test provides an immediate diagnosis with a sensitivity of around 80% 
(110, 111). For incubating disease; DGM negative primary disease; secondary disease with no 
moist lesions and screening for later disease stages testing relies on a combination of 
serological tests.  
 
The first serological test for syphilis was described in 1906 and became known as the 
Wasserman reaction (WR). Wasserman extracted what he thought to be treponemal antigens 
from the livers of newborns who succumbed to congenital syphilis and used them in a 
complement fixation test to identify reactivity with patients’ sera (16). It was later discovered 
that the target of patient antibodies in the WR was not treponemal in origin, rather it was a 
phospholipid called cardiolipin (112). In a complex with lecithin and cholesterol this antigen, 
which could be extracted and standardized as a test reagent, became the basis for both the 
venereal disease research laboratory (VDRL) and rapid plasma reagin (RPR) tests, which are 
still in use (4, 113). These tests are often referred to as non-treponemal, because they are 
based on the detection of anti-cardiolipin antibodies as opposed to anti-treponemal antibodies 
and it is commonly asked why these anti-cardiolipin antibodies are produced in response to T. 
pallidum infection. One theory is that the antibodies are an auto-immune phenomenon and are 
raised against cardiolipin released from cells damaged by T. pallidum, although we have seen 
previously that the cytopathic effects of the bacteria are limited. Another is that they are 
raised against treponemal lipids directly. A third theory, and perhaps the most tangible, is that 
T. pallidum incorporates host lipids onto its surface during infection, which are subsequently 
presented to the immune system resulting in what is actually a T. pallidum-specific response 
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(4). Whatever the source, both the RPR and VDRL tests are sensitive for the diagnosis of 
primary disease (86% and 78%, respectively) and secondary disease (both said to be 100%) 
(111, 114). Of course, neither test is positive from the moment of infection nor has a 
specificity of 100%. A reported 30% of patients with primary disease will have a positive 
anti-cardiolipin test at presentation, and seroconversion is typical one to four weeks after the 
appearance of the chancre (115). False positive results are common in acute non-treponemal 
infections and in chronic auto-immune conditions, thus care must be taken to correlate 
serological results with clinical history and examination findings (104). As a final note, the 
difference between the two ‘non-treponemal’ tests, (VDRL and RPR) is essentially a practical 
one. The VDRL uses a single test slide per patient and requires a serum sample. The RPR is 
automatable, its antigen is more stable and, as the name suggests, requires plasma not serum. 
Both tests are quantifiable by using serial dilution to determine the strength of the antibody 
response, and the RPR is the most commonly used today (116). Antibody titres are low in 
primary infection, rise in secondary disease (typically to above 1:8) and then fall as disease 
passes into latency. As seen in Figure 1.6, they also fall following treatment and a four-fold 
drop in titre is taken to indicate treatment success. In most patients with early disease, the titre 
will decline, often to negativity in under a year, and is expected to have fallen four-fold within 
three to four months (117). For latent disease, the decline may be more gradual and may 
persist well beyond two years in 50% of patients (118). This state is often called ‘serofast’ 
and is not thought to indicate treatment failure, although the significance of a persistently 
positive RPR after treatment is not known and often causes clinical uncertainty (104). In 
addition to ‘non-treponemal’ antibodies, the humoral response to syphilis also comprises 
specific IgM and IgG antibodies. These can be detected from the sixth day of infection and 
are targeted against a broad range of T. pallidum surface-exposed lipids, lipoproteins 
(including the 47kDa and tpr proteins) and flagella proteins (4). In addition to opsonisation, 
these antibodies block the attachment of T. pallidum to host cells and some are immobilising 
(in conjunction with complement) (119). It is notable that while some antibodies are specific 
to the genus Treponema and others target only the pathogenic T. pallidum subspecies, none of 
the currently identified antibodies are specific to the syphilis-causing T. pallidum subspecies. 
Following their discovery, these ‘specific’ antibodies were harnessed as syphilis serological 
tests to improve the specificity of diagnosis. Immoblising antibodies were the first to be 
exploited as the T. pallidum immobilisation test (TPI) whereby Nichols organisms were 
immobilised by (syphilis-infected) patient serum and visualized by DGM (119). This 
laborious and insensitive technique was soon replaced with the fluorescent treponemal 
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antibody (FTA) test which involved coating slides with T. phagadenis antigen (from killed 
organisms), adding patient serum and then staining with fluorescein-labelled anti-human IgG. 
A subsequent modification with an absorption step gave rise the current to FTA-ABS (Figure 
1.7) (120). Another technique, described in 1965, and also still used, is the T. pallidum 
haemagglutination (TPHA) test (121). In this assay, sheep erythrocytes are sensitised with 
antigens from a T. pallidum lysate and added to patient sera. A positive result is indicated by 
agglutination of the red blood cells into a ‘mat’ on the test slide. A modification of the test, 
the T. pallidum particle agglutination (TPPA) assay is also available where micro-particles 
replace the erythrocytes. One of the concerns with the TPHA/TPPA and FTA-ABS is that 
because they are produced from T. pallidum whole-organism lysates there is potential for 
cross-reactivity with other trepomenes and indeed other bacteria entirely. To overcome this, a 
number of tests have been developed using recombinant T. pallidum antigens, of which the 
enzyme immunoassays (EIA) are the most widely used and are commercially available. 
However, even this latest generation of tests fails to differentiate between infections caused 
by the four T. pallidum sub-species (111). Traditionally, syphilis screening began with the 
RPR and was then confirmed with a ‘specific’ test such as the TPPA or FTA-ABS. The high-
throughput capability of the EIA, however, has led many laboratories to screen with a 
‘specific’ test and then confirm results with the TPPA (which they were designed to replace). 
Either way, once two positive ‘specific’ test results are obtained, a VRDL or RPR is carried 
out to give an indication of the level of disease activity (122). A final consideration of 
serological tests is their use in the diagnosis of neurosyphilis. CSF analysis can help to predict 
risk of developing neurological disease, but results can be difficult to interpret. An abnormal 
CSF (raised protein, raised white cell count, positive VDRL test) portends a high risk of 
developing neurosyphilis if present two years or more after infection (123). However, in 
general only one to five percent of the 30-50% who have abnormal CSF results will go on to 
develop neurological disease and CSF abnormalities are frequently seen in neuro-
asymptomatic early disease. Moreover, normal CSF results do not exclude neurosyphilis as a 
proportion of these patients will still have T. pallidum detectable by DGM or PCR and the 
sensitivity of VDRL in the CSF is only 30-70% (107, 123). 
 
The detection of B-cells responsive to stimulation with T. pallidum protein in the peripheral 
blood of patients with syphilis has also been assessed (124). An Enzyme-Linked 
Immunoadsorbant Spot (ELISpot) assay was developed in which PBMCs were isolated from 
the blood of 35 patients with early and latent syphilis. Following separation, cells were 
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stimulated with recombinant Tpp17 protein and proliferation detected with a biotin-labelled 
anti-human IgG antibody. The assay had comparable sensitivity to RPR testing for the 
identification of primary and secondary disease and identified 46% of patients with latent 
disease. A total of six patients had a second blood sample taken following treatment and in 
five the ELISpot assay could no longer identify reactive B-cells. The sixth patient, whose B-
cells remained reactive was deemed to be a treatment failure according to standard serological 
follow-up. 
 
While molecular diagnostic tests are now gaining ground, most bacterial infections were 
traditionally diagnosed with culture. T. pallidum, being largely uncultivable, was one of the 
exceptions to this rule, hence our reliance over the years on direct visualisation and 
serological testing. It is possible, however, to use a modification of the method of propagating 
strains in rabbits as a diagnostic test, referred to as the rabbit infectivity test (RIT). The 
procedure, which can detect a single treponeme, remains the most sensitive method available 
for diagnosing syphilis but is expensive, can take up to 120 days to give a definitive result and 
requires the sacrifice of one or two rabbits. It is not widely used (125, 126). 
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Figure 1.6 Serum levels of syphilis antibodies following treatment 
 
 
 
Fig 1.6. Following adequate treatment the non-treponemal antibody titre (RPR (blue 
diamonds) and VDRL (red squares) are pictured here) is expected to fall four-fold after 
approximately four months. It should then remain low or negative (111).  
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Figure 1.7 The FTA-Abs test for syphilis 
 
 
 
 
Fig 1.7. Following staining with a fluorophore-labelled antibody, T. pallidum in patient serum 
is viewed under a fluorescent microscope. This is the basis of the current FTA-Abs test for T. 
pallidum. Image courtesy of the Wellcome Trust Image Collection. 
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1.8 T. pallidum PCR 
 
The prospect of PCR as a sensitive, specific and quick test for the diagnosis of syphilis was an 
inviting one. The first description of T. pallidum detection by PCR was made in 1990 using 
CSF samples collected from patients under-going lumbar puncture for the investigation of 
syphilis; HIV-related CNS disease or other non-STI related conditions (127). Overall, the 
clinical sensitivity of the assay was 47% (the assay sensitivity was 65 organisms/500l 
sample) and specificity was 93% for the detection of T. pallidum DNA (tmpA and 4D gene 
targets) in the CSF of patients with serologically confirmed syphilis. Of note, seven patients 
with latent disease and five patients who had previously received treatment were found to 
have positive CSF. The authors questioned the significance of T. pallidum DNA in the CSF 
i.e. whether the organisms detected were actively contributing to CNS disease. 
 
 It is notable that a previous study using RIT had found no viable T. pallidum in the CSF of 18 
patients with latent disease compared with 30% positivity in early disease CSF (128). A 
subsequent study demonstrated that five patients with acute neurosyphilis who were 
symptomatically cured following treatment still had T. pallidum (bmp gene) detectable in 
their CSF following treatment (129).  
 
This raised the question in both studies as to whether the DNA detected in the CSF was from 
viable or dead organisms, moreover if PCR inhibition or contamination were affecting results. 
A partial explanation came when a tpp047 PCR was compared with RIT for the detection of 
T. pallidum in amniotic fluid, sera and CSF of neonates under investigation for congenital 
syphilis. The overall reported sensitivity was 80% (100% for amniotic fluid, 67% for sera and 
71% for CSF) and specificity was 100% for all confirming the validity of PCR on CSF 
samples (130). However, further samples were not taken following treatment to assess the 
persistence of both DNA and viable organisms. This study also established that the method of 
sample preparation impacted on PCR sensitivity, namely that separating DNA from samples 
prior to PCR led to more reliable detection.  
 
Following these initial successes, attention turned to a number of other sample types, DNA 
extraction methods and PCR targets. There is great appeal in being able to detect T. pallidum 
DNA in blood samples, especially in situations where serological tests can be ambiguous, 
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such as latent disease and treatment monitoring. In 1969, Turner and Hardy used RIT to 
demonstrate viable T. pallidum in 5/13 whole blood samples and 0/2 serum samples from 
patients with secondary syphilis. A single whole blood sample from a patient with primary 
disease was RIT negative (126). Wicher et al described a similar picture by employing a 
nested PCR to detect T. pallidum DNA (bmp gene) in rabbit whole blood and serum 
following intra-testicular injection. The only positive serum sample was partly haemolysed 
whereas 9/10 whole blood samples were PCR-positive at day eight (compared with 3/10 on 
day four).  
 
In another study, whole blood from women with syphilis in pregnancy whose babies died as a 
result of the infection was analysed retrospectively with a polA PCR. Overall, 72% were 
found to have been bacteraemic at the time of syphilis screening. Many other studies have 
since examined the best blood fraction for T. pallidum PCR, which were summarised in a 
recent meta-analysis of 46 suitably controlled studies (52). The authors concluded that serum 
and plasma had greater sensitivity than whole blood, but not significantly so. Moreover, these 
data were a pooled analysis including different stages of disease, PCR targets and extraction 
techniques. If only whole blood is considered and detection compared with disease stage, 
however, a biologically plausible unity is found between studies that is supported by RIT 
data: Sensitivity is greatest in secondary disease (54.2%) compared with 36.1% for primary 
and 20.2% for latent disease. These results were confirmed in a second meta-analysis of 15 
quantitative studies that found T. pallidum DNA in 55.8% of secondary disease blood samples 
compare with 34.1% for primary and 33.6% for latent (p=0.007) (83) It seems, therefore, that 
blood samples taken during highly active disease (secondary, congenital in the neonate, 
symptomatic neurosyphilis, fatal pregnancy outcomes) are more likely to be positive by PCR, 
and likely reflects the target DNA copy number.  
 
Given the wide range of organs and tissues that T. pallidum has been show to invade, it is not 
surprising that PCR has also been employed to look for the organism in a number of sites of 
infection other than the bloodstream. The greatest success has been found in primary disease 
ulcer samples, with most studies reporting a sensitivity of 80-100% and with characteristically 
high specificity (131). For example, Orle et al developed a multiplex PCR for the diagnosis of 
genital ulcer disease (chancroid, genital herpes and syphilis), which demonstrated a sensitivity 
of 91% when multiplex PCR was compared with DGM (132). Moist secondary lesions have 
also proved rich in T. pallidum DNA, with a sensitivity of 72% in the recent meta-analysis 
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(52). Other samples examined include urine; placenta; gastric lesions; aorta and brain tissue 
and results of these investigations are summarised in Table 1.3. One final sample type which 
merits consideration is whole blood collected from ear lobe capillaries. In a study of 69 
patients with serologically confirmed (RPR, TPHA and FTA-ABS positive), asymptomatic 
and untreated latent syphilis, 57.1% had detectable T. pallidum DNA (tpp047 gene) in ear 
lobe capillary blood compared with 39.1% in whole blood samples from the same patients 
(133). The authors postulated that like Borellia spriochetes T. pallidum hide in capillary beds 
during latent infection and, thus, ear lobes, which are rich in capillaries, make an ideal 
sampling site. The sensitivity seen with this sample type far exceeds any other sample for the 
detection of T. pallidum DNA in latent syphilis, although it has yet to be replicated.  
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Table 1.3 Samples found to contain T. pallidum DNA  
 
Sample 
(reference) 
Sample provenance Assay Results 
    
Urine (134) Dermatology outpatient 
attendees.  
126 samples from 76 
patients 
VDRL and TPHA testing 
and stage according to 
CDC criteria (135) 
Real-time 
PCR 
tpp047 target 
Primary disease (2/7, 
29%) 
Secondary disease 
(4/9, 44%) 
Both 100% specific 
    
Ejaculate (136) 4 samples (1 primary, 2 
secondary, 1 early latent) 
Nested PCR 
tpp047 target 
2/4 positive (50%). 1 
primary and 1 
secondary 
    
Formalin-fixed 
paraffin 
embedded 
placenta (137) 
49 placenta samples, 11 
from mothers with 
negative serology (RPR 
and FTA-ABS) 38 from 
sero-positive mothers 
tpp047 PCR 
with southern 
blot target 
confirmation 
0/11 from 
seronegative mothers 
4/4 from positive 
mothers with syphilis 
consistent histology. 
4/38 samples with 
inconsistent 
histology 
    
Formalin-fixed 
gastric biopsy 
specimens 
(138) 
2 patients with gastric 
syphilis thought to be 
lymphoma at endoscopy 
tmpA gene 
confirmed 
with gene 
sequence and 
SmaI 
restriction 
digestion 
Both samples were 
PCR positive.  
    
Brain tissue 
(syphilitic 
gumma) (139) 
Case report of a single 
patients with a brain lesion 
found to be a gumma 
bmp gene 
Nested PCR 
PCR-positive. 
    
Post-mortem 
aortic biopsy 
(140) 
Case report of an aortic 
aneurysm with typical 
morphological and 
histological appearance of 
tertiary syphilis 
tpp047 PCR 
with southern 
blot 
confirmation 
PCR-positive 
 
Table 1.3. A summary of clinical samples in which T. pallidum DNA has been identified by 
PCR. 
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The most commonly described T. pallidum PCR target is the tpp047 gene, which encodes a 
cell-membrane associated 47kDa lipoprotein that is highly conserved, highly expressed and 
antigenically dominant in the human syphilis immune response (57, 76, 132, 141-143). Genes 
encoding other surface-associated proteins have also been targeted (tmpA (127); bmp(144)), in 
addition to other targets, such as polA which is involved in the regulation of genome 
duplication (133, 145, 146). Three of these targets (tpp047, bmp and polA) were compared in 
a study of 86 ulcer and blood specimens from patients with suspected syphilis and results 
(according to PCR target used) were found to be 100% concordant (147). However, when 
tpp047 and polA were compared in blood samples from patients with latent disease, tpp047 
showed improved sensitivity of between three and 12 percent, depending on the blood 
fraction assessed (133).  
 
As PCR technology has evolved, successive researchers have been quick to assess new 
techniques in the quest for sensitive and specific T. pallidum detection. As a qualitative 
diagnostic tool, real-time PCR (qPCR) can provide a result within two to three hours and, in 
one study, had a sensitivity comparable to nested PCR for the detection of polA in ulcer 
samples (148). Subsequent studies have validated qPCR with TaqMan probe detection of 
polA as a useful tool for the diagnosis of infectious syphilis by comparison with both 
serological results (sensitivity 80.38%) and DGM (sensitivity 72.8%) (149, 150). The true 
power of qPCR is in its ability to quantify the starting amount of the target DNA under 
investigation. The first study to describe T. pallidum qPCR was a cross-sectional study of 
secondary syphilis in Columbia. The authors were able to detect polA in 11/26 (46%) of 
whole blood samples (having previously determined that whole blood was the optimal sample 
type). By comparing the PCR cycle detection thresholds with an absolute quantification 
standard of purified T. pallidum DNA, they established a range of copies between 194.92 and 
1954.2 copies/ml blood (151). Another study presented semi-quantitative real-time PCR data 
for the detection of tpp047 demonstrating a greater number of PCR cycles required for the 
detection of T. pallidum in blood, urine and CSF compared with skin or mucosal swabs. They 
did not, however, compare these thresholds to those of a quantification standard thus their 
results are more difficult to interpret (152). 
 
Reverse transcriptase PCR (RT-PCR) to amplify T. pallidum sequences is more sensitive than 
DNA detection for a variety of sample types. A 16S ribosomal RNA (16S rRNA) target was 
predicted to be present at 5000-10000 copies per organism, in contrast to the 2 known copies 
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of the gene (153). As sequence variation in the 16S rRNA gene between bacterial species and 
within the Treponema genus is limited, primers specific for T. pallidum were identified and 
non-specific amplification was not observed. Messenger RNA (mRNA) targets may also be 
useful for sensitive and specific T. pallidum quantification. Smajs et al examined the T. 
pallidum transcriptome using a novel microarray and real-time PCR to discover that a number 
of genes, including those coding flagella proteins (flaB3, flaB2 and flaB1) and the 47kDa 
protein (tpp047), were all highly transcribed (141). Lower stability of these mRNA targets 
compared with rRNA or DNA may impact on sensitivity of detection (154). However, it may 
make RNA a more attractive target for monitoring T. pallidum treatment response, as DNA 
from dead organisms persists for up to 15 days in rabbit skin lesions, and DNA appears to 
have persisted for up to 24 months in human CSF following neurosyphilis treatment 
(assuming that patients were not re-infected and did not fail treatment) (129, 155).  
 
In summary, PCR is an effective tool for the diagnosis of early syphilis where swabbed 
lesions are rich in T. pallidum DNA. The sensitivity of T. pallidum bacteraemia detection is 
lower, but varies according to stage and is highest in early disease and whole blood appears to 
be the optimal sample. There is a wealth of evidence that the tpp047 and polA genes are 
reliable targets for T. pallidum detection in both conventional and real-time assays and tpp047 
has been employed successfully for qPCR (52). Finally, RT-PCR may provide a more 
sensitive and responsive measure of spirochetaemia, but is yet to be used in a quantitative 
manner. 
 
1.9 Treatment and antibiotic resistance 
 
The earliest effective anti-syphilitic was arsphenamine (salvarsan), an arsenic-based drug 
developed by Paul Erlich in 1910 (20). Although toxic and difficult to administer, it was 
nonetheless an improvement on the inorganic and somewhat ineffective mercury-based drugs 
it superceded (15). It was the discovery and mass production of penicillin, however, which 
revolutionised the treatment of syphilis. Following the initial description of its efficacy, but 
without prior clinical trials, penicillin was widely used in mass treatment programmes in the 
1940s (156). As a result, morbidity and mortality from syphilis declined in the USA between 
1944 and 1954 by 75% and 98%, respectively and penicillin remains the mainstay of 
treatment today (104, 157). Initially, the drug was administered in its aqueous form as 
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multiple daily injections in order to maintain the stated MIC of >0.018mg/L. The subsequent 
co-formulation of penicillin with oil to make benzathine penicillin, meant that it could be 
given as a single dose and maintain a treponemocidal level for at least seven days (158). This 
long period is needed to cover the slow generation time of T. pallidum (30-33 hours) (4). 
Indeed, treatment is extended to 21 days (three weekly benzathine injections) in latent disease 
where T. pallidum are less metabolically active. For the treatment of neurosyphilis it is widely 
recommended that patients receive aqueous penicillin (procaine or benzylpenicillin), which, 
unlike benzathine, reaches adequate levels in the CSF (104, 158). For the treatment of patients 
with penicillin allergy, and those who decline parenteral treatment, oral second-line 
treatments are available and include amoxicillin with probenecid; doxycycline; erythromycin 
and azithromycin. With the exception of azithromycin the use of these alternatives, which all 
appear in treatment guidelines, has no basis in randomised controlled clinical trials (159-161).  
 
It is remarkable that T. pallidum has developed no resistance to penicillin, despite the 
identification of several penicillin-binding proteins on the surface of the organism, which are 
likely to have a role in peptidoglycan and cell wall synthesis pathways (73, 162). Of particular 
interest is the abundant 47kDa lipoprotein which, in addition to penicillin-binding ability, has 
high beta-lactamase activity and can hydrolyse the beta-lactam bonds of penicillin (163). 
Fortunately, the activity of the enzyme is limited by strong product inhibition, thus, has not 
led to resistance, although the possibility of a mutant variant over-coming this inhibition is 
disconcerting. The only antibiotic class to which T. pallidum has become resistant is the 
macrolides, which includes the drugs erythromycin, spiramycin and azithromycin. In contrast 
to penicillin, macrolides are bacteriostatic antibiotics, which bind reversibly to the 23S rRNA 
in the 50S bacterial ribosomal subunit and block bacterial protein synthesis resulting in death 
(160). Azithromycin, which became available in the late 1980s, was of interest as a syphilis 
treatment due to its long half-life, good tissue penetration and good oral bioavailability (164). 
Following clinical trials showing comparable efficacy to benzathine penicillin, single-dose 
and orally-administered azithromycin (1g-2g) entered into clinical practice for the treatment 
of incubating and early syphilis in the United States (1999-2000), Canada (2000) and Uganda 
(mid-1990s) (164).  
 
The story of macrolide resistance in T. pallidum, however, begins some time before the 
introduction of azithromycin. Erythromycin had already been available since the 1950s and 
was used for the treatment of syphilis in some patients with penicillin allergy, especially 
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pregnant women for whom tetracyclines are contra-indicated. Case reports during the 1970s 
of babies born with congenital syphilis to mothers who were treated in pregnancy with 
erythromycin were alarming, although it was not clear whether the cause of this treatment 
failure was resistance or transplacental transfer of the drug (165, 166). A more clear-cut case 
of resistance was reported in 1977 following treatment failure in a man with secondary 
syphilis who was given a prolonged course of erythromycin (167). The T. pallidum strain 
from this patient was isolated and became known as, ‘street strain 14’. It was well-known 
from other bacterial species that A to G point mutations in the 23S rRNA gene at positions 
2058 and 2059 could confer macrolide resistance and in 1988 the A2058G point mutation was 
identified in the street strain 14 (167). Following this discovery, it was demonstrated in vitro 
that this strain was insensitive to the macrolide erythromycin. It was not until 2002, following 
the azithromycin treatment trials and the introduction of the drug into clinical practice, that 
the Centres for Disease Control (CDC) in the USA began to receive reports of syphilis 
treatment failures (168). These failures included patients who were contacts of infectious 
syphilis treated with azithromycin who went on to develop positive treponemal serology and 
patients with primary disease whose chancres continued to evolve following treatment. This 
prompted a study showing that rabbits infected with Nichols (wild-type) strain T. pallidum 
were cured with erythromycin and others infected with street 14 (mutant) T. pallidum were 
not (169). The same group then used restriction digestion and gene sequence analysis to 
describe the prevalence of mutant T. pallidum strains in Dublin (88%), Baltimore (11%), 
Seattle (13%) and San Francisco (22%) (169). This lead to the first 23S rRNA A2059G 
mutation being discovered in a T. pallidum strain isolated from a Czech patient who had 
failed syphilis treatment with spiramycin (170). Treponemes harbouring both the A2058G and 
A2059G have since been found world-wide and appear to be increasingly prevalent, reaching 
100% in one Shanghai centre (Figure 1.8) (164, 171, 172). 
 
Finally, it is important to note the potential that exists for T. pallidum to develop resistance to 
other antibiotics. Despite the prior description of plasmids in T. pallidum, this was not 
confirmed when the genome sequence became available, nor were any other transposable 
genetic elements identified (14, 28, 173). This suggests that the only mechanism available to 
T. pallidum to develop drug resistance is through point mutations in genes coding for 
antibiotic targets. It is of concern that tetracycline resistance is easily conferred by 16S rRNA 
gene point mutations and that the same mechanism has been predicted in T. pallidum (160). In 
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addition, T. pallidum has been shown to have innate resistance to rifampicin and clindamycin, 
which has a binding site on 23S rRNA overlapping that of the macrolides (160).  
 
 47 
Figure 1.8 The worldwide prevalence of T. pallidum macrolide resistance 
 
 
 
Fig 1.8. A summary of the prevalence of both A2058G and A2059G 23S rRNA mutations 
detected in T. pallidum strains worldwide between 1999 and 2011 (84, 85, 91, 93, 169, 171, 
174-180). 
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1.10 Inflammation and disease pathogenesis  
 
Nearly 70 years ago, Stokes et al observed that the histological changes in early stage 
syphilitic lesions were essentially identical and deduced that the inflammatory response to T. 
pallidum was key in syphilis disease pathogenesis (15). Turner and Hollander made a similar 
observation in their review 10 years later, noting that the infiltration of inflammatory cells 
into rabbit skin following injection with T. pallidum was essential for lesion development 
(125). Another 40 years on, researchers noted that the development and resolution of early 
syphilis lesions is directly related to the immune response and concluded that the contribution 
of T. pallidum cytotoxicity to disease pathogenesis is minimal (181). This is confirmed in a 
study where rabbits were innoculated with T. pallidum antigens and were observed to develop 
lesions morphologically and histologically identical to those caused by living T. pallidum 
(182).  
 
While not highly immunogenic, the outer membrane of T. pallidum contains lipoproteins, 
which following inoculation are stimulatory to dendritic cells and macrophages via CD14 and 
toll-like receptor (TLR) TLR 1 and 2 receptors (183, 184). Following antigen presentation 
and T-cell activation in draining lymph nodes, monocytes and T-cells are recruited to the site 
of inoculation by day three of infection and a predominantly Th1-type immune response 
develops (185-187). Secretion of IFN-, IL-2 and IL-12 by T-cells results in the activation of 
macrophages and the subsequent phagocytosis and clearance of the bacteria(187). In rabbits, a 
peak in the production of IFN- preceded the clearance of T. pallidum from lesions and 
marked the beginning of lesion resolution. The production of opsonising antibodies is also 
thought to be important, although the presence of B-cells in the inflammatory exudate is 
variable (187, 188). While CD4 cells predominate and IL-4 is absent, the number of CD8 
cells present is seen to rise as lesions progress towards resolution although the significance of 
this observation is unclear (187). 
 
A previously discussed (Chapter 1.6), haematogenous spread of T. pallidum is key to disease 
pathogenesis and by the time the primary chancre has resolved, the organism is widely 
disseminated. The patient, however, may be mostly unaware of this dissemination until the 
lesions of secondary disease appear as a result of local inflammation at the sites of bacterial 
replication, which are predominantly peri-vascular. It is often shortly after treatment that 
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patients feel most unwell, due to an inflammatory reaction described by Jarisch in 1895 and 
again in 1902 by Herxheimer and Krause (189). The Jarish-Herxmeimer reaction (JHR), as it 
became known, affects approximately 30% of patients following the treatment of syphilis 
(190). It occurs predominantly in early disease (although can certainly occur in late disease) 
and results in fever, myalgia, headache and increased prominence of skin lesions typically 4-6 
hours after treatment (190). It is widely thought to result from rapid bacterial killing following 
treatment and the release of bacterial antigens into the circulation. The JHR has also been 
noted in other spirochetal diseases. For example, following the treatment of tick-bourne 
relapsing fever (seconday to infection with Borellia spp.) there is an inflammatory reaction 
characterised immunologically by increased levels of the cytokines IL-6, IL-8 and TNF 
(191). Cytokine release during the syphilis JHR is yet to be measured, but is predicted to be 
similar. Histologically, capillaries and small veins in the skin become congested, the vascular 
endothelium swells and an inflammatory exudate appears. These changes are maximal by 14-
18 hours and are typically resolved by 72 hours (190). Bryceson et al studied physiological 
parameters of the JHR in humans by admitting 15 patients with early syphilis to hospital for 
intensive monitoring following the administration of penicillin. Patients experienced fever at 
around two hours following treatment which peaked between four and eight hours at an 
average of 1.5C above baseline (39.5C max) (189).  
 
In another study, the acute phase response protein C-reactive protein (CRP) was measured 
before and after penicillin injection. Increases were noted at 12 hours and were maximal at 24 
hours. Those patients with the highest CRP levels prior to treatment had the more severe 
JHRs although no association was found between VDRL titre and strength of JHR. 
Furthermore, the single patient not to develop a JHR was the only patient included in the 
study with early latent as opposed to primary or secondary disease (192). In a 1948 review the 
percentage of patients with neurosyphilis experiencing the JHR was between 64% and 79%. It 
often resulted in worsening of neurological symptoms; was more common when the results of 
CSF analysis were abnormal and has been associated with death (193). For this reason, it is 
recommended that patients with neurosyphilis receive corticosteroid therapy before and after 
treponemocidal antibiotics (104).  
 
In summary, it is the host inflammatory response to T. pallidum infection rather than a direct 
pathogen effect which charactersises clinical signs and symptoms of syphilis and its 
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treatment. The immune response, predominantly Th1 in nature, results in the rapid clearance 
of T. pallidum from both primary and secondary lesions, although the highly invasive nature 
of the bacterium means that the immune system is often one step behind.  
 
1.11 HIV-1 and syphilis co-infection 
 
The clinico-pathological and epidemiological interactions between syphilis and HIV-1 are 
significant. HIV-1 impacts on the clinical presentation of syphilis and potentially on the 
response of the disease to treatment. Despite active interest and research in the field, a 
consensus on the management of syphilis in the context of HIV-1 co-infection has still not 
been reached. 
 
HIV-1 and syphilis co-infection is common. In 1991, 515 patients attending an STD 
outpatient clinic in Chicago were tested for both diseases. Among the 8% of patients found to 
be HIV-1 infected, 31.7% were co-infected with syphilis compared with 5.9% of HIV-1 
uninfected patients (194). A subsequent literature review identified 10 case-control studies 
comparing the risk of syphilis in patients with and without HIV-1 infection and nine showed 
statistically significant relationships with odds ratios between 1.7 and 8.6. The tenth study 
found an association, but this was not significant when adjusted for other factors in a logistic 
regression (195). In the United Kingdom, 27% of syphilis diagnoses are made in the context 
of HIV-1 co-infection and 34% are among HIV-1-infected MSM (1). On an epidemiological 
level, high rates of co-infection have been associated with sex between men; sero-sorting, the 
practice of choosing sexual partners with the same HIV-1 infection status; recreational drug 
use and unprotected oral sex (196-198). In a recent review, the authors cite a rising incidence 
of early syphilis and falling HIV-1 incidence in San Francisco and suggest that by sero-
sorting and engaging only in oral sex the transmission of syphilis is enhanced and that of 
HIV-1 decreased as syphilis is readily transmitted by the oral route (perhaps 30% of cases 
among MSM) and HIV-1 rarely so (<1%) (199). This does not, however, take note of the 
significant reduction on HIV-1 transmission of anti-retroviral therapy nor the body of 
evidence that demonstrates sero-sorting increases the transmission of other sexually 
transmitted infections (STIs) whilst only modestly decreasing HIV-1 transmission (200, 201). 
Moreover, a mathematical model suggested that syphilis is responsible for an extra 1000 cases 
of heterosexual HIV-1 transmission in the Unites States annually (202). 
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It seems unlikely that high rates of HIV-1 and syphilis co-infection can be explained by 
epidemiological factors alone and a number of plausible biological factors have been 
identified. In terms of HIV-1 transmission risk, STIs that cause genital ulcers have been 
associated with increased shedding of HIV-1 in the genital tract; higher HIV viral loads in 
semen and ulcers may bleed during sexual intercourse. Moreover, T. pallidum lipoproteins 
can upregulate HIV-1 gene expression and multiplication in tissue culture models using 
monocytes (203).  
 
In all these scenarios an HIV-1 uninfected sexual partner is exposed to increased levels of 
HIV-1 (204, 205). Mechanisms to explain enhanced HIV-1-acquisition in patients with 
syphilis have also been identified. Firstly, genital ulcers damage mucosal integrity and 
provide a point of entry for HIV. Secondly, both living treponemes and T. pallidum 
lipoproteins have been shown to enhance the expression of CCR5, to which HIV-1 can bind, 
on the surface of macrophages and dendritic cells which are present in primary chancres 
(182). The potential for syphilis to increase the risk of contracting HIV is supported in a 
number of clinical studies. The risk ratio of HIV-1 acquisition was found to be 4.7 in a study 
of 149 cases of chancroid or primary syphilis and ranged between 2.2 and 13.5 in six other 
studies of genital ulcer disease (not necessarily caused by syphilis) (206, 207). Furthermore, 
in a retrospective cohort of 5164 patients in Miami the incidence ratio between patients 
diagnosed with syphilis prior to a positive HIV test and those who developed syphilis in the 
interval between a negative and a positive HIV test was 2.9 (95% CI 1.9-4.3) and compares 
with that of several other studies (207, 208). 
 
Co-infection with HIV-1 has been shown to impact of the clinical course of syphilis. This 
interaction was first described early in the HIV epidemic through a number of case reports of 
patients experiencing increased neurological complications in addition to unusually 
aggressive disease. Subsequently, two prospective, multi-centre clinical trials aimed to assess 
the differences in the presentation and outcomes of syphilis treatment according to HIV-1 
infection status. In the first, HIV-1 co-infected patients were more likely to present with 
multiple and deeper chancres than those without HIV-1 infection. Moreover, HIV-1 was 
associated with an increased risk of the primary chancre persisting into the secondary stage 
(209).  
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The second study was a randomised, controlled trial comparing standard benzathine therapy 
with enhanced therapy in patients with early syphilis both with and without HIV-1 co-
infection. No significant differences were seen in the systemic manifestations of syphilis, 
although the study did not examine inpatients, was probably underpowered (recruiting 590 
patients of a planned 1200) and included few patients with advanced HIV-1 related disease. 
Despite these limitations it was noted that HIV-1 infected patients have significantly higher 
RPR titres (1:128 vs 1:64, p<0.05) at presentation; that the JHR was more common in co-
infected patients (p=0.02) and chancre resolution was slower in the context of HIV-1 
infection (16.5 days vs 13 days, p=0.08). Finally, on multivariate logistic regression more 
serological treatment failures (failure of RPR to fall four-fold) were identified at six and 12 
months in co-infected patients but this did not translate into clinical failure, nor was it seen at 
any other stage of disease.  
 
A major concern regarding HIV-1 and syphilis co-infection is the potential for more severe T. 
pallidum-associated neurological disease, which is recalcitrant to treatment. In a study by 
Lukehart et al, patients with early syphilis underwent lumbar puncture before and after 
syphilis treatment. CSF analysis in 40 patients included RIT to identify viable T. pallidum and 
seven samples from patients with secondary disease were positive. Of those seven, three 
patients received two or three doses of IM benzathine penicillin and were cured (according to 
a repeat RIT result). Four patients received a single dose of IM benzathine and three, all HIV-
1 infected, were found to have failed treatment while the fourth (HIV-1 uninfected) was cured 
(128). This study led to the adoption of more rigorous treatment regimes for patients with 
early syphilis and HIV-1 co-infection.  
 
Subsequently, during the randomised treatment trials of azithromycin vs benzathine penicillin 
discussed in Chapter 1.9, a proportion of patients underwent lumbar puncture following 
treatment and T. pallidum detection by PCR or RIT was found to be no more common in 
those with HIV-1 infection despite a higher baseline rate of CSF abnormalities (210). 
Subsequent researchers have attempted to identify risk factors associated with neurosyphilis 
in the context of HIV-1 co-infection and have identified association with baseline CD4 counts 
below 350 and RPR titres of 1:32 or more (123, 211). Additionally, those patients with a CD4 
count of less than 200 were 3.7 times less likely to become CSF VDRL negative following 
treatment (212). There is, however, no evidence from longitudinal clinical trials to support the 
use of enhanced syphilis therapy in HIV-1 infected patients. Accordingly, the UK syphilis 
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treatment guideline now advises a single penicillin injection for the treatment of early syphilis 
regardless of HIV-1 seropositivity, although the need for close monitoring for treatment 
failure and CSF examination in the case of suspected treatment failure is stated (104). 
 
The diagnosis of syphilis can also be more difficult in HIV-1 infected patients. There can be a 
delay, seemingly unrelated to CD4 counts, in seroconversion for both treponemal specific and 
non-specific tests; false-positive non-treponemal serological results may be more common 
(213). A new diagnosis of syphilis has also been shown to impact on CD4 counts and viral 
loads of patients with HIV-1 infection. In a study of 41 patients with early syphilis, CD4 
count decreased by an average of 106 cells/mm
3
 (p=0.03) and rose by an average of 66 
cells/mm
3
 following treatment (214). In a larger study comparing HIV-1 infected men with 
(77 patients) and without (205 patients) an incident case of early syphilis the odds ratio of an 
HIV-1 viral load increase was 1.87. Even in those with suppressed HIV-1 replication (HIV-1 
RNA <500 copies/ml blood) on anti-retroviral treatment, a syphilis diagnosis was associated 
with risk of HIV viral load becoming detectable (OR 1.52). CD4 cell counts were also seen to 
fall by an average of 28 cells/mm
3
 following syphilis diagnosis, but returned to previous 
levels after treatment (215). The longer-term impact of these changes, if anything, is unknown 
(216). As a final note, many of the observations made about syphilis treatment failures and 
atypical serological and CSF findings were made in the pre-highly active anti-retroviral 
therapy (HAART) era. It is important to note that HAART reduced the risk of serological 
failure in one study by 60% and thus the impact of HIV-1 on syphilis and vice versa may 
follow a different pattern in the context of effective anti-retroviral treatment (217).  
 
1.12 Measuring the efficacy of treatment 
 
A problem that often faces clinicians is how to ensure that syphilis has been adequately 
treated. The UK syphilis management guideline recommends that serological tests are 
followed for 12 months, or 24 if the patient is HIV-1 infected (104). Treatment failure is 
defined serologically as less than a four-fold fall in the patient’s RPR titre, but is complicated 
by the non-specific nature of the RPR and by patients with latent disease who may have a low 
RPR titre at baseline (104, 218). Moreover, in the context of a clinical trial of a new syphilis 
treatment, such as the recent azithromycin trials, it is necessary to wait for a minimum of six 
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months following the administration of the trial drug to identify treatment success or failure 
(161, 219, 220). 
 
In the early post-penicillin era, silver staining or dark field microscopy of lymph nodes and 
RIT were used to assess T. pallidum persistence both in humans and animals. In one study, 
lymph nodes from 45 patients with penicillin-treated syphilis were examined. Five were 
found to contain treponemal forms on microscopy and two were shown to harbor virulent 
organisms by RIT (221). The authors subsequently re-confirmed their findings but this time 
identifying T. pallidum in 11 of the 45 lymph node samples (222). In a similar study, 40 
patients with treated syphilis and three with untreated disease were investigated for evidence 
of T. pallidum persistence. Of the three untreated patients, one was positive by RIT and 
another had T. pallidum identified by DGM in a sample of aqueous humour. T. pallidum was 
identified by microscopy in samples from 13 of the treated patients, but all were negative by 
RIT (223). These may have been false positive results, as the identification of treponemal 
forms on microscopy is difficult, however, it may also represent the presence of attenuated 
organisms with greatly reduced virulence (224). More recently, researchers have explored the 
use of PCR to replace RIT for direct detection of T. pallidum and for the evaluation of 
patients following treatment. Sensitivity in all specimens except ulcer swabs precludes the 
routine use of PCR in diagnosis, however the persistence of T. pallidum DNA has been noted 
in the CSF of patients following neurosyphilis treatment. In rabbits, PCR has also 
successfully demonstrated the kinetics of T pallidum dissemination following inoculation 
where DNA was reliably detected in the animal’s blood during the active early stage of 
disease (51, 155). No study, however, has used PCR either qualitatively or quantitatively to 
detect T. pallidum in animal or human samples before and immediately following therapy in 
order to measure the treatment response directly. It remains to be seen, therefore, how quickly 
T. pallidum DNA levels fall following the administration of effective treatment and how this 
correlates with standard serological testing. 
 
1.13  Summary 
 
Syphilis is a systemic bacterial infection caused by T. pallidum, which is transmitted both 
sexually and from mother-to-child and is currently resurgent in the UK (1). The primary stage 
consists of bacterial invasion with subsequent haematogenous spread and is characterised by a 
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self-limiting mucosal ulcer. The disease then progresses to the secondary stage and, if 
untreated, to tertiary disease after two to four decades (44). The humoral response to T. 
pallidum infection can be divided into ‘non-treponemal’ antibodies, directed against 
cardiolipin-lecithin-cholesterol complex, and treponemal antibodies directed against bacterial 
proteins. Both antibody types have been exploited for diagnostic tests, the former for 
screening and as a measure of disease activity and the latter for confirmatory testing. An 
arbitrary two-dilution (four-fold) fall in non-treponemal titre is considered to represent an 
adequate treatment response and it is recommended that titres be followed for a year after 
treatment (two years in HIV-positive patients) to diagnose cure. Treatment for syphilis 
became widely available from the mid-20th century following the discovery of penicillin, and 
this remains the preferred treatment option for those without allergy to the antibiotic. Second-
line treatment is usually tetracycline antibiotics, which have been shown in small, 
uncontrolled trials to be effective, but which are contra-indicated in pregnancy. A second 
alternative, the oral macrolide antibiotic, azithromycin, has equivalent efficacy to penicillin 
for the treatment of incubating and early disease but resistance is emerging.  
 
It has been shown using PCR in a rabbit model that the dissemination of T. pallidum after 
inoculation is rapid and wide-spread. Studies exploring PCR for syphilis diagnosis in humans 
find sensitivities of 72-91% in primary chancres, and 24-73% in blood samples and detection 
of treponemal bacteraemia varies according to stage, being greatest in early disease and 
pregnancy (for mother’s with adverse neonatal outcomes) and lowest in latent disease. RT-
PCR has also been described for T. pallidum detection in vitro and has the potential to 
improve detection sensitivity. The use of qPCR has been described in a cross-sectional study, 
but T. pallidum bacterial loads have never been measured longitudinally as a measure of 
treatment response. Syphilis and HIV-1 co-infection is common in the UK and those with 
early syphilis are more likely to both acquire and transmit HIV. It is not known, however, 
whether co-infected patients are more likely to transmit syphilis than those who are HIV-1 un-
infected. The publication of the T. pallidum genome, and that of other treponemal species has 
provided insight into the origins of syphilis and enabled the detailed characterisation of strain 
types. Molecular techniques for strain type analysis have been described and are providing 
useful information for epidemiologists but no data are currently available in England. Finally, 
the genetic identification of macrolide antibiotic resistance mutations is able to inform the use 
of these drugs in specific populations but prevalence of these mutations is currently unknown 
in many countries including the United Kingdom and Sri Lanka. 
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1.14 Hypotheses and aims of the thesis 
 
1.14.1 Hypotheses  
 
1. T. pallidum nucleic acids can be quantified in blood and ulcer exudates taken from 
patients with syphilis. 
2. Bacterial load will correlate with stage of disease and disease activity. 
3. The efficacy of single-dose benzathine penicillin for the treatment of early syphilis can be 
monitored by molecular means. 
4. Macrolide-resistant T. pallidum strains are increasingly prevalent in London as a result of 
antibiotic selection pressure and are likely to be unusual in Colombo, Sri Lanka. 
5. T. pallidum strain types identified in London are distinct from those in Colombo and in 
both populations, strains are associated with demographic and behavioural factors. 
 
1.14.2 Aims 
 
1. To establish the most efficient methods for T. pallidum DNA and RNA extraction from 
blood and ulcer samples.  
2. To select the most appropriate molecular targets for quantification of T. pallidum in 
clinical samples (blood and ulcer exudates). 
3. To design and validate, using samples from human subjects, two qPCR assays for the 
quantification of T. pallidum DNA and RNA. 
4. To establish the blood compartment (whole blood, plasma, PBMCs) in which T. pallidum 
bacteria are most numerous. 
5. To measure T. pallidum bacterial load in samples from patients with different stages of 
syphilis and to correlate this load with standard serological tests. 
6. To design an internal control for monitoring the efficiency of T. pallidum DNA extraction 
from clinical samples and its subsequent amplification by qPCR. 
7. To monitor the clearance of T. pallidum DNA and RNA from blood and ulcer exudates 
collected from patients with primary and secondary syphilis and to correlate these data 
with standard serological outcomes. 
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8. To establish the best clinical samples for strain-type analysis; the utility of including 
tpp0548 sequence analysis in the strain type and to optimise the PCR amplification of the 
typing target gene arp. 
9. To determine the prevalence of macrolide resistant T. pallidum strains at St Mary’s 
Hospital, London, UK and the Colombo district clinics of the National STD/AIDS control 
programme in Sri Lanka. 
10. To determine whether the prevalence of T. pallidum macrolide resistant strains has 
increased over time. 
11. To compare T. pallidum strain types in London and Colombo and to make associations 
between strains and patient demographics.  
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Chapter 2 
Materials and Methods 
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2.1 Controls 
2.1.1 T. pallidum organisms 
Nichols strain T. pallidum organisms were required both for the construction of nucleic acid 
quantification standards and as a source of syphilis DNA for the positive control of PCRs. 
Bacteria were obtained from both Newmarket Laboratories (Newmarket, UK) and the 
University of Washington (Seattle, USA). In both cases the bacteria were passaged in male, 
adult white New Zealand rabbit testes according to a well-defined method (225). Prior to 
suspension in either Phosphate buffered saline (PBS) and 20% glycerol or RNAlater
®
 solution 
(Life technologies, UK), organisms were quantified with darkfield microscopy according to 
the formula: 
              
                                        
                                
 
 
2.1.2 T. pallidum nucleic acids 
 
RNA, to be used as a positive control for reverse transcription and PCR, was extracted from 
10
6
 T. pallidum, stored in RNAlater
®
, using the Roche High Pure RNA Isolation Kit (Roche, 
Mannheim, Germany). The bacteria were first lysed during a 10-minute, 30C incubation with  
4l of 50mg/ml lysozyme solution (Sigma, Gillingham, UK). Following the addition of 400l 
Lysis/Binding buffer the lysed bacteria were applied to a spin column and centrifuged for 15s 
at 8,000g. On column DNAse treatment was then performed for 60 minutes at room 
temperature following the addition of 100l DNAse I (Roche). The column was then washed 
twice, first with 500l of Wash Buffer I, then Wash Buffer II. Following the second wash, the 
column was dried by centrifuging at 13000g for two minutes. Finally, RNA was eluted into 
100L of Roche elution buffer (EB) by passing two 50l aliquots of EB through the column 
each following a one-minute incubation at room temperature. The eluted RNA was stored in 
20L aliquots at -80C. 
 
DNA was also extracted from Nichols strain T. pallidum for use as a positive control. DNA 
from 6x10
6
 organisms in PBS and glycerol was extracted with a Qiagen DNA mini kit 
(Qiagen, Crawley, UK). Nichols organisms were added to Qiagen tissue lysis buffer ‘ATL’ to 
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give a total volume of 180l. Next, 20l Qiagen proteinase K was added and the mixture 
incubated for three hours at 56C. A second lysis step was then performed by adding 200L 
of Qiagen lysis buffer (AL) and incubating for 10 minutes at 70C. Once lysis was complete 
the mixture was added to 200l molecular grade ethanol (Sigma, Gillingham, UK) and 
applied to a spin column. The column was centrifuged at 6,000g for one minute to capture the 
bacterial DNA. Following capture, DNA was washed with 500l of buffer AW1 and then 
500l of buffer AW2. Following the second wash, the column was dried by centrifuging at 
14,000g for three minutes and DNA eluted into 60L of proprietary elution buffer to give a 
concentration of 1x10
6
 genome-equivalents per 10L. 
 
2.1.3 Other pathogenic organisms 
DNA from a number of other bacteria, viruses and fungi, obtained from the Department of 
Microbiology at Imperial College Healthcare NHS Trust, was extracted with the same Qiagen 
method as detailed for T. pallidum above. A full list of organisms is available in Appendix 1. 
 
2.1.4 Tomato Yellow Leaf Curl Virus (TYLCV) 
TYLCV DNA to be used as an internal control for nucleic acid extraction and amplification 
from clinical samples was obtained which had been extracted from approximately 0.15g of 
leaf tissue from Tomato plants (Lycopersicon esculentum) with TYLCV symptoms (Consiglio 
Nazionale delle Ricerche, Istituto per lo Studio degli Ecosistemi, Li Punti, Italy) (226).  
 
2.1.5 Syphilis-negative human blood 
Blood was collected into EDTA or Tempus™ collection tubes from healthy human 
volunteers. It was deemed syphilis-free using the Newmarket IgM/IgG enzyme immunoassay 
(EIA), (Alere, Stockport, UK). Additional syphilis-free human whole blood was obtained 
from the NHS Blood and Transplant Service. Blood from both sources was stored in 500L 
aliquots at -80C.  
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2.2 Clinical sample handing 
 
2.2.1 Whole blood samples 
Following the withdrawal of two or three 500l aliquots of whole EDTA blood, the remainder 
of the sample was added gently to a 15ml Falcon tube containing histopaque (Sigma, UK). 
(The volume of Histopaque was equivalent to 60% that of the blood volume). The sample was 
then centrifuged at 1000g for 20 minutes at room temperature. The plasma and buffy coat 
were removed carefully with Pasteur pipettes and stored separately at -80C prior to DNA 
extraction.  
 
For samples received after Dec 2006, EDTA blood was no longer separated with Histopaque. 
Instead, either two 500l aliquots of blood were added to 500l of 2x lysis buffer (20mM Tris 
pH 8, 0.2M EDTA, 1% SDS) and stored at -80C, or whole blood was simply stored at -80C 
in 400l aliquots. From Jan 2011, a further 1ml aliquot was centrifuged for five minutes at 
8,000g and room temperature to separate plasma, which was then stored at -80C. 
 
2.2.2 Snostrip samples 
Sterile filter paper Snostrips (Chauvin, France) were used to collect the exudate from ulcers 
(genital, perianal, oral) and condylomata lata. Ulcers were first cleaned and abraded with 
sterile gauze and water, as though preparing for dark ground microscopy. Exudate from the 
ulcer was then absorbed onto the snostrip until it reached the notch (see Figure 2.1), or until 
the ulcer was dry (whichever was sooner). The strip was then cut transversely along line two 
using a sterile, disposable scalpel blade and section ‘A’ placed either into 1.3mL of 
RNAlater
®
 solution or into an empty, sterile 1.5ml microcentrifuge tube. 
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Figure 2.1 Method for ulcer exudate collection 
 
 
 
Fig 2.1 Exudate was absorbed onto a filter paper snotrip in the direction of the arrow (1) until 
it reached the notch. The strip was then cut transversely along line two with a sterile blade and 
section ‘A’ retained. 
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2.2.3 Tempus™ tubes for blood collection and RNA stabilisation  
 
Three millilitres of blood were collected directly from patients into Tempus™ vacutainer 
tubes (Applied Biosystems, Carlsbad, CA). The tubes were supplied pre-filled with 9ml of a 
proprietary solution containing guanidine and detergent which simultaneously inhibited 
RNAses; stablilised RNA; lysed blood cells and selectively precipitated RNA in micelles. If 
RNA was not being extracted immediately, tubes were frozen at -80C. 
 
2.3 Nucleic acid extraction techniques 
2.3.1 DNA extraction from whole blood, plasma and PBMCs 
 
T. pallidum DNA was extracted from whole blood, plasma and PMBCs using one of two 
methods. The first method, for samples prior to Jan 2011, was based on the Qiagen QIAamp 
DNA Blood Mini Kit, protocol version Feb 2003 as follows: 400l of whole blood, buffy coat 
or plasma were added to 40l of Proteinase K (Qiagen, Crawley, UK). Following the addition 
of 400l of lysis buffer (AL) the sample was incubated at 56C for three hours. Next, 200l 
of molecular grade ethanol (Sigma, UK) were added and the mixture applied to a QIAamp 
spin column. The DNA was then washed with ethanol-containing buffers AW1 and AW2 
prior to elution into 120l of PCR-grade water (Sigma, UK). 
 
The second method, for DNA extraction from whole blood in 2x lysis buffer, used the Qiagen 
QIAamp DNA blood midi kit. A positive control of 500L syphilis seronegative blood spiked 
with 5000 T. pallidum organisms in RNAlater
®
 and a negative control of 1mL 2x lysis buffer 
were included with each extraction. A maximum of eight samples were extracted 
simultaneously. 
Firstly, 1ml of blood and lysis buffer mixture was added to 100L proteinase K (Qiagen, 
Crawley, UK) and 1.2ml AL buffer, then vortexed and incubated at 65C for three hours. 
Next, 1ml molecular grade ethanol was added to the sample and the voretexed mixture 
applied to a midi prep glass-fibre column. Following centrifugation at 1850g and 4C for 
three minutes, the filtrate was discarded and the column washed first with 2ml of buffer AW1, 
then 2ml of buffer AW2. For elution of extracted DNA, the column was placed into a clean 
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tube and 200l of water applied to the membrane. Following a five-minute incubation at room 
temperature, the column was centrifuged at 4500g for five minutes. The process is then 
repeated with a second 200l of EB. The eluted DNA was then concentrated by ethanol 
precipitation. 
2.3.2 Ethanol precipitation of DNA 
 
Extracted DNA in water was added to 2.5 volumes of 100% molecular-grade ethanol; 0.1 
volumes of 3M sodium acetate; 2l glycogen from mussels (Roche, Paisley, UK) and mixed 
by inverting the tube. Glycogen is a carrier that binds to DNA, making it visible and easier to 
handle. Following precipitation at -20C for two hours (or overnight), samples were 
centrifuged for 30 minutes at 16,000g and 4C. Two washes with 500l 75% ethanol and 5 
minute centrifuges of 9,500g at room temperature produced a DNA-glycogen pellet, which 
was dried at 62C for 1-2 minutes, then re-suspended in 60l of EB and stored at -80C in 
four 15l aliquots. 
 
2.3.3 RNA extraction from blood 
2.3.3.1 Tempus™ collection and extraction system 
RNA from blood collected into Tempus™ tubes was extracted according to the 
manufacturer’s protocol. Positive (Tempus™ tubes filled with 3ml of syphilis-negative blood 
and 5000 T. pallidum organisms in RNAlater
®
) and Negative (3ml PBS) controls were 
extracted together with up to 8 clinical samples in each batch. Following storage at -80C, 
samples and controls were thawed, then added to 3ml of PBS in 50ml Falcon tubes to give a 
total volume of 12ml and vortexed for 30 seconds. The mixture was then centrifuged at 3000g 
and 4C for 30 minutes. Next, the lysed blood was decanted carefully, the tube allowed to dry 
partially, and the remaining RNA pellet re-suspended in 400l of resuspension solution. The 
RNA was adsorbed onto silica contained in a spin column and DNA digested enzymatically 
by adding 100l of AbsoluteRNA wash solution (DNAse) (Applied Biosystems, Carlsbad, 
CA) and incubating at room temperature for 15 minutes. The captured RNA was washed 
twice with wash solutions one and two and, finally, eluted into 100L of elution solution 
following a two-minute incubation at 70C. 
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2.3.3.2 Alternative methods assessed 
Ambion Ribopure™ Kit 
 
The Ribopure™ kit (Ambion, UK) comprised cell lysis in a guanidinium-based solution, 
followed by purification with phenol/chloroform and solid-phase extraction on a glass fibre 
filter. To assess suitability of the method, 500L of EDTA whole blood in 1.3ml RNAlater® 
solution were spiked with 2,000 T. pallidum organisms. Following centrifugation at 14,000g 
for 1 minute, the pellet was resuspended in a proprietary lysis solution and 3M sodium 
acetate. Acid-Phenol Chloroform was added and the RNA, which dissolved in the upper 
aqueous layer. This RNA-containing layer was then removed and applied to a column-based 
glass fibre filter. Now bound to the filter, the RNA was washed and finally eluted into 50L 
of proprietary elution solution. Next, contaminating gDNA was removed by the addition of 
2.5l of DNAse buffer (Ambion, UK) and eight units of DNAseI (Ambion, UK). Following 
incubation at 37C for 30 minutes, 10l of DNAse inactivation agent (Ambion, UK) were 
added, the mixture vortexed and incubated at room temperature for one minute. The 
inactivation agent was then removed by pelleting it in a centrifgue at 12,000g for one minute. 
The DNAse-treated RNA was then transferred to a clean RNAse-free micro-centrifuge tube. 
 
Magnetic-bead capture of human RNA species (Ambion MicrobEnrich™ kit) 
 
Human mRNA was depleted from blood-extracted RNA samples (Tempus™ extraction 
system) in order to reduce T. pallidum PCR inhibition. The MicrobEnrich™ system was 
designed to enrich bacterial RNA from mixtures also containing human RNA. Human mRNA 
is polyadenylated at the 3’ end and, in this procedure, becomes bound to magnetic beads 
bearing polythymidylated capture oligonucleotides. The beads are then pulled out of the 
sample using a magnet and discarded, leaving only bacterial RNA in solution. Briefly, in the 
final step of Tempus™ RNA extraction, EDTA (Sigma, Gillingham, UK) was added to the 
elution buffer at a final concentration of 1mM, to chelate any divalent cations present. The 
RNA was mixed with RNA binding buffer and capture oligonucleotide mix, heated to 70C 
for 5 minutes to denature any RNA secondary structures, then incubated for an hour at 37C 
to allow hybridization. Prepared and equilibrated magnetic beads were added to the RNA-
oligonucleotide mixture and incubated at 37C for 15 minutes to allow binding. Finally, the 
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mixture was placed on a magnetic stand, the beads were captured and bacterial RNA in the 
resultant supernatant was precipitated and concentrated with ethanol-glycogen precipitation.  
 
2.3.4 Nucleic acid extraction from Snostrip samples 
 
In the T. pallidum qPCR validation study, ulcer exudates were absorbed onto snostrips as 
described in Figure 2.1, then stored ‘dry’ in screw-cap microcentrifuge tubes. Those samples 
collected for the Communciable Diseases Tissue Biobank (CDTB) were added to 500l 1x 
lysis buffer (10mM Tris pH 8, 0.1M EDTA, 0.5% SDS) prior to storage. Finally, samples 
collected for the in vivo treatment kinetics study (Chapter four) and the cross-sectional study 
of T. pallidum macrolide resistance in Sri Lanka (Chapter five) were stored in 1.3mL of 
RNAlater
®
 solution. 
2.3.4.1 DNA extraction from ulcer samples (snostrips)  
 
Snostrips stored in lysis buffer were first vortexed, then a 200l aliquot was added to 25l 
Proteinase K and incubated at 56C for one hour. An aliquot of 200l of buffer AL was then 
added, the sample vortexed and incubated for a further 10 minutes at 70C. Next, 200l 
molecular grade ethanol were added and the mixture applied to a QIAamp spin column. 
Following one minute of centrifugation at 6,000g, the filtrate was discarded and the sample 
washed with buffers AW1 and AW2 before a final centrifugation (to dry the column) at 
20,000g for one minute. The DNA was eluted using 200 l of EB, passed through the column 
in two 100l aliquots, each with a five-minute incubation prior to a one-minute centrifuge at 
6,000g.  
Those strips stored dry were first added to 400l PBS and 20l Proteinase K prior to 
incubation at 56C for three hours. Following this enzymatic digestion, 400l ethanol were 
added and the mixture applied to a QIAamp mini-prep spin column (Qiagen, Crawley, UK). 
The column-adsorbed DNA was then washed with buffers AW1 and AW2 prior to elution 
into 120l of molecular grade water. 
Finally, DNA from strips stored in RNA later solution was extracted in combination with 
RNA using an all-prep DNA/RNA mini kit (Qiagen, Crawley, UK). 
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2.3.4.2 DNA/RNA co-extraction from ulcer snostrip samples using a Qiagen all-prep mini  
kit 
 
The manufacturers of RNAlater
® 
solution, designed to protect RNA from degradation during 
storage, state that DNA can also be efficiently extracted from samples stored in the solution. 
For the study of clearance kinetics, one ulcer sample was to be taken at each time point, but 
both RNA and DNA needed to be quantified in that sample. During this process, the DNA 
and total RNA from samples were extracted concurrently. A positive control (snostrip spiked 
with 5,000 T. pallidum organisms in RNAlater
®
) and a negative control (an unspiked snostrip 
in RNAlater
®
) were extracted together with up to eight clinical samples in each batch. 
Samples were kept on ice whenever possible, and RNAse ZAP solution (Ambion, UK) was 
used to decontaminate thoroughly pipettes; racks; centrifuges and work-surfaces prior to 
handling RNA. 
 
Snostrips in 1.3ml RNAlater
®
 (stored at -80C) were first thawed thoroughly, then 
centrifuged at 14,000g and 4C for 30 minutes. Next, 1.1ml of RNAlater® were carefully 
removed and discarded. The remaining sample (200l) was added to 600l of buffer RLT 
plus which contains a highly denaturing guanidine-isothiocyanate buffer and 0.143M β-
mercaptoethanol (β-ME), both to disrupt cells and to inactivate DNAses and RNAses. The 
mixture and the paper strip, were placed into a QIAshredder column (Qiagen, Crawley, UK) 
and centrifuged at 14,000g and 4C for one minute to homogenise the lysate. The lysate was 
passed through a DNA all-prep spin column, which due to the high salt buffer selectively 
bound DNA, leaving the unbound RNA from the sample in the eluate. This RNA, once added 
to an equal volume of ethanol to allow efficient RNA binding, was captured on an RNeasy 
spin column. Leaving the DNA columns on ice, the column-captured RNA was washed with 
700l buffer RW1, then two 500l aliquots of buffer RPE. Finally, the RNA was eluted into 
60l of RNAse-free water and stored in 4x15l aliquots and DNA extraction was completed 
with two wash steps, as described in 2.3.4.1, and elution into 100l of water (stored as 5x20l 
aliquots). Both DNA and RNA aliquots were stored at -80C prior to qPCR (or RT-qPCR). 
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2.4 Extraction of DNA from agarose gels 
 
The following methods for gel extraction and PCR purification were carried out according to 
the Qiagen QIAquick spin protocol, March 2008. The DNA fragment to be purified was 
separated and identified according to size by 2% agarose gel electrophoresis. The fragment 
was then excised with a clean scalpel and added to three volumes of buffer QG prior to 
incubation at 50C for 10 minutes. Once fully dissolved, the agarose was added to one 
volume of isopropanol, mixed and applied to a Qiaquick column. The column-adsorbed DNA 
was then washed with 500l of buffer QG, to remove any remaining agarose, then 750l of 
ethanol-based buffer PE to remove unwanted salts. The column was dried by full-speed 
centrifugation and DNA eluted with 50l of the basic and low-salt buffer EB. 
 
2.5 PCR product purification 
 
PCR product was added to 5 volumes of buffer PB and 10l of 3M Na acetate (pH 5), as a pH 
<7.5 is required for efficient DNA binding to the purification column. Once applied to the 
column, the DNA was washed with 750l of buffer PE and then eluted into 50l of buffer 
EB. 
 
2.6 Gene sequence analysis 
 
Chain-termination or ‘Sanger’ gene sequence analysis confirmed the presence of macrolide 
resistance-associated point mutations; to confirm the cloned plasmid sequences and to 
identify the requisite tpp0548 sequence for T. pallidum strain type analysis. In this method, a 
DNA polymerase was used to amplify the target sequence of either the sense or antisense 
strand of the target DNA in a primer-specific reaction. (227) The sequencing reaction mix 
contained additional modified nucleotides which lack a 3’-hydroxyl group and are 
fluorescently labeled – each nucleotide (A,C, T or G) emitting light at a different wavelength. 
During the sequencing reaction, DNA polymerase was blocked at random each time a 
modified nucleotide was incorporated resulting in different length oligonucleotides. 
Subsequently, when separated electrophoretically, the fluorescence of each oligonucleotide 
length was read in ascending order of nucleotide size to produce a DNA sequence. 
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Sequencing reactions and electrophoresis were achieved using the Applied Biosystems 
dRhodamine kit and 3100 capillary sequencer. 
 
Target DNA was generally sequenced in both the forward and reverse directions by addition 
of sense or antisense primers, respectively. A consensus sequence was then established by 
comparing the chromatograms of both sequences. 
 
2.7 Reverse transcription of RNA to cDNA 
 
This method used the enzyme reverse transcriptase to convert RNA into complementary DNA 
(cDNA). It was performed either in a ‘one-tube’ reaction, where sequence specific primers 
both reverse transcribed and subsequently PCR-amplified the target sequence, or in two 
separate reactions.  
 
Two-step reverse transcription began with elimination of any contaminating gDNA by 
DNAse treatment. gDNA wipeout buffer (Qiagen, Crawley, UK) was added to RNA and 
water to give a total volume of 14l. The reaction was then incubated at 42C for two minutes 
before being placed on ice. Following DNAse treatment, all 14l of the reaction were added 
to 1l of reverse transcriptase (Qiagen, Crawley, UK), 4l 5x reaction buffer (containing 
magnesium and an RNAse inhibitor) and 1l of dNTPs and the resulting mixture incubated at 
42C for 15 minutes. The reverse transcriptase was then inactivated during a final incubation 
for 3 minutes at 95C. 
 
2.8 Site-directed mutagenesis 
 
A splice-overlap PCR created a mutated allele of the T. pallidum tpp047 gene in which a 25 
base-pair sequence is replaced with an alternative probing sequence. (228) Ultimately, a 
known amount of the mutated sequence was added to clinical samples prior to processing to 
serve as an internal control of the efficiency of DNA extraction and PCR amplification of 
tpp047. Co-extraction and amplification of the internal control from samples with wild-type 
sequence thus controlled for PCR inhibition and the efficiency of extraction, amplification, 
and quantification of tpp047.  
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Three rounds of PCR were required for the creation of the internal control sequence (Figure 
2). In round one, primers TP3 and TP4 were used to amplify a 1357 base-pair section of the 
Nichols T. pallidum strain tpp047 gene. PCR product was identified by agarose gel 
electrophoresis and gel-extracted as before. 
 
In the second round of PCR, the gel-extracted PCR product from round one was added to two 
reactions. The first contained the sense primer from round one (TP3) and an antisense primer 
(TP5) complementary to 19bp of the negative strand immediately downstream of the probe-
binding site. The second contained the antisense primer from round one (TP4) and a sense 
primer (TP6) complementary to 19bp of the positive strand upstream of the probe-binding 
site. Both primers, TP5 and TP6, were 5’-tailed with the internal control probe sequence. 
Reactions conditions were as for round one. The two reactions of this round of PCR created 
two amplicons, both tailed with the internal control probe sequence. 
 
In the third round, equimolar concentrations of the round two amplicons were added to a 
single PCR with conditions and primers otherwise identical to round one. During this 
reaction, the complementary internal control sequences from the two amplicons anneal and 
are extended by the TP3 and TP4 primers to produce DNA where the internal control 
sequence is flanked on either side by the tpp047 sequence from round one.  
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Figure 2.2 Construction of an internal control  
 
 
 
 
Fig 2.2. Three rounds of PCR were performed. In the first (not shown), primers TP3 and TP4 
(Appendix 2) amplified the target section of the tpp047 gene. During round two the primer 
pairs TP3&TP5 and TP4&TP6 produced two tpp047 amplicons, during two separate 
reactions, which were 5’-tailed with the 19bp internal control sequence. In the third round, the 
round two products annealed and were extended using primers TP3&TP4. Thick lines 
represent internal control sequence and dashed lines show extension of annealed 
complementary internal control probe sequence (228). 
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2.9 Construction and quantification of plasmids  
 
TA-cloning was employed to create six plasmid constructs, each containing one of the six 
sequences described in Table 2.1. Following PCR-amplification of the relevant sequence, 
ligation into 1l of pcr4-TOPO cloning vector (Invitrogen, Paisley, UK) (Appendix 4) was 
carried out at room temperature for five minutes using 4L of the relevant PCR product and a 
salt solution containing 200mM NaCl and 10mM MgCl2. The cloning vector is supplied in a 
linearised form with a single thymidine 3’ overhang and the enzyme topoisomerase bound 
covalently to the vector in an activated form. Taq polymerase automatically adds an adenine 
base to the 3’ end of the DNA it synthesizes, in a non-template dependent process, thus the 
complementary overhangs of vector and PCR product allow efficient combination. TOP-10 
chemically competent E. coli (Invitrogen, Paisley, UK) were then transformed with the 
plasmids produced. An aliquot of 2l of the ligated cloning vector was added to the E. coli 
and mixed gently prior to a 30-minute incubation on ice. The bacteria were then heat-shocked 
by placing in a 42C water bath for 45 seconds followed immediately by a further two-minute 
incubation on ice. During this process, the bacteria are transformed by internalising ligated 
cloning vector. Transformed cells were incubated for one hour at 37C in 250l SOC 
medium, to allow expression of the plasmid-encoded ampicillin (Bla) resistance gene, prior to 
inoculation onto ampicillin-containing agar plates and incubation at 37C overnight. 
Successful transformants produced colonies from which one was chosen for further culture 
and added to 100ml of lysogeny broth (LB) containing 100mg/ml ampicillin for incubation in 
a 37C shaking incubator overnight.  
 
Plasmid DNA was extracted from the above culture using a Qiagen Plasmid mini kit (Qiagen, 
Crawley, UK). Bacteria were harvested from the 100ml LB culture by centrifugation at 6000g 
and 4C for 15 minutes. Pelleted bacteria were then resuspended in 0.3ml of buffer P1 (50mM 
Tris.Cl pH 8.0;10mM EDTA). Next, 0.3ml of alkaline Buffer P2 (200mM NaOH; 1% SDS) 
was added and the bacteria lysed during a 5-minute incubation. Following the addition of 
300l of chilled buffer P3 (3.0M Na acetate, pH 5.5) and incubation on ice for 5 minutes, the 
precipitated gDNA, proteins and cell debris are removed by centrifugation at full-speed for 10 
minutes. A Qiagen-tip column was next equilibrated with 1ml buffer QBT (750 mM NaCl; 
50mM MOPS, 15% isopropanol, 0.15% Triton X-100) and the supernatant, containing 
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plasmid DNA, applied to the column. Captured in the column resin, the plasmid DNA was 
then washed with 2 x 2ml aliquots of buffer QC (1 M NaCl; 50mM MOPS; 15% 
isopropanol). The DNA was finally eluted, by passing 800l buffer QF (1.25 M NaCl; 50mM 
Tris.Cl, pH 8.5; 15% isopropanol) through the column, then precipitated by adding 560l 
isopropanol, mixing and centrifuging at 15,000g for 30 minutes at room temperature. The 
DNA pellet was then washed by adding 1ml of 70% ethanol and centrifuging for another 10 
minutes at 15,000g. Once washed, the pellet was air-dried and re-dissolved in 200l of 
Qiagen buffer TE (10mM Tris.Cl, pH 8.0; 1mM EDTA). 
 
The concentration of extracted plasmid DNA (g/l) was determined by spectrophotometry 
using a P360 UV/visible nanophotemeter (Implen, Munich, Germany) The number of plasmid 
copies was then calculated by first multiplying this by Avogadro’s constant and subsequently 
dividing this concentration by plasmid weight. The weight of one plasmid is equal to its 
length (in base pairs) multiplied by the molar mass (g/mol) of a single base pair. 
 
 
             
                                                            
                                   
 
 
 
Confirmation that the plasmids contained the desired T. pallidum or TYLCV sequences was 
achieved with gene sequence analysis.  
 
Following construction, plasmids were linearised in order to improve the efficiency of 
downstream reactions and assays. Linearisation was achieved either with the restriction 
enzyme nco-I (New England Biolabs, Ipswich, MA), which makes a single cut in the plasmid, 
or by excision of the requisite T. pallidum sequence from the plasmid by restriction digestion 
with Eco-R1 (New England Biolabs, Ipswich, MA) and subsequent gel-extraction. 
Nco-I restriction digestion was performed on plasmids pTYLCV, pTp47, pTpQC and 
p16SRNA. The remainder were Eco-RI digested. The conditions used for endonuclease 
restriction digestion are detailed in Appendix 3. 
 
Following linearisation and quantification by spectrophotometry, plasmids pTp47; p16SRNA 
and pTYLCV were re-analysed with real-time PCR in a series of limiting dilution assays in 
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order to construct standard curves for T. pallidum and TYLCV quantification. By knowing 
the starting quantity of DNA and the probability of a negative reaction at a given dilution it is 
possible, using the following equation, to calculate gene copy number. (229) 
 
                         
   [                                ]                  
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Table 2.1 Plasmids constructed for the project 
 
Table 2.1. A total of seven plasmids were constructed for use as quantification standards and 
positive controls. 
1. pTpQc 
Partial tpp047 sequence (1357bp) mutated to contain the internal control sequence. 
 
2. pTp47 
Partial (326bp from 409 to 715) tpp047 sequence from T. pallidum Nichols strain (Genbank 
ref: AE000520). Sequence amplified with primers Tpnest4F and Tpnest4R (Appendix 2). 
 
3. pTp2058 
Partial (629bp) 23S rRNA gene sequence from Street 14 strain (Genbank ref: AF200365). This 
section of the gene is identical for both copies of the gene (located 231950 to 234850 and 
280394 to 283294). Sequence amplified with primers A2058G_F and A2058G_R (Appendix 
2). 
4. pTp2059 
Partial (629bp) 23S rRNA gene from UW228B, an A2059G mutant. Sequence amplified with 
primers A2058G_F and A2058G_R (Appendix 2). 
 
5. p16SRNA 
Partial (131bp) 16SrRNA gene from T. pallidum nichols strain (Genbank ref: AE000520, bases 
231464 to 231593). Sequence amplified with primers 16S_F(seattle) and 16S_R7. 
 
6. pTYLCV 
Partial (100bp) sequence of TYLCV virus (Genbank ref: X61153.1). Sequence amplified with 
the primers TYLCV_F3 and TYLCV_R3 (Appendix 2). 
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2.10 Point mutation analysis for macrolide resistance 
 
The identification of two base substitutions, from adenine to guanine at positions 2058 and 
2059 of the T. pallidum 23S rRNA gene, was achieved with PCR-amplification followed by 
restriction digestion and gene sequence analysis. (169)  
 
Two 629 base-pair sections, one from each copy of the T. pallidum 23srRNA gene (Genbank 
ref. AF200367), were PCR-amplified from extracted DNA using two rounds of PCR. In the 
first round, the primers TP0226_F and TP0226_R amplified the first allele, and TP0267_F 
and TP0267_R the second allele (Appendix 2). Each reaction contained: 1 unit FastStart Taq 
DNA polymerase (Roche, Mannheim, Germany), 0.2 M of each primer, 1x reaction buffer 
containing 20mM MgCl2 (Roche, Mannheim, Germany), 0.2mM PCR grade nucleotide mix 
(Roche, Mannheim, Germany) 5L of target DNA and PCR-grade water to a total volume of 
50L. Cycling conditions were as follows: three minutes at 93C followed by 35 cycles of 
93C for one minute, 62C for 2 minutes and 72C for one minute and a final 72C extension 
step for 10 minutes.  
 
Conditions for the second round were identical, except for an annealing temperature of 63C; 
the primers A2058G_F and A2058G_R (Appendix 2) for both alleles and the addition on 1L 
of product from round one in place of 5L DNA. 
 
Separate aliquots of each amplicon were subject to restriction digestion using the 
endonuclease Mbo-II (New England Biolabs, Ipswich, MA) at 37C for 1 hour, or Bsa-I (New 
England Biolabs, Ipswich, MA) at 50C for one hour, as previously described (169, 170) 
(Appendix 3). The resultant DNA fragments were analysed by two percent agarose gel 
electrophoresis, which revealed bands of 440bp and 188bp for a positive Mbo-II digest (ie. an 
A2058G mutant) and 432bp and197bp for a positive Bsa-I digest (ie. an A2059G mutant). 
Additionally, the gene sequence of a third, undigested, aliquot was determined using the 
primer A2058G_F. The plasmids pTp2058 and pTp2059, containing DNA from Street 14 
strain (A2058G mutant) or UW228B (A2059G mutant) respectively, constituted positive 
controls for restriction digestion and Nichols strain T. pallidum was the negative (wild-type) 
control.  
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2.11 T. pallidum strain type analysis 
 
T. pallidum strain identification was based on the analysis of the genes arp, tpr and tpp0548, 
as described previously. (82, 86) A no-template control (molecular-grade water) and a 
positive control (Nichols strain T. pallidum) were included in each PCR. 
 
2.11.1 arp analysis by PCR 
arp analysis began with PCR-amplification of the arp gene by adding 0.4M each of the  
primers ARP_F and ARP_R (Appendix 2); 2 units of FastStart Taq polymerase; 200M PCR 
grade nucleotide mix; 1mM MgCl2 and 1x PCR reaction buffer to 5L DNA and making up 
to 50L with molecular-grade water. Cycling conditions were as follows: 94C for 4 minutes; 
40 cycles of 94C, 60C and 72C, each for one minute, and finally 10 minutes at 72C. The 
amplicons were of varying size depending on the number of identical 60bp repeats they 
contained. Determination of the number of repeats gave the arp type. 
 
For size-determination, samples were applied to a 2% agarose gel and run, together with a 
100bp ladder (Invitrogen, paisley, UK), at 70V for around six hours. The gel was analysed 
using LabWorks Image Acquisiton and Analysis Software version 4.6 (Media Cybernetics 
Inc, Bethesda, USA). The size of each amplicon was compared to that of the Nichols strain, 
known to have 14 60bp repeats. Each 60bp difference represented a different type, and was 
numbered accordingly.  
 
2.11.2 tpr analysis 
tpr analysis also begins with PCR amplification by adding 0.4M each of the primers EGJ_F 
and EGJ_R (Appendix 2); 1 unit of FastStart Taq polymerase; 200M Roche PCR grade 
nucleotide mix; 1x Roche PCR reaction buffer containing 20mM MgCl2) to 5L DNA and 
making up to 50L with molecular-grade water. Cycling conditions were as for arp 
amplification. Amplicons were subsequently PCR-purified using the QIAquick purification 
system, as described before, and digested for one hour at 37C with the endonuclease Mse-I 
(New England Biolabs, Ipswich, MA) (Appendix 3). In order to compare restriction digestion 
patterns, DNA fragments were separated by two percent agarose gel electrophoresis run at 
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100v for 2-5 hours with a 1kb ladder. The resultant band compositions were compared with 
standard profiles (82).  
 
2.11.3 tpp0548 typing 
tpp0548 typing requires amplification and sequence analysis of a section of the tpp0548 gene. 
(86) The PCR used the primers 548_S and 548_AS3 (Appendix 2) in a reaction with the same 
reagents and concentrations as for tpr amplification described previously. Cycling conditions 
were as follows: 95C for 4 minutes; 40 cycles of 95C, 62C and 72C each for one minute 
and finally 10 minutes at 72C. The amplified DNA was then PCR purified, as before, and 
sequenced in both directions using the primers 548_S and 548_AS (Appendix 2). The 
sequence is matched to one of eight established sequences and assigned a letter (Figure 2.3). 
The three components of the strain type are then assembled and presented in the order arp, 
tpr, tpp0548. For example: ‘14d/g’ which has 14 60bp repeats in arp, MseI tpr digestion 
pattern ‘d’ and tpp0548 gene sequence ‘g’. 
 
 79 
Figure 2.3 T. pallidum subtypes identified by gene sequence analysis 
 
                10        20        30        40        50        60        70        80      
       ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|. 
 
a      CAGGCGGCAGTGGCCACAGCCGC---AGGGTCCAGTGGTTCCGGCAGTGATGGCAAGCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
b      CAGGCGGCAGTGGCCACAGCCGC---AGGGTCCGGTGGTTCCGACAGTGATGGCAAGCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
c      CAGGCGGCAGTGGCCACAGCCGC---AGGGTCCAGTGGTTCCGACAGTGATGGCAAGCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
d      CAGGCGGCAGTGGCCACAGCCGC---AGGGTCCAGTGGTTCCGACAGTGATGGCAAGCACCCCGGCAAGGAACAGTTTCTCAAGTT  
 
e      CAGGCGGCAGTGGCCACAGCCGCTGGAGTGTCCAGTGGTTGCAGCGATAATGGCAACCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
f      CAGGCGGCAGTGGCCACAGCCGCTGGAGGGTCCAGTGGTTGCAGCGATAATGGCAACCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
g      CAGGCGGCAGTGGCCACAGCCGCTAGAGAGTCCAGTGGTTGCAGCGATAATGGCAACCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
h      CAGGCGGCAGTGGCCACAGCCGC---AGGGTCCAGTGGTTCCGACAGTGATGGCACGCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
i      CAGGCGGCAGTGGCCACAGCCGCTGGAAGGTCCAGTGGTTGCAGCGATAATGGCAACCACCCCGGCAAGGAACAGTTTCTCCAGTT  
 
 
Fig. 2.4. In the enhanced method for strain-type analysis, a third T. pallidum gene, tpp0548, is 
PCR-amplified and its sequence determined in both direction with dye-termination 
sequencing. The consensus sequence is then compared with published sequences a-i (86). 
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2.12 T. pallidum quantification by polymerase chain reaction 
 
Real-time, quantitative PCR (qPCR) was used to quantify T. pallidum nucleic acids in clinical 
samples. In a qPCR, fluorescent dyes included in the reaction are used to measure the amount 
of DNA present at the end of each cycle. Changes in fluorescence are used to calculate the 
amount of DNA present in samples at the beginning of the qPCR. The LightCycler 2.0 real-
time system (Roche, Mannheim, Germany) and SYBR-green I dye were used initially, but 
subsequently replaced with the CFX96 real-time system, C1000 thermal cycler (Biorad, 
Hercules, USA) and fluorescently labeled TaqMan probes. 
 
2.12.1 DNA quantification 
2.12.1.1 Quantification of tpp047 in vitro by Roche LightCycler  
 
A 178bp segment of the 1377bp T. pallidum tpp047 gene (Genbank accession number 
M88769.1) was amplified using the primer pair TP1 and TP2 (Appendix 2) (nucleotides 525 
to 547 and 702 to 680 respectively). Each reaction contained: 10µL extracted DNA; 0.6 units 
LightCycler Uracil-DNA Glycosylase (UDG) (Roche, Mannheim, Germany); 0.5μM of each 
primer; 4µL FastStart Plus reaction mixture (Roche, Mannheim, Germany) (containing 
FastStart Taq DNA polymerase, reaction buffer, MgCl2, SYBR Green I dye and dNTP mix), 
and PCR-grade water to a final 20µL volume.  
Real-time PCR was performed using a Roche LightCycler 2.0, software version 4.0, with the 
following conditions: UDG activation at 40°C for 10 minutes, pre-incubation at 95C for 10 
minutes and then 46 cycles of: 95°C for 10 seconds; 60°C for five seconds; 72°C for eight 
seconds, and 81°C for 10 seconds (acquisition). Two no template controls (water) were 
included in each experiment and standard precautions to avoid contamination were employed. 
Samples were run in duplicate and discordant results were repeated. Negative samples were 
diluted 1:10 and repeated if inhibition suspected. Melting curve analysis was performed on all 
amplicons from clinical samples and compared to an in-run standard in order to confirm 
amplification of the correct target. Fluorescence emission in the 530nm channel at a linear 
temperature transition rate of 0.1º/s from 60ºC to 95ºC was monitored with continuous 
acquisition. The melting temperature (Tm) of the correct 178bp amplicon was 82.5ºC.  
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The T. pallidum DNA used for both the in-run standard curve and positive PCR control was 
derived from Nichols organisms as described in Chapter 2.1.2. 
2.12.1.2 tpp047 quantification with the Biorad CFX Real-time system 
 
This method replaced SYBR green I (above) with a fluorescent TaqMan probe. The probe 
was a 25bp oligonucleotide with the dye Carboxyfluorescein (6-FAM) added to the 5’ end 
and the ‘quencher’ tetramethylrhodamine (TAMRA) capping the 3’ end. When in proximity 
(ie. bound to the oligonucleotide) the fluorescence of 6-FAM is quenched by TAMRA. 
During the PCR, the probe binds to the single-stranded DNA template. Taq polymerase 
exhibits 5’-3’ exonuclease activity and when it meets the probe during the extension phase it 
cleaves the fluorophore such that its fluorescence is no longer quenched (Figure 2.4). As the 
PCR proceeds, the level of fluorescence increases in parallel with the amount of PCR product.  
As with the SYBR green I assay, a crossing point is established which represents the starting 
copy number. In contrast, the quantification standard used with this method is the plasmid 
pTp47. 
Each reaction contained 12.5l 2x Quantitect PCR mix (Qiagen, UK) (reaction buffer, 8mM 
MgCl2, dNTPs and HotStarTaq DNA polymerase); 0.4M each of the primers TP1 and TP2; 
0.2M of TPP probe; 5l DNA and water to a total volume of 25l. Cycling conditions 
consisted of 15 minutes at 95C for Taq activation, then 44 cycles of 95C for 15 seconds and 
80 seconds at 60C (combined annealing and extension step). Samples were run in triplicate 
and those with only a single positive replica were repeated. Each run contained a 
quantification standard of pTp47 diluted 1:10 from 10
5
 to 10 copies and two no-template 
(water) controls.  
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Figure 2.4 Mechanism of action of ‘TaqMan’ PCR probes 
 
 
 
 
 
Fig. 2.5. Initially, the ‘TaqMan’ probe (black line) ‘fluorophore’ (F) is in close proximity to 
the ‘quencher’ (Q) and does not fluoresce. Following sequence-specific binding to template 
DNA the fluorophore and quencher are separated when taq polymerase (T), which possesses 
5’-3’ exonuclease activity, arrives at the probe binding site from the downstream primer (red 
arrow) cleaving the fluorophore and probe nucleotides (black blocks). Following its release, 
the fluorophore fluorescence (green arrows) is no longer quenched and can be detected by the 
real-time PCR instrument.  
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2.12.1.3 Multiplex detection T. pallidum and an internal control  
 
This multiplex PCR uses two distinct primer pairs and two probes, each with a different 
fluorophore, to co-amplify tpp047 and pTYLCV DNA. Spiking each blood sample with the 
same quantity of pTYLCV (5000 copies) and then quantifying T. pallidum and plasmid DNA 
simultaneously allows determination of the efficiency of DNA extraction and PCR 
amplification.  
The reaction conditions for the multiplex PCR included a Uracil-N-Glycosylase (UNG) step. 
This hydrolytic enzyme removed uracil from dUMP in any contaminating molecules in the 
PCR. The resultant DNA, with apyrimidinic sites, was subsequently destroyed by hydrolysis 
of the phosphate backbone at these sites during the Taq activation step at 95C. The final 25l 
reaction thus contained: 12.5l of 1x Qiagen Quantitect Multiplex PCR reaction mix; 0.5units 
UNG; 0.4 M of each of the four primers (TP1; TP2; TYLCV_F3 and TYLCV_R3); 0.2M 
each of the probes TPP and PTYCLV; 5l of DNA and water to a total volume of 25l. 
Cycling conditions were as follows: 50°C for 2 minutes (UNG step); 95°C for 15 minutes 
(Taq activation and UNG inactivation) then 45 cycles of 94°C for 1 minute; 60°C for 75 
seconds (annealing, extension and plate read). Two standard curves were included in every 
run, each comprising a 1:10 dilution series from 10
5
 to 10 copies per reaction. The standards 
were the plasmids pTp47 and pTYLCV, constructed as described previously. A no-template 
(water) control and extraction controls, both positive and negative, were also run 
simultaneously.  
 
2.12.2  16SrRNA quantification with Biorad CFX Real-time system  
 
This one-step RT-qPCR assay was selected for T. pallidum RNA quantification in blood and 
ulcer samples using the 16S rRNA target. Each 25l reaction contained: 1l enzyme mix 
(Omniscript reverse transcriptase; Sensiscript reverse transcriptase and HotStarTaq DNA 
polymerase) (Qiagen); 1l DNTP mix (0.4mM final concentration of each nucleotide); 5l of 
reaction buffer (including 12.5mM MgCl2); 0.6M each of the primers 16S_F_Seattle and 
16S_R7; 0.2M of the probe 16S_P3; 5l RNA and water. Cycling conditions began with a 
30-minute step at 50C for reverse transcription followed by 15 minutes at 95C both to 
inactivate the two RT enzymes and to activate the Taq polymerase. Next were 44 cycles of 
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95C for 15 seconds then 60C for 90 seconds. Fluorescence at 530nm was measured at the 
end of each round of PCR. Samples were run in triplicate and runs contained two no-template 
(water controls). A 1:10 dilution series of the plasmid p16SRNA was included in each run as 
an absolute quantification standard. 
 
2.13 Development of an RNA standard for T. pallidum quantification 
 
2.13.1 RiboMAX T7 RNA polymerase  
 
Several methods of producing T. pallidum RNA in sufficient quantities for use as 
quantification standard were assessed and ultimately the RiboMAX Express T7 RNA 
polymerase (Promega, Southampton, UK) was selected. This DNA-dependent phage RNA 
polymerase binds with high specificity to its priming site (T7 promoter sequence) and 
subsequently produces RNA from a DNA transcriptor vector downstream of the T7 promoter.  
The pCR4-TOPO cloning vector, used to produce the T. pallidum DNA quantification 
plasmid (pTp47), contains a T7 priming site 31 bases upstream from the cloning site which 
enabled a T7 polymerase to produce RNA copies of the plasmid p16SRNA.  The T7 Ribomax 
express system contains the polymerase T7 Express, 2l of which were added to 8x105 copies 
of Nco-1 linearised p16SRNA. The reaction also contained the recombinant enzymes 
Ribonuclease inhibitor (RNAseIn) and Inorganic Pyrophosphatase (in the T7 polymerase 
enzyme mixture) and 10l of reaction buffer (HEPES, pH7.5; NTPs and Magnesium). The 
reaction volume was made up to 20l with water and incubated at 37C for 30 minutes. To 
remove contaminating template DNA, 2l of RQ1 DNAse (Promega, Southampton, UK) 
were added, then the reaction stirred and incubated for 15 minutes at 37C. To purify the 
resultant RNA and remove any unincorporated rNTPs, the entire reaction volume was applied 
to a Roche Highpure extraction column (as described previously), washed and eluted into 
100l water.  
2.13.2 Invitrogen T7 polymerase  
 
Invitrogen T7 polymerase was assessed as an alternative to RiboMAX T7 polymerase. The 
basic manufacturer’s protocol was as follows: 10L (1x final concentration) trans-optimised 
buffer were added to 5mM DTT; 50 Units RNAseIn; 1mM rNTP mix; 50 Units bacteriophage 
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RNA polymerase; 10l of plasmid DNA (106 plasmid copies) and water to a total volume of 
50l. The reaction was then mixed and incubated at 37C for one hour. Following the T7 
polymerase reaction, template plasmid DNA was removed with on-column DNAse treatment 
and RNA was eluted into 100l water using the Roche highpure method described in Chapter 
2.1.2.  
 
2.13.3 Incorporating T7 promoter sequence into TYLCV target sequence 
 
This modification of the splice-overlap PCR described previously was designed to add the T7 
promoter sequence to the 5’ end of the TYLCV target sequence. New primers were 
synthesised: The primer TYLCV_F3 was modified by adding the 20bp T7 promoter sequence 
(shown here in bold) to the 5’end (TAA TAC GAC TCA CTA TAG GGC GTC CGT CGA) 
and the primer TYLCV_R3 was elongated (shown in bold) to produce a comparable melting 
temperature (AGG TCA GCA CAT TTC CAT CCG AAC ATT CAG GGA GCTA). During 
the first cycle of PCR, the primers annealed to the TYLCV target sequence and the T7 
promoter sequence, which was initially a 5’ overhang, was reverse complemented. During the 
second cycle, the TYLCV-T7 hybrid sequence, was replicated and soon became the dominant 
species in the PCR. The predicted product size of 136bp was confirmed by agarose gel 
electrophoresis. The PCR product was purified and used as a template for T7 polymerase, 
with the standard conditions described previously (Chapter 2.5).  
 
2.14 Clinical Studies 
 
The data from four separate clinical studies are described in this thesis. Recruitment criteria 
and details of ethical approvals for each are detailed here and copies of the associated 
approvals and protocols are included in the appendices.  
2.14.1 Validation of T. pallidum DNA quantification in blood and ulcer samples  
 
Patients were recruited for the initial validation of T. pallidum detection and quantification by 
SYBR-green base qPCR in a prospective, cross-sectional study, conducted at St Mary’s 
Hospital London, following ethical approval from The Hounslow and Hillingdon LREC 
(06/Q0407/29, 26
th
 May 2006). All patients being investigated for syphilis (including routine 
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screens) were eligible. A sample of 6ml of whole blood was collected into EDTA and for 
patients 25-99, an additional 3ml of blood was collected into a Tempus™ tube. Samples 
collected between July and December 2006 were processed immediately and DNA extracted 
as described previously. Samples collected after this period were stored at -80°C until DNA 
and RNA were extracted. Ulcer exudate was collected with snostrips according to the method 
in Chapter 2.3.4. The strips were stored dry in microcentrifuge tubes until DNA extraction. 
DGM was performed on genital ulcers according to clinic policy prior to the collection of 
study samples.  
 
Baseline and convalescent syphilis serology were documented for all patients in addition to 
the results of investigations for other STIs. The Newmarket IgM/IgG enzyme immunoassay 
(EIA), (Alere, Stockport, UK) was used to screen for T. pallidum infection. Fujirebo T. 
pallidum particle agglutination (TPPA) (Mast Diagnostics, Bootle, UK) and Bio-kit rapid 
plasma reagin (RPR) (Launch Diagnostics, Longfield, UK) were used to confirm and quantify 
the serological response respectively.  
 
Patients’ final clinico-microbiological diagnoses were recorded as one of the following: 
Herpes simplex virus (HSV); primary syphilis; secondary syphilis; other syphilis (comprising 
latent and symptomatic late disease); neuro-syphilis; asymptomatic contacts of syphilis and 
non-specific genital ulceration. Case definitions are given in Appendix 5. 
 
2.14.2 Cross-sectional study of T. pallidum quantification  
 
A second set of cross-sectional samples was collected prospectively from patients presenting 
to St Mary’s Hospital, London with untreated syphilis of any stage between January 2011 and 
December 2012. Ethical approval for sample collection was granted from the Communicable 
Diseases Tissue Biobank (CDTB), Imperial College London.  
Whole blood (3-5ml) was collected into EDTA from each patient in addition to 3ml of blood 
into a Tempus™ collection tube. Ulcer swabs were taken from patients with a positive DGM 
result and stored in microcentrifuge tubes containing 1.3ml RNA later. CSF was also 
collected from patients undergoing Lumbar Puncture examination for suspected 
neurosyphilis.  
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Additional EDTA blood samples were also collected from patients who were admitted to 
hospital for their syphilis treatment. These samples comprised EDTA blood surplus to 
requirement for full blood count measurement, which had been stored at 4C after collection. 
The same demographic data, clinical details and serological results were documented for 
patients in this study as for the validation study. In addition, information on previous syphilis 
treatment and recent treponemocidal antibiotics was collected. All samples were stored at -
80C prior to nucleic acid extraction. 
2.14.3 Molecular characterisation of T. pallidum in Colombo, Sri Lanka 
 
Patients attending the Central STD clinic, Colombo between January and October 2012 with 
confirmed symptomatic early syphilis (primary chancre or moist lesion of secondary syphilis) 
were considered eligible for the study. Ethical approval was granted by the Ethics Review 
Committee, Faculty of Medicine, University of Colombo (Approval No EC-11-194, 19
th
 Jan 
2012) to recruit up to 40 patients. Following informed consent, ulcer exudate was collected 
using filter paper snostrips as described previously. Samples were stored in 1.3ml of 
RNAlater
®
 solution at -80C until they were shipped to the UK, at ambient temperature. 
Approval for the transfer of samples to the Communicable Disease Tissue Biobank at 
Imperial College London was granted by way of a Material Transfer Agreement between 
Imperial College London and The National STD/AIDS Control Programme of Sri Lanka (24
th
 
November 2011). Demographic data were recorded for each patient in addition to the results 
of standard serological tests (T. pallidum EIA and RPR) and dark ground microscopy. No 
patient identifiable information was transferred from Sri Lanka to London. 
 
2.14.4 Study of treatment kinetics 
 
Ethical approval was gained to recruit 4 patients with confirmed late primary or early 
secondary syphilis to this longitudinal study. Primary Disease was defined as a typical 
looking genital ulcer, which was beginning to heal, confirmed as syphilis by either dark 
ground microscopy (DGM) OR a positive ulcer multiplex PCR result from the HPA and/or 
serology consistent with a new infection. Positive serology was not an absolute requirement 
for study entry as it may not have been available on the day of recruitment. Secondary 
Disease was defined as a new positive EIA result with an RPR of 1:16 or more with or 
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without any relevant symptom or sign of secondary syphilis (listed in the national guideline 
for the management of syphilis and including deranged liver function tests) (104). If 
symptoms or signs were present and of recent onset then the case could have been classified 
as early secondary disease. In the absence of symptoms or signs the patient may still have 
been eligible for study entry if the RPR titre was high (>1:128). Previous syphilis did not 
exclude a patient from study entry. However, they must have had serology showing either a 
negative RPR or a ‘serofast’ RPR titre (≤ 1:4) before the current new infection. All patients 
had to have the ability to give informed consent for participation in the study and needed to be 
available for a 7-day period, including the first three potentially as an inpatient. Participating 
patients then needed to be available for serological follow-up, to a maximum of 6 months. 
Every effort was made to give patients the maximum amount of time to consider their 
decision to enter the study without unduly delaying their treatment or prolonging their stay in 
clinic. Potential subjects were given preliminary information about the study by their doctor 
or nurse prior to meeting the study team and posters were displayed in the waiting rooms 
detailing the study. 
 
Exclusion criteria for study entry were as follows: 
1. Exposure to any class of anti-treponemocidal antibiotic within 90 days of enrolment 
(macrolides, tetracyclines, penicillins, cephalosporins, other b-lactams eg. 
carbopenems) 
2. Presence or suspicion of concomitant bacterial sexually transmitted infections (STI) or 
other bacterial infections (skin, chest etc) that require treatment with treponemocidal 
antibiotics. 
3. Pregnancy. Potential female participants of child-bearing age who are not sterilized 
were tested for pregnancy prior to study entry. 
4. Following full discussion with patients about the study, those who seemed 
insufficiently committed were not recruited. 
5. Patients with significant drug or alcohol dependence and/or mental health issues were 
excluded. 
 
Once recruited and once the treating physician had established the management plan, the 
patient was transferred immediately to an inpatient study unit. An intravenous cannula was 
sited (23g) to facilitate frequent venesection and samples were collected from patients 
according to the sample schedule in Appendix 7. Ulcer samples were collected using filter 
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paper snostrips, as described previously. Prior to collecting the first sample, however, the 
ulcers were photographed and measured with a disposable paper ruler. EDTA and Tempus™ 
blood samples were taken from a peripheral vein using an intravenous cannula and either a 
4ml EDTA vacutainer tube pre-marked to 2mL or a Tempus™ vaccutainer collection tube. 
Once collected, EDTA samples were stored on dry ice until DNA extraction was performed, 
typically in batches of 6-8 samples. Tempus™ tubes were placed immediately in dry ice, then 
stored at -80C for up to two weeks prior to RNA extraction  
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Chapter 3 
 
Cross-sectional studies of T. pallidum nucleic acid quantification 
in vivo 
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3.1 Introduction 
 
3.1.1 Background  
 
The primary stage of syphilis consists of a self-limiting mucosal ulcer. If untreated, the 
bacteria invade and spread widely through the bloodstream, giving rise to the secondary stage 
(rash; alopecia; hepatitis; eye and neurological symptoms). Again, these symptoms will 
resolve spontaneously if left untreated, but a small number of slowly dividing bacteria lodged 
in the brain; spinal cord; cardiovascular system or elsewhere may eventually cause destructive 
tertiary disease over two-three decades. The disease is called ‘early’ in the primary and 
secondary stage and ‘latent’ when asymptomatic between stages (4, 104). Using PCR in a 
rabbit model the dissemination of T. pallidum after inoculation has been shown to be quick 
and wide-spread (51). Studies exploring the sensitivity of PCR for syphilis diagnosis in 
humans find sensitivity of 72-91% in primary chancres, and 24-73% in blood samples (133, 
145, 151). RT-PCR was described as having the potential to enhance the qualitative detection 
of T. pallidum in vitro, but failed to do so in one subsequent ex vivo study (57, 153). No 
previous description of T. pallidum RT-qPCR has been made and only a single study of 
secondary syphilis has presented any T. pallidum qPCR (151). The humoral response to T. 
pallidum infection can be divided into nontreponemal antibodies and treponemal antibodies 
(100). Both antibody types have been exploited for diagnostic tests, the former for screening 
and as a measure of disease activity and the latter for confirmatory testing (230). Non-
treponemal antibody titres are low in incubating disease, elevated in early disease and fall as 
disease passes into latency or after treatment.  
 
The current study describes the development of novel qPCR and RT-qPCR assays for the 
measurement of T. pallidum bacterial load in clinical samples. This includes a determination 
of the most efficient methods for extracting nucleic acids and finding optimal PCR targets. It 
subsequently describes the validation of these assays using clinical samples collected in three 
separate cross-sectional studies; compares qPCR data with standard serological results; 
establishes the optimal blood compartment (whole blood, plasma, PBMCs) for T. pallidum 
detection and correlates bacterial load with disease stage and HIV-1 co-infection.  
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3.2 Results: assay development 
 
In order to quantify T. pallidum nucleic acids in clinical samples it was paramount both to 
identify robust methods for sample collection and storage and to optimise techniques for 
nucleic acid extraction and quantification. DNA and RNA extraction from blood and ulcer 
samples is described in Chapter 2.3 and was largely based on previously published methods. 
However, the preservation of T. pallidum RNA in ulcer samples using RNAlater
®
 solution 
and in blood with Tempus™ vaccutainer tubes was novel as were qPCR assays for both DNA 
and RNA quantification. Each of the steps taken in the development of a qPCR and an RT-
qCPR capable of quantifying T. pallidum in clinical samples are now described. 
 
3.2.1 T. pallidum nucleic acid extraction from snostrips. 
 
The ability to co-extract DNA and RNA from a single ulcer sample was important as only one 
sample would be available at each time-point during the treatment monitoring study (Chapter 
4) and both nucleic acids were to be quantified. Of equal importance was the need for the 
DNA extraction method to be compatible with RNA later solution in which snostrip-adsorbed 
ulcer exudates were to be stored. Two DNA extraction methods were assessed for use with 
snostrips stored in RNAlater
®
 solution. In the first, an aliquot of RNAlater
®
 was withdrawn 
and DNA extracted leaving a second aliquot for subsequent RNA extraction. The second 
method lysed and homogenised the entire sample and was followed by DNA and RNA 
extraction in parallel. Table 3.1 demonstrates that DNA extracted from 5000 T. pallidum 
organisms with the second method was detected an average of 1.08 PCR cycles sooner 
(p=0.0058) than DNA extracted with the first method. Moreover, by extracting DNA and 
RNA in parallel, the second method allowed subsequent RNA extraction both without the 
need for a separate process or the potential for RNA degradation as a result of re-freezing the 
sample. 
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Table 3.1 A comparison of two methods for T. pallidum DNA extraction from Snostrips  
 
 Mean
†
 cycle threshold   
 Experiment 1 Experiment 2  
 
Method Sample 1 Sample 2 Sample 1 Sample 2 Mean 
All-prep 34.62 35.07 34.19 34.68 34.64 
p=0.0058* 
QIAamp 36.26 35.67 35.53 35.43 35.72 
 
 
Table 3.1. T. pallidum organisms (n=5,000) were added to Snostrips and stored in 1.3ml 
RNA later solution. DNA was extracted with either a Qiagen ‘all-prep’ mini kit (DNA/RNA 
co-extraction) or a Qiagen ‘QIAamp’ kit (DNA extraction alone). Two samples were 
extracted in duplicate (samples one and two) and the experiment repeated to ensure 
reproducibility (experiments one and two).  
*A two-sided student’s t-test was used to determine statistical significance. 
†Three technical replicates of each sample were performed. 
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3.2.2 The Tempus™ blood tubes are suitable for T. pallidum RNA preservation and 
extraction. 
 
Maximising the efficiency of RNA extraction was key in order to improve T. pallidum 
detection in blood, which had previously been reported to be low (52). Two techniques for 
RNA extraction from whole blood samples were assessed. The first was the Tempus™ 
system, where blood was drawn from the patient directly into a tube containing a proprietary 
detergent (for sample lysis) and guanidine thiocyanate (for RNAse inactivation). The RNA 
extraction process (Chapter 2.3.3.1) subsequently took around 60 minutes. The second 
technique, using Ambion’s Ribopure™ system, involved an aliquot of blood being stored in 
RNAlater
®
 solution and then extracted using a phenol:chloroform-based method taking 50 
minutes. Both techniques included a DNAse step to remove any contaminating gDNA. A 
comparison of the two techniques was made by spiking whole blood with T. pallidum at a 
final concentration of 4000 bacteria/ml, extracting RNA according to the method described in 
Chapter 2.3.3.2 and quantifying extracted RNA by RT-qPCR (Chapter 2.12.2). Table 3.2 
compares the mean Cts of an RT-qPCR amplifying the extracted RNA and shows that 
Tempus™-extracted RNA was detected 0.5 cycles earlier at 40.53 cycles. The mean cycle 
thresholds for positive control RNA (5x10
4
 T. pallidum organisms per reaction) was 31.60 
cycles and a no template (water) control was negative. In addition to this marginal 
improvement in extraction efficiency, the Tempus™ system immediately preserved RNA 
without the need for a laboratory (important in the clinical studies). Moreover, whilst the total 
time taken for extraction was similar, the Tempus™ protocol was less complex as it included 
a 30-minute centrifugation step.  
 
Tempus™ tubes are designed to extract RNA from human lymphocytes, not bacteria in blood 
samples, thus two potential optimisation steps were assessed. The first was additional 
proteinase K digestion to enhance the bacterial lysis achieved with Tempus™ detergent alone. 
Two Tempus™ samples containing 3mL of blood drawn from syphilis negative controls were 
spiked with 5000 RNAlater
®
-preserved T. pallidum control organisms. Following the initial 
30-minute centrifugation one sample was resuspended in 200L PBS and 10L Proteinase K 
(Qiagen, Crawley, UK), mixed and incubated at 56C for 3 hours. A second sample was 
resuspended in 400L resuspension solution (as per the Tempus™ extraction protocol). RNA 
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extraction from both samples was then completed according to the Tempus™ protocol 
(Chapter 2.3.3.1).  
 Figure 3.1 demonstrates that this extra step increased the cycle threshold for T. pallidum 
detection by over 10 cycles and it was not adopted. The second was selective removal of 
human mRNA from samples prior to RT-qPCR with magnetic bead oligonucleotide capture. 
As Table 3.3 demonstrates, the extraction of 5000 T. pallidum organisms with the Tempus™ 
system alone (condition ‘a’) resulted in a mean cycle threshold of 31.70 (std. dev. 0.59) 
(measured by SYBR-green RT-qPCR). Following human mRNA depletion, the cycle 
threshold for T. pallidum detection was later at 34.20 (std. dev. 0.73) cycles. A control step 
with the omission of the capture oligonucleotide mix (condition ‘b’) also resulted in a 
reduction of RNA starting quantity (cycle threshold 32.31 (std. dev. 0.49) cycles). 
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Table 3.2 T. pallidum RNA extraction from blood  
 
Method 
Mean* cycle 
threshold (std. 
dev.) for tpp047 
gDNA detection 
Cost of 
extraction 
(£/sample) 
Time taken for 
extraction (minutes) 
Tempus™ with on column 
DNAse treatment
1
 
 
40.53 (0.87) 8.80 60 
Ribopure™ RNA extraction 
with Ambion DNAse 
treatment
2
 
 
41.04 (1.1) 8.70 50 
Positive Control
3
 
 
31.60 (0.29) - - 
NTC (water) Negative   
 
 
Table 3.2. Whole human blood was spiked with 5,000 T. pallidum which had previously been 
stored in RNAlater
®. Following RNA extraction with either the Tempus™ or Ambion 
Ribopure systems, tpp047 was quantified by RT-qPCR and the cycle thresholds of detection 
were compared. The cost and time taken for each method were also compared. 
1
3ml blood collected into a Tempus™ tube and spiked with 4000 T. pallidum/ml). 2500l of 
blood spiked with 4000 T. pallidum/ml and added to 1.3ml RNAlater. 3RNA extracted from 
5x10
4
 T. pallidum/reaction. 
* Mean of three replicas in a single experiment. 
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Figure 3.1 Comparison of T. pallidum RNA extraction methods  
 
 
 
Fig. 3.1. T. pallidum organisms (n=5,000) were added to syphilis-negative blood stored in 
Tempus™ tubes and RNA was extracted both with and without an additional Proteinase K 
digestion step. Following reverse transcription, cDNA from a positive control (a); Tempus™-
extracted samples without Proteinase K digestion (b) and Tempus™-extracted samples with 
additional Proteinase K digestion (c) were quantified, in triplicate, in a SYBR-green based 
qPCR. Aliquots of (a), (b) and (c) taken prior to reverse transcription were also subject to 
qPCR to control for gDNA carry-over. The mean cycle threshold for (a), (b) and (c) detection 
was 26.04 (std. dev. 0.91), 28.84 (std. dev. 0.91) and 40.37 (std. dev. 1.48), respectively. No 
amplification was observed from no-template or from gDNA carry-over controls (d). 
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Table 3.3 T. pallidum RNA extraction from blood  
 
 
Method 
Mean cycle threshold 
(cycles)* 
Standard 
deviation 
a Tempus™ extraction alone  31.70 0.59 
b No oligonucleotide control  32.31 0.49 
c Human RNA depleted  34.20 0.73 
d PCR no template control 
(water)  
neg n/a 
e PCR positive control  25.59 0.32 
 
Table 3.3. T. pallidum negative blood (3ml) stored in Tempus™ tubes was spiked with 5000 
T. pallidum organisms. RNA was extracted and divided into three aliquots: (a) Tempus™ 
extraction alone; (b) Tempus™ extraction with a negative bead control (where magnetic 
beads were added, but the capture oligonucleotide omitted) and (c) Tempus™ extracted RNA 
with bead-mediated depletion of human RNA. Together with a no-template control (d) and a 
positive control of T. pallidum RNA (e), the extracted RNA was reverse-transcribed and 
cDNA quantified in a SYBR-green based qPCR. 
* cycle thresholds given are a mean of three replicas in a single experiment. 
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3.2.3 Designing a qPCR for T. pallidum DNA quantification 
3.2.3.1 tpp047 quantification in a qPCR using SYBR green 
 
Initially, the genome copy number of T. pallidum in blood and ulcer exudates was determined 
with qPCR using the Roche LightCycler 2.0 instrument in a SYBR green-based assay 
(Chapter 2.12.1.1). Enumeration of T. pallidum was achieved by amplifying and detecting a 
177bp section of the tpp047 gene, which appears once on the bacterial chromosome and 
encodes an integral membrane protein (28). The gene is specific to the species pallidum, thus 
the qPCR was expected to detect other pallidum subspecies (e.g. pertenue), but not other 
organisms of the genus Treponema.  
 
DNA was extracted from 6x10
6
 DGM-quantified T. pallidum Nichols strain organisms and 
diluted in a 1:10 dilution series to create an absolute quantification standard against which 
samples containing an unknown quantity of T. pallidum could be compared. The qPCR 
quantified the amount of DNA present after each round of PCR by detecting the green 
fluorescence emitted by SYBR green I dye (λmax = 520 nm) which had bound to double-
stranded DNA. By calculating the rate of rise of fluorescence, the cycle of PCR where the 
fluorescence curve of the sample turned sharply upward represented the Crossing point (Cp) 
for the reaction. This Cp was therefore a maximum on the second derivative plot of the 
reaction. Figure 3.2.B demonstrates the sigmoidal amplification plots of the PCR, which 
depict a near-doubling of detectable DNA after each round of PCR until a plateau where 
declining substrate concentrations limit reaction efficiency. Amplification curves shifted to 
the right with each 10-fold dilution of the starting amount of DNA, which represents the 
additional number of PCR cycles required to achieve detectable fluorescence. 
 
By plotting the known starting quantity for each standard curve dilution against its crossing 
point, the LightCycler software produced a regression line (the standard curve) which it could 
then use to calculate the starting amount of target DNA in unknown samples. The standard 
curve showed a linear relationship between starting quantity and crossing point, with an 
efficiency of 1.818 and an error of 0.005 (Figure 3.2.). Next, by diluting the standard curve 
1:10 to reach a concentration 100-fold less than one genome copy and showing no detection 
beyond a single genome equivalent, the analytical sensitivity of this assay was determined to 
be a single T. pallidum organism.  
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In order to ensure the correct target was being amplified in the reaction, melting curve 
analysis was performed as described in Chapter 2.12.1.1. Figure 3.2. demonstrates the melting 
curve analysis for T. pallidum pallidum, T. pallidum pertenue and T. denticola. Fluorescence 
increased gradually until 82.5C, the temperature at which the amplicon DNA strands 
dissociated (melting temperature, Tm) and no longer bound SYBR green, resulting in a sharp 
fall in fluorescence. The Tm for the two T. pallidum subspecies is seen to be the same. 
Neither T. denticola nor the reaction negative control showed any detectable fluorescence. In 
addition to melt curve analysis, gene sequence analysis was performed on the tpp047 
amplicon and showed complete homology with published Nichols strain sequences. 
Verification of assay specificity had been previously sought by confirming that the assay did 
not amplify DNA from healthy human volunteers in addition to sexually transmitted bacteria 
and viruses and common skin bacteria and fungi (Full list of organisms given in Appendix 1) 
(231).  
 
The inter-assay variance was determined by quantifying three dilutions of the Nichols strain 
standard curve (1x10
4 
to 1x10
2
) in five separate experiments. The coefficient of variation 
(Table 3.4) was less than 1.2% for all three dilutions. 
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Figure 3.2 Development of a qPCR for T. pallidum quantification  
 
 
 
Fig. 3.2. T. pallidum tpp047 detection and quantification was peformed with the Roche 
Lightcycler. Two technical replicates of each dilution were assayed. Panel A. Melt curve 
analysis of the product of tpp047 PCR amplification from T. pallidum pallidum and T. 
pallidum pertenue. Neither the negative (water) control nor T. denticola show detectable PCR 
product. Panel B. Sigmoidal amplification curves resulting from PCR amplification of a 
pTp47 dilution series from 10
6
 to 100 copies per reaction. Panel C. Plot of log pTp47 starting 
concentration (1:10 dilution series from 10
4
 to 10) against crossing point for each 
concentration. The calculated reaction efficiency from this plot was 1.818.  
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Table 3.4 Inter-assay variance of tpp047 qPCR  
 
Dilution Mean crossing point Standard deviation 
Coefficient of 
variation (%) 
1 (10
4
) 23.21 0.23 0.97 
2 (10
3
) 26.96 0.31 1.13 
3 (10
2
) 30.61 0.36 1.18 
 
Table 3.4. Three dilutions of DNA extracted from T. pallidum Nichols strain organisms were 
quantified by qPCR using SYBR green I and a LightCycler 2.0 instrument. The mean 
crossing point for the detection of each dilution was calculated from five separate 
experiments.  
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3.2.3.2 tpp047 qPCR using a plasmid quantification standard in a TaqMan assay 
 
qPCR based on the detection of SYBR green I was an efficient method of T. pallidum 
quantification. Another goal, however, was to design a multiplex qPCR capable of 
quantifying tpp047 and an internal control sequence concurrently. The TaqMan assay has the 
capability to detect two distinct fluorescent probes and thus to measure amplification of both 
tpp047 and a control sequence in the same reaction tube. As described in Chapter 2.12.1.2 a 
FAM-TAMRA TaqMan probe was designed for the quantification of tpp047 in a qPCR using 
the same amplification primers as for the SYBR-green assay (TP1 and TP2, Appendix 2). The 
assay detected Nichols strain T. pallidum DNA, but amplified neither human DNA nor the 
test organisms listed in Appendix 1. Two further modifications were made to the assay. The 
first was replacing the Roche LightCycler 2.0 instrument with a Biorad CFX 1000, which 
allowed quantification of an additional 96 samples in a single experiment. Secondly, the 
standard curve DNA extracted from T. pallidum organisms was replaced with a recombinant 
plasmid, pTp47. Construction of this plasmid is described in Chapter 2.9. Biorad CFX 
manager 2.0 software was used to analyse qPCR data. In a similar way to the Roche light-
cycler instrument software, fluorescence is measured at the end of each round of PCR, 
although this time the fluorescent source is hydrolysed Taqman probe molecules. The rate of 
rise in fluorescence is then subject to regression analysis and used to determine the cycle 
threshold - the cycle of PCR where fluorescence begins to rise exponentially and which is 
closely associated with the starting quantity of DNA in the reaction. Importantly, the 
determination of cycle threshold is calculated by the software and is not, therefore, subject to 
observer error. 
 
Before use as a quantification standard, the plasmid pTp47 was linearised and determined to 
have a concentration of 6.06x10
9 
tpp047 copies/l using spectrophotometry. The plasmid was 
then resuspended to obtain a concentration of 1x10
9
 copies/l and subject to serial 1:10 
dilution down to a single copy per microlitre. qPCR of dilutions five (10
5
 copies/l) to nine 
(one copy/l) was performed in quadruplicate and calculated to be 103% efficient with an 
average of 3.17 cycles between each 10-fold dilution of pTp47 (Figure 3.3). The lowest 
dilution at which tpp047 was amplified in all four replicas was 10 copies/l – the analytical 
sensitivity of the assay. The probability of a negative reaction at one copy per microliter (the 
volume of DNA added to each PCR) was 0.75. According to the equation in Chapter 2.9 this 
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probability at a dilution factor of 10
9
 equated to an original concentration of 4.7x10
9
 
copies/l, which is comparable to the 6.06x109 copies/l calculated by spectrophotometry.  
 
Inter-assay variability was determined by quantifying pTp47 (tpp047) in dilutions of the 
newly constructed standard curve containing 10
4
, 10
3
 and 10
2
 copies/l. Four separate 
experiments were averaged (Table 3.5) and the coefficient of variation was found to be below 
2.4%. Intra-assay variability was also low, at less than 1.05% for all three concentrations 
assessed (Table 3.6).  
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Figure 3.3 Construction of a standard curve for tpp047 quantification 
 
A. Amplification curves 
 
 
B. Standard Curve Efficiency 
 
 
 
Figure 3.3. The plasmid pTp47 was serially diluted in water from 1x10
5
 copies/L to 1 
copy/L and quantified in a TaqMan qPCR using the primers TP1&TP2 and the probe TPP 
(Panel A). Four (technical) replicates of each sample were quantified using the Biorad CFX 
real-time PCR instrument. A standard curve was produced where each 10-fold dilution 
corresponded to an increase in cycle threshold of 3.17 cycles (Panel B).  
 106 
Table 3.5 Inter-assay variation of the tpp047 qPCR  
 
Dilution Mean cycle 
threshold 
Standard deviation Coefficient of 
variation (%) 
1 (10
4
) 26.98 0.63 2.35 
2 (10
3
) 30.41 0.70 2.32 
3 (10
2
) 34.56 0.67 1.95 
 
 
Table 3.5. Three dilutions of the plasmid pTp47 were quantified by qPCR using a TaqMan 
assay with the primers TP1 and TP2 and the probe TPP (Appendix 2). The mean cycle 
threshold for the detection of each dilution was calculated from four separate experiments.  
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Table 3.6 Intra-assay variation of the tpp047 qPCR  
 
 
Dilution Mean cycle 
threshold 
Standard deviation Coefficient of 
variation (%) 
1 (10
4
) 26.08 0.172 0.66 
2 (10
3
) 29.40 0.308 1.04 
3 (10
2
) 32.57 0.308 0.95 
 
Table 3.6. Three dilutions of the plasmid pTp47 were quantified by qPCR using a TaqMan 
assay with the primers TP1 and TP2 and the probe TPP (Appendix 2). The mean cycle 
threshold for a given plasmid concentration was calculated from four technical replicas 
quantified in a single experiment. 
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3.2.4 Designing a qPCR for T. pallidum RNA quantification 
 
3.2.4.1 16S rRNA was selected as the target gene for T. pallidum RT-qPCR 
 
Three candidate T. pallidum RNA targets (tpp047 mRNA, flaB2 mRNA and 16S rRNA were 
investigated for use in an RT-qPCR assay. The targets tpp047 and flaB2 were selected as both 
have demonstrated a high level of expression in a rabbit model of syphilis, moreover they 
have sequences specific to T. pallidum. (141) The third target was bacterial 16S rRNA, 
previously shown to a sensitive target for RT-PCR, and for which T. pallidum specific 
primers had been identified, despite considerable homology of 16S rRNA among bacteria. 
(153)  
During an initial assessment, T. pallidum Nichols strain DNA was amplified in two novel 
TaqMan assays (flaB2 and 16S rRNA detection). The primer and probe sequences for these 
assays are given in Appendix 2 and all three assays were able to detect T. pallidum DNA. 
Given the potential for 16S rRNA to be present in large amounts in actively replicating 
organisms, this gene was selected as the target of choice, despite the later cycle threshold seen 
for DNA detection when initially compared with tpp047 and flaB2.  
 
3.2.4.2 RT-qPCR for 16S rRNA quantification was optimised 
 
Despite showing no cross-reactivity with a panel of bacterial DNA (Table 3.7), the initial 16S 
rRNA assay primers (16S_F1, 16S_R1) amplified a human gene when tested against reverse-
transcribed T. pallidum RNA extracted from spiked Tempus™ blood samples (Figure 3.4). 
This non-specific amplification was confirmed by agarose gel electrophoresis, where the 
expected 366bp band was seen together with a second band at 450bp and a third at 840bp. In 
order to identify the bands, these were gel-extracted and sequenced bidirectionally using the 
16S_1F and 16S_1R primers, according to the methods described in Chapters 2.4 and 2.6. 
The 366bp band was confirmed to be T. pallidum 16S rRNA. The 840bp band had significant 
homology with homosapien non-muscle myosin heavy chain 9 (MYH9) mRNA on a NCBI 
Nucleotide database BLAST search. Gene sequence analysis of the 450bp band failed, 
suggesting it was amplified non-specifically. 
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In order to improve the efficiency and specificity of the 16S rRNA qPCR a new TaqMan 
probe (16S_P3) and five new antisense primers were designed (Table 3.8). The sense primer 
(16S_F(seattle)) selected had been shown previously to amplify a section of the T. pallidum 
16S rRNA gene that has little homology with other bacteria including members of the genus 
Treponema (153). These four new primer pairs were compared with each-other and tpp047 
RNA quantification in a one-step RT-qPCR (Chapter 2.12.2) quantifying RNA extracted from 
10
4
 T. pallidum organisms. Table 3.8 shows the mean cycle thresholds for each of the new 
primer pairs. The cycle threshold for tpp047 was significantly higher (34.75 cycles, 
p=<0.005) than any of the 16S rRNA assays and when used to quantify RNA from human 
blood spiked with T. pallidum all four assays amplified only a single product (Figure 3.4). 
Finally, an attempt was made to quantify bacterial DNA from the test panel with the anti-
sense primers 16S_R4 and 16S_R7 in combination with the sense primer 16S_F(Seattle) and 
the probe 16S_P3 (Table 3.7). The 16S_R4 primer proved to be non-specific and amplified 10 
other bacterial species, however 16S_R7 proved specific and following confirmation that the 
correct target was amplified using gene sequence analysis this assay was selected for T. 
pallidum RNA quantification by RT-qPCR. 
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Figure 3.4 Specificity of T. pallidum RNA detection 
 
 
 
 
Fig. 3.4. Human whole blood collected into Tempus™ RNA preservation tubes was spiked 
with 5,000 T. pallidum organisms and RNA was extracted. Panel A. T. pallidum RNA was 
amplified in a one-step TaqMan assay with the sense primer 16S_F(Seattle), the probe 
16S_P3 and one of four different anti-sense primers (sequences are given in Table 3.8). 
Amplicons were subsequently visualised with 2% agarose gel electrophoresis to ensure 
amplification of a single product. Lane 1) positive control (tpp047 amplification); lane 2) 
16_R4; lane 3)16_R5; lane 4) 16S_R6; lane 5) 16S_R7. Panel B. Following reverse 
transcription, cDNA was amplified with the primers 16S_F1 and 16S_R1. Three products 
were identified with 2% agarose gel electrophoresis: Band A, an 840bp product (subsequently 
identified as human MYH9 mRNA); band B, an unidentifiable 450bp product and band C, the 
expected 366bp 16S rRNA product. 
 111 
Table 3.7 Specificity of three T. pallidum qPCRs  
 
Organism Assay and Primers 
 
 TaqMan qPCR 
(I) 
 
16S_F1 
16S_R1  
16S_P1 
TaqMan qPCR 
(II) 
 
16S_F(seattle) 
16S_R4 
16S_P3 
TaqMan qPCR 
(III) 
 
16S_F(Seattle) 
16S_R7 
16S_P3 
Methicillin Resistant 
Staphylococcus aureus 
- + - 
Staphylococci spp. - - - 
Coliforms - + - 
Streptococcus pyogenes - - - 
Group B Streptococci - - - 
E. coli - + - 
Campylobacter - - - 
Staphylococcus aureus - + - 
Corynebacterium - - - 
Haemophilus influenzae - + - 
Neisseria gonorrhoeae - + - 
Enterococcus spp - - - 
alpha-haemolytic 
Streptococci 
- + - 
Streptococcus agalactiae - - - 
Lactobacillus spp - + - 
Neisseria meningitidis - - - 
Haemophilus parainfluenzae - + - 
Streptococcus pneumoniae - + - 
T. pallidum subspecies 
pertenue (Gauthier strain) 
not tested + + 
T. denticola not tested - - 
T. pallidum (Nichols strain) + + + 
No Template Control (water). - - - 
 
 
Table 3.7. DNA from 22 different bacterial cultures/propagations was subjected to qPCR 
with three different primer combinations (I, II and III) in order to assess species specificity of 
T. pallidum 16S rRNA gene amplification. Positive (+) and Negative (-) reactions are shown. 
All samples were run in duplicate. 
 
 112 
Table 3.8 Determination of the optimal assay for T. pallidum RT-qPCR 
 
 Sequence 5’- 3’ 
Tm 
(C) 
Length 
(bp) 
Product 
size 
(bp) 
Mean* 
cycle 
threshold 
(cycles) 
Probe  
16S_P3 
6-FAM-
CGGCCTCGCTCAGAGATGAGC-
TAMRA 
69.1 21 - - 
Sense Primer    - - 
16S_F(seattle) CTCTTTTGGACGTAGGTCTTTGAG 60.7 24   
Anti-sense 
Primers 
     
16S_R4 TCTCAGGTCGGATACCCATC 59.9 125 125 23.51 
16S_R5 ACCCTCTCAGGTCGGATACC 60.3 129 129 23.46 
16S_R6 CACCCTCTCAGGTCGGATAC 59.5 130 130 23.95 
16S_R7 TCACCCTCTCAGGTCGGATA 60.6 131 131 24.15 
 
 
Table 3.8. Four anti-sense primers were designed for use in a one-step RT-qPCR with the 
sense primer 16S_F(Seattle) and the TaqMan probe 16S_P3. RNA. Tempus™ tubes were 
filled with 3ml of syphilis seronegative blood and spiked with 5000 T. pallidum organisms. 
RNA was extracted and the mean cycle threshold for T. pallidum 16S rRNA detection was 
then determined with each of the four reaction conditions.  
*Mean of three replicas from the same experiment 
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3.2.4.3 Constructing an RNA standard curve for 16S rRNA quantification 
 
Chapter 2.9 describes the production of a recombinant plasmid containing 131bp of the T. 
pallidum 16S rRNA gene for use as a template to produce an RNA quantification standard. 
This 4086bp plasmid (p16SRNA) had a spectrophotometric concentration 210.9ng/l, which 
equated to an initial concentration of 4.75x10
10
 copies/l. The parent PCR-4 TOPO plasmid 
vector contained a T7 promoter site to allow T7 polymerase binding and RNA transcription of 
the plasmid. Prior to T7 polymerase treatment, a linear plasmid structure was needed to 
enable the production of separate copies of the plasmid sequence and not a single large 
transcript containing multiple copies. The restriction enzyme ncoI sucessfully cut the plasmid 
at a single site to produce a linear structure (Figure 3.5). The linearised plasmid was then 
quantified with spectrophotometry and diluted in water to give a starting concentration of 
1x10
10
 copies/l and a 1:10 dilution series made down to a single copy/l. Dilutions 
containing 10
6
 to one copy/l were then quantified in quadruplicate in the 16SrRNA TaqMan 
qPCR (Table 3.9). At a concentration of one copy/reaction, there was a 50% chance of a 
negative reaction, which equated to 6.93x10
9
 copies/l and comparable to the starting 
concentration of 1x10
10
 copies/l.  
 
An RNA quantification standard was constructed by using the plasmid p16SRNA as a 
template for RNA transcription. Initially, the Invitrogen T7 polymerase was assessed and 
found to produce RNA detectable at an average of 20 RT-qPCR cycles when 50 units were 
added to 10
6
 copies of p16SRNA for one hour (Chapter 2.13.2). When less than 10
4
 copies of 
plasmid were added to the reaction, no detectable RNA was produced and when 10
7
 or more 
copies were added, unacceptable amounts of plasmid DNA were still detectable following 
DNAse treatment (Figure 3.6). Three method modifications to increase the amount of RNA 
produced by this enzyme were subsequently assessed (Table 3.10). The first was extending 
the one-hour polymerase incubation time to 20 hours, which was found to lower the cycle 
threshold for RNA detection by 1.97 cycles compared with one hour, but this difference did 
not reach significance (p=0.123). The second modification was to incubate the reaction at 
30C and 40C in addition to the usual 37C. Over two experiments, the mean cycle threshold 
for RNA detection at 30C was not significantly different from 37C, however incubation at 
40C (19.16 cycles) compared with 37C showed a 2.3 cycle improvement (p=0.050). 
Finally, the concentration of rNTPs was increased from 1mM to 2mM, which resulted in a 
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significant (p=<0.05) 1.86 cycle improvement in RNA detection. The maximum difference in 
cycle threshold observed for any of the modifications was less than three cycles, and the 
amount of RNA produced too low for the construction of a standard curve with an adequate 
quantification range.  
 
A final attempt to improve the amount of RNA produced compared two new T7 polymerases 
with the original Invitrogen polymerase. Table 3.11 shows the detection of 16S rRNA and 
residual plasmid DNA following T7 polymerase transcription of 10
6
 copies of the plasmid 
p16SRNA with three different polymerases (each used in accordance with its manufacturer’s 
protocol). RNA produced with all three methods was subject to the same DNAse treatment 
with a Roche highpure column-based method (Chapter 2.1.2). The Ambion T7 RiboMAX 
express kit produced RNA detectable at 17 cycles of RT-qPCR, significantly more (p<0.001) 
than either of the other enzymes. Minimal residual plasmid DNA was detected in the 
RiboMAX-produced RNA after DNAse treatment (29.17 cycles). 
 
Carrier RNA (poly-adenylated RNA) was added to the RNA transcribed from p16SRNA to 
reduce the potential for RNAse degradation during handling and storage. In order to assess 
the potential impact of carrier RNA on target detection during RT-qPCR, eight different 
amounts of carrier RNA (0.1g, 0.15g, 0.2g, 0.25g, 0.3g, 0.35g, 0.4g and 0.45g) 
were added to 2.3x10
5
 copies of p16SRNA-produced RNA in a total volume of 100l water 
and quantified in a one-step TaqMan RT-qPCR with the primers 16S_F(Seattle) and 16S_R7 
and the probe 16S_P3. Compared with the addition of no carrier RNA (26.73 cycles), the 
average number of PCR cycles for detection was 0.32 higher with a carrier RNA 
concentration of 0.01g/l and 1.14 higher with a concentration 0.045g/l carrier RNA. To 
make the final standard for 16S rRNA RT-qPCR, 80l of RNAse-free water were added to 
10l of a 0.1g/l solution of carrier RNA (final concentration 0.01g/l) and 10l of water 
containing 2.3x10
7
 copies/l of 16S rRNA (final concentration 2.3x106 copies/l). This RNA 
was stored at -80C in 10 aliquots of 10l. 
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Figure 3.5 Linearisation of the plasmid p16SRNA  
 
 
 
 
Figure 3.5. The plasmid p16SRNA (4086bp) was subject to restriction digestion with the 
enzyme ncoI and visualised following electrophoresis in a 1% agarose gel. Lane 1 shows the 
open (A) and supercoiled (C) species of an uncut control. In lane 2 there is only band B 
(linearised plasmid). 
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Table 3.9 Limiting dilution assay to quantify p16SRNA  
 
Starting concentration 
(copies/reaction) 
Number of replicas 
positive 
Mean (std. dev) cycle 
threshold 
1x10
6
 + + + + 19.27 (0.07) 
1x10
5
 + + + + 22.70 (0.04) 
1x10
4
 + + + + 25.85 (0.09) 
1x10
3
 + + + + 28.98 (0.04) 
1x10
2
 + + + + 32.19 (0.23) 
10 + + + + 35.80 (0.78) 
1 + + - - 38.84 (2.96) 
 
 
Table 3.9. The primers 16S_F(Seattle) and 16S_R7 were used to PCR-amplify of a 131bp 
section of the T. pallidum 16S rRNA gene from a 1:10 dilution series of the recombinant 
plasmid p16SRNA. The hydrolysis (TaqMan) probe 16S_P3 was used to detect amplification 
in real-time and four technical replicates of each dilution were analysed. 
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Figure 3.6 Assessment of T7 polymerase activity 
 
A. 16S rRNA quantification 
 
 
B. gDNA carry-over 
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Fig. 3.6. Panel A. Amplification of T. pallidum 16SrRNA in a TaqMan RT-qPCR with the 
primers 16S_F(Seattle) and 16S_R7 and the probe 16S_P3. Template RNA was transcribed 
using Invitrogen T7 polymerase from a 1:10 dilution series of plasmid p16SRNA ranging 
from 10
9
 to 10 copies/reaction and subject to DNAse treatment prior to quantification. Panel 
B. Quantification of p16SRNA DNA in a TaqMan qPCR with the primers 16S_F(Seattle) and 
16S_R7 and the probe 16S_P3 to assess gDNA ‘carry-over’ into the RT-qPCR. 
Two technical replicates of each sample were included for both 16S rRNA and gDNA. 
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Table 3.10 Optimisation of T7 polymerase reaction conditions 
 
Variable 
Mean** cycle 
threshold 
RNA (std. 
dev.) 
Mean cycle 
threshold DNA 
(std. dev) 
t-test 
(2-sided) 
T7 polymerase incubation temperature     
30C 20.87(2.20) 30.83 (0.26) p=0.050 
37C* 21.49 (0.57) 30.75 (0.03) - 
40C 19.16 (1.58) 30.25 (0.31) p=0.62 
Incubation time     
1 hour* 25.25 (2.46) 31.7 (3.62) p=0.272 
20 hours 23.29 (1.65) 33.45 (0.73) 
rNTP concentration     
1mM* 26.87 (1.05) 29.94 (0.30) 
p=0.046 
2mM 24.70 (0.41) 32.39 (1.06) 
 
 
Table 3.10. A total of 10
6
 copies of the plasmid p16SRNA were added to 50 units of 
Invitrogen T7 polymerase and, following DNAse treatment, resultant RNA quantified by RT-
qPCR with the primers 16S_F(Seattle) and 16S_R7 and the probe 16S_P3. Residual plasmid 
DNA was then quantified by qPCR with the same primers and probe. Changes to reaction 
conditions were assessed individually. Incubation at 40C and doubling the rNTP 
concentration improved polymerase activity, whereas increasing the incubation time 
decreased it.  
*Standard reaction conditions with which modified conditions were compared.  
** Mean of three replicas in two separate experiments. 
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Table 3.11 Comparison of T7 RNA polymerases 
 
Method and Reaction Conditions 
Mean† (std. dev.) 
cycle threshold of 
DNA detection 
Mean† (std. dev.) 
cycle threshold 
RNA detection 
Reagent [final]   
I. Promega T7 Polymerase  
rNTP mix (Invitrogen, UK) 2mM 
33.39 (0.63) 27.62 (0.99) 
Reaction buffer 1x 
DTT (Promega, UK) 10mM 
RNAse inhibitor 50units 
T7 polymerase 40units 
II. Invitrogen T7 Polymerase 
rNTP mix (Invitrogen, UK) 2mM 
37.28 (1.03) 26.53 (0.18) 
Reaction buffer 1x 
DTT (Promega, UK) 5mM 
RNAse inhibitor 50units 
T7 polymerase 50units 
III. Promega T7 RiboMAX Express 
Ribomax buffer (contains 
rNTPs) 
 
1x 
 
29.71 (0.15) 17.11* (0.06) T7 express enzyme (contains 
RNAsin) 
Not given. 
2l used in 
20l 
reaction 
 
 
Table 3.11. A total of 10
6
 copies of ncoI-linearised p16SRNA were used as a template for the 
assessment of three T7 polymerases (I, II and III). Reaction components are listed beneath the 
name of each enzyme.  DNA was quantified in a TaqMan qPCR with the primers 
16S_F(Seattle) and 16S_R7 and the probe 16S_P3. RNA was quantified in a one-step RT-
qPCR with the same primers and probe. *p=<0.001 (two-sided t-test) compared with 
Invitrogen T7 polymerase. † The mean of three technical replicates in a single experiment. 
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3.2.4.4 Sensitivity of 16S rRNA detection 
 
RNA for standard determination was diluted in a 1:10 dilution series from a 
spectrophotometry-determined concentration of 10
9
 copies/ 5l to 102 copies/l. A total of 10 
replicas of each of the dilutions 10
4
, 10
3
 and 10
2
 were then quantified by RT-qPCR according 
to the method in Chapter 2.12.2. None of the dilutions at 10
3
 copies/reaction showed any 16S 
rRNA amplification and nine of 10 replicas at the 10
4
 copies/reaction concentration were 
positive with a mean cycle threshold of 40.82 cycles (std. dev. 1.365). At a dilution factor of 
10
5 
(a starting concentration of 10
4 
copies/reaction by spectrophotometry), the natural log of a 
10% probability of a negative reaction equated to a starting concentration of 2.3x10
6
 
copies/l. This suggested that the original 104 dilution contained approximately 23 copies 
which, given an average cycle threshold of 40.82 cycles for this dilution, was deemed 
accurate. A quantification standard curve was then constructed comprising a 1:10 dilution 
series from 2.3x10
5
 to 23 copies/reaction. In order to confirm its analytical sensitivity, 
efficiency of amplification and to ensure acceptable inter and intra-assay variability, three 
separate dilution series were quantified (each dilution was quantified in triplicate). A fourth 
dilution series, containing both 16S rRNA and carrier RNA was also quantified for 
comparison. The results of these four experiments are shown in Figure 3.7 and Table 3.12 
summarises the variability of the assay. With perfect amplification efficiency, the amount of 
DNA in a PCR should have doubled with each cycle – every copy of DNA becoming the 
template for a new copy. In reality, an amplification efficiency of 90-105% is ideal and was 
shown here to vary from 85.2% to 92.9% (mean 87.77%). The slope of the plot cycle 
threshold vs starting copy number was also a measure of efficiency. In the perfect reaction, 
where the quantity of DNA doubles after each round of PCR, there would have been a 3.32 
cycle difference (or a slope of -3.32 on a plot of cycle threshold vs DNA quantity) between 
each 1:10 dilution of the standard according to the equation: 
              
(
  
     )    
For example,  
The mean slope calculated for this standard curve was -3.66 (std. dev. 0.10). Finally, the 
‘linearity’ of the plot was calculated by the real-time instrument software and indicated 
variability across replicates by measuring how well the experimental data fitted the regression 
line. Also referred to as the coefficient of variation, the target for linearity is  0.98 and was 
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shown here to be 0.97 (std. dev 0.04). Intra-assay variability was calculated to be low and 
inter-assay variability, dependent on RNA stability, reverse transcriptase and PCR efficiency 
was around three percent.  
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Figure 3.7 Construction of a standard curve for 16S rRNA quantification 
 
A. Standard curves 
 
 
B. Absolute quantification  
Calculated copies 17/05/12 18/05/12 22/05/12 25/5/12* Mean** std. dev. 
2.3x10
5
 25.71 25.61 23.24 24.45 24.85 1.40 
2.3x10
4
 28.46 28.68 26.84 27.65 27.99 1.00 
2.3x10
3
 31.88 32.45 30.18 30.92 31.50 1.18 
2.3x10
2
 36.14 35.7 34.04 34.47 35.29 1.11 
2.3x10
1
 40.83 40.88 37.29 39.11 39.67 2.06 
 
C. Standard curve parameters 
 
Amplification efficiency (%) Linearity (R
2
) Slope (cycles) 
18.5.12 86.40 0.98 -3.70 
22.5.12 91.70 0.99 -3.53 
17.5.12 85.20 0.92 -3.74 
25.5.12* 92.90 0.99 -3.50 
mean** 87.77 0.97 -3.66 
st dev   3.46 0.04 0.10 
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Fig. 3.7. Four dilution series of RNA to be used as a quantification standard for T. pallidum 
16S rRNA were amplified in a TaqMan RT-qPCR. Panels A and B compare the mean cycle 
threshold (red squares) during the PCR for target detection with the starting concentration of 
RNA for each of the four experiments conducted. All four were identical, except for the 
addition of carrier RNA to the dilution series 25/5/12 (blue crosses). Panel C demonstrates 
the amplification efficiency (a perfect doubling of DNA after each cycle would have an 
efficiency of 100%) together with a measure of linearity (coefficient of determination) and the 
slope of the line (where doubling each cycle would give a gradient 3.32 cycles). 
* This replica contained carrier RNA  ** Excluding dilution series containing carrier RNA 
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Table 3.12 Intra-assay and inter-assay variability of 16S rRNA quantification 
 
Copies/reaction 
Mean Cycle 
Threshold 
Standard 
Deviation 
Coefficient of 
variation (%) 
Intra-assay variability* 
2.3x10
4
 26.80 0.09 0.34 
2.3x10
3 30.18  0.23 0.75 
2.3x10
2
 34.04  0.38 1.12 
Inter-assay variability** 
2.3x10
4
 28.64 0.87 3.05 
2.3x10
3
 32.09 0.93 2.90 
2.3x10
2
 35.75 0.94 2.63 
 
Table 3.12 Intra-assay variation of T. pallidum 16S rRNA quantification was assessed by 
comparing the cycle thresholds of three technical replicates at three RNA starting 
concentrations. Inter-assay variation was determined by repeating the assay on three separate 
days. 
*Mean of three replicas in a single experiment 
**Mean of four separate experiments 
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On the basis of the results in this section methods described for use with clinical samples were 
finalised. To summarise: 
 
 DNA and RNA extraction from snostrip samples were to proceed in the same extraction 
process using the Qiagen all-prep kit (Chapter 2.3.4.2). 
 Blood for RNA extraction was to be collected into Tempus™ tubes and extracted 
according to the method in Chapter 2.3.3.1). No additional steps for bacterial lysis or 
human mRNA capture were required. 
 T. pallidum DNA was to be quantified in a TaqMan qPCR assay with the primers TP1 and 
TP2 and the FAM-labelled probe TPP. A calibration curve was to be included in each run 
constructed from ncoI linearised plasmid pTp47 (Chapter 2.12.1.2). 
 T. pallidum RNA was to be quantified in a one-step RT-qPCR. The RNA target was 16S 
rRNA and the quantification assay used the primers 16S_R7 and 16S_F(seattle) and the 
probe 16S_P3 (Chapter 2.12.2). An in-run RNA absolute quantification standard was to 
be used which was made by the activity of T7 polymerase on the recombinant plasmid 
p16SRNA (2.13.1). 
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3.2.5 Clinical validation of T. pallidum quantification in blood and ulcer samples 
 
Samples for T. pallidum quantification were collected from patients during three separate 
studies, which are described in Chapter 2.14. The first study was a clinical validation of the 
SYBR-green based qPCR described in Chapter 3.2.3.1 which recruited patients with 
suspected syphilis, and was conducted in London between July 2006 and January 2008. The 
study was designed to recruit both those with syphilis and non-syphilis diagnoses in order to 
compare cases (those in whom syphilis was confirmed) and controls (with non-syphilis 
diagnoses). The results of this validation described here were then followed by both further 
assay development and patient recruitment for two subsequent studies. 
 
3.2.5.1 Patient recruitment and demographic data 
 
A total of 99 patients were recruited between July 2006 and January 2008. Figure 3.8 
demonstrates that 44 patients had a microbiologically confirmed diagnosis of syphilis 
comprising 14 primary cases; 19 secondary cases; eight latent cases and three patients with 
neurosyphilis (all during the secondary stage). Of the syphilis-uninfected patients, 19 were 
confirmed to have infection with Herpes simplex virus and 19 patients, for whom no evidence 
of an STI could be found, were deemed to have non-specific genital ulceration (which is 
consistent with other studies examining the causes of genital ulceration) (232, 233). The final 
17 patients were asymptomatic sexual contacts of infectious syphilis who received treatment 
and subsequently showed no clinical or microbiological sign of infection during follow-up. 
Case definitions for both syphilis and non-syphilis diagnoses are given in Appendix 5. The 
study population was representative of the current UK syphilis epidemic being predominantly 
male (97/99, 98%), of which 80.9% were homosexual; Caucasian (88/99, 88.7%) and around 
half (52/99, 52.5%) were HIV-1 infected. Neither of the two women recruited were HIV-1 
infected. (1) 
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Figure 3.8 Patient recruitment to qPCR validation study 
 
 
 
 
 
 
Fig. 3.8. Summary of patient recruitment to a study between July 2006 and January 2008 
which aimed to validate a method for T. pallidum DNA and RNA quantification in blood and 
ulcer samples   
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3.2.5.2 T. pallidum detection in three blood components 
 
An aliquot of each EDTA whole blood sample collected during the current study was 
separated into plasma and PBMCs using Histopaque, as described in Chapter 2.2.1. Table 
3.13 shows qPCR results for 16 samples where at least one of the three blood components 
(whole blood, plasma, PBMCs) contained detectable T. pallidum tpp047 DNA. Plasma and 
whole blood results were available for all 16 samples and PBMC results for eight. In total, T. 
pallidum was detected in 94% (15/16) of the whole blood samples, in the plasma of 75% 
(12/16) and PBMC fraction of 75% (6/8). The mean T. pallidum load in whole blood (269.19 
copies/ml) exceeded that of both plasma (154.88 copies/ml) and PBMC (143.63 copies/ml) 
fractions. These differences (whole blood vs plasma and whole blood vs PMBCs) were not 
statistically significant, but whole blood appeared to be the better sample for T. pallidum 
detection, both qualitatively and quantitatively.  
 
3.2.5.3 Qualitative PCR: Sensitivity and Specificity analysis of tpp047 detection in ulcer 
and whole blood samples 
 
Patients’ final clinico-microbiological diagnoses (Appendix 5) were compared with T. 
pallidum tpp047 qPCR results. Table 3.14 illustrates the proportion of whole blood and ulcer 
samples that contained tpp047 DNA for each stage of disease. All ulcer samples from patients 
with primary or secondary disease and one sample from a patient with a non-specific ulcer 
contained T. pallidum DNA. This equates to a sensitivity of 100% and a specificity of 
97.14%, respectively. The potentially false positive ulcer PCR result was from a patient with 
a one-week history of multiple non-tender genital ulcers thought to be atypical genital herpes 
and treated with Acyclovir. The DGM was negative, as was the contemporaneous and 
convalescent syphilis serology and PCR for both herpes simplex virus types. It is not known 
whether this patient received coincidental treponemocidal antibiotics that could have 
prevented seroconversion (111). All 14 patients with primary syphilis had PCR-positive 
ulcers and 10 were DGM-positive. All four patients with DGM-negative ulcers had positive 
serology at enrolment (and thus microbiological confirmation of their diagnosis). Three of the 
five patients with ulcers in secondary disease had DGM performed and two were positive. 
Compared with the final diagnosis, the sensitivity and specificity of DGM for syphilis ulcers 
(primary and secondary combined) were 70.59% and 87.88%, respectively, with no 
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significant difference observed for primary or secondary cases analysed individually. The 
sensitivity of PCR for the diagnosis of primary disease was 100%. 
 
Whole blood samples from all 44 patients with a syphilis diagnosis (primary, secondary, 
latent or neurosyphilis) were subjected to T. pallidum tpp047 PCR and a total of 14/44 
(31.80%) were positive (Table 3.14). No patient with a non-syphilis diagnosis had detectable 
T. pallidum DNA in their blood, including the 17 who were contacts of infectious syphilis. 
When all 99 whole blood PCR results were compared with the donor patients’ final clinical 
diagnosis, the sensitivity for T. pallidum detection was 31.80%, with a specificity of 100%. 
When calculated according to disease stage, the sensitivity of whole blood PCR to identify 
secondary disease was 74.0% (specificity 100%); 21.0% for primary disease (specificity 
100%) and 12.5% for latent disease. Sensitivity and specificity results, including 95% 
confidence intervals are given in Table 3.15.  
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Table 3.13 Comparison T. pallidum detection in three blood components 
 
  tpp047 quantification 
 
Patient Study 
Number 
Plasma 
(copies/ml) 
Whole Blood 
(copies/ml) 
PBMC 
(copies/ml 
equivalent) 
Primary Syphilis 
 9 195 127 120 
 32 614 168 0 
 90 122 127 † 
Secondary Syphilis  
 16 673 886 119 
 17 203 1026 309 
 22 121 518 0 
 27 0 632 185 
 29 10 58 242 
 34 0 495 † 
 45 0 6 † 
 49 16 10 † 
 53 284 28 † 
 61 144 91 † 
 81 95 65 † 
Latent Syphilis 
 28 0 70 174 
Neurosyphilis 
 56 1 0 † 
     
Mean  154.88 269.19 143.63 
Std. dev  210.66 333.99 108.29 
t-test (2 tailed)*  p=0.26  p=0.32** 
 
Table 3.13. An aliquot of EDTA whole blood samples from 16 patients was separated into 
plasma and PBMC fractions. DNA was extracted and T. pallidum tpp047 DNA was 
quantified by qPCR. Whole blood contained the largest amounts of detectable T. pallidum, 
although the difference between detection in whole blood compared with PBMCs or plasma 
was not statistically significant. 
† Result was unavailable for analysis 
*statistical significance versus quantification in whole blood. 
**Missing were results excluded from the analysis. 
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Table 3.14 T. pallidum quantification according to clinico-microbiological diagnosis 
 
Diagnosis 
HIV-1 co-
infected 
n (%) 
Mean 
CD4 
(cells/l) 
 (std. 
dev.) 
Median 
RPR 
 (min-max) 
Mean 
tpp047 
copies/ml of 
Whole 
Blood 
(std. dev.) 
Mean tpp047 
copies/snostrip 
(std. dev.) 
Primary  
(n=14) 
7 (50.0) 
 
501 
(234) 
n=12 
6 
(0-64) 
3/14 +ve 
140.67 
(23.67) 
14/14 +ve 
2480.96 
(3419.15) 
Secondary 
(n=19) 
15 (78.9) 
 
469 
(152) 
n=19 
128 
(8-512) 
 
10/19 +ve  
346.82 
(380.02) 
5/5 +ve 
303.10 
(236.15) 
Latent  
(n=8) 
4 (50.0) 
 
450 
(178) 
n=8 
0.5 
(0-256) 
1/8 +ve 
70 
n/a 
Neurosyphilis 
(n=3) 
2 (67.7) 
 
475 
(261) 
n=3 
32 
(18-64) 
0/3 +ve n/a 
Contact  
(n=17) 
9 (52.9) 
 
515 
(143) 
n/a 
0/17 +ve 
 
0/2 +ve 
 
HSV  
(n=19) 
4 (21.1) 
 
595 
(177) 
n/a 
0/19 +ve 
 
0/18 +ve 
 
Non-specific 
genital ulcer 
(n=19) 
8 (42.1) 
 
433 
(210) 
n/a 
0/19 +ve 
 
1/15 +ve 
46 copies/strip 
 
Table 3.14. T. pallidum DNA was quantified in blood and ulcer samples (collected with 
Snostrips) taken from 99 patients with suspected syphilis. Following examination and 
investigation, including a Rapid Plasma Reagin (RPR) syphilis test, patients were given a 
clinic-microbiological diagnosis. Detection was most reliable in the blood of patients with 
secondary disease, and was found at higher load that those with primary or latent infection. A 
single sample from a patient with a non-syphilis diagnosis was found to contain T. pallidum 
DNA. 
n/a = not applicable 
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Table 3.15 Sensitivity and Specificity of T. pallidum detection in whole blood 
 
   95% Confidence Interval 
 
 %* 
Upper Limit 
(%) 
Lower Limit 
(%) 
     
All Stages 
(n=44) 
Sensitivity 31.8 19.0 48.0 
Specificity 100.0 91.0 100.0 
    
Secondary Disease 
(n=19) 
Sensitivity 74.0 49.0 90.0 
Specificity 100.0 92.0 100.0 
    
Primary Disease 
(n=14) 
Sensitivity 21.0 8.0 51.0 
Specificity 100.0 91.0 100.0 
    
Latent Disease 
(n=8) 
Sensitivity 12.5 1.0 53.0 
Specificity 100.0 92.0 1.0 
     
 
 
Table 3.15. The clinical sensitivity and specificity of T. pallidum tpp047 DNA detection in 
whole blood samples from patients with syphilis was assessed according to stage of disease. 
Samples from patients given a non-syphilis final diagnosis were used as negative controls.  
* Sensitivity and specificity (expressed as a percentage) compared with 55 syphilis-uninfected 
controls.  
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3.2.5.4 Quantitative PCR results according to stage of disease 
 
Whole blood and ulcer specimens were collected and handled as described in Chapter 2.2. 
The first 39 samples collected were processed immediately, DNA extracted (according to the 
methods in Chapter 2.3) and T. pallidum DNA quantified by qPCR (Chapter 2.12.1). The 
remaining 60 samples were stored at -80C for up to two years prior to DNA extraction and 
quantification. DNA from 400l whole blood was extracted and resuspended in 120l of 
water. Ulcer exudate was absorbed onto a single snostrip and extracted DNA was similarly 
resuspended in 120l water. The tpp047 gene was quantified in three separate 10l replicates 
and a mean starting copy number calculated by the instrument software, according to cycle 
threshold results obtained from an in-run quantification standard. The starting concentration 
of tpp047 copies/ml a whole blood was calculated as follows: 
 
                                                  (
                
  
)        
† DNA was extracted from 400l of blood. 
 
For snostrips, the equation was as follows: 
 
                 ⁄                                    (
                
  
) 
 
Quantification data for all patients are presented in Appendix 6.  
 
Primary syphilis  
 
A total of 14 patients were diagnosed with primary syphilis, of whom half were HIV-1 
infected, 11 had a positive T. pallidum EIA result and 13 had a positive RPR (mode 4, range 
64). T. pallidum tpp047 DNA was detected in ulcer exudates of all 14 patients diagnosed with 
primary disease. Figure 3.9 A shows the mean copy number of tpp047 DNA from ulcers to be 
2480 copies/strip (std. dev. 3419). When sub-divided, a statistically significant difference was 
not observed between samples processed immediately (mean 3233 copies/strip, std. dev. 
4116) and those processed after storage (mean 1126 copies/strip, std. dev. 734) (p=0.29). A 
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DGM result was available for all patients and 10 were positive. A mean of 562 (std. dev. 464) 
copies/strip were detected in DGM negative ulcers vs 3248 (std. dev. 3811) in those which 
were DGM positive (p=0.196) (Figure 3.10). Three patients had tpp047 DNA detectable in 
their blood with a copy number one to two logs lower (mean 30.14 copies/mL, std. dev. 
60.61) than for ulcers.  
 
Secondary syphilis  
 
Secondary syphilis was diagnosed in 19 patients of whom 15 (78.9%) were HIV-1 infected. 
All patients had both a positive T. pallidum EIA and RPR (modal RPR was 128 with a range 
of 504). As seen in Table 3.14, DNA was detected in 10/19 whole blood samples with an 
average (excluding negative samples) of 346 tpp047 copies/ml (std. dev. 380). Moreover, 
Figure 3.9 B demonstrates that immediate DNA extraction improved T. pallidum detection 
and was associated with higher (602 copies/ml vs 40 copies/ml) bacterial load (p=0.005).  
 
A total of five ulcer samples were available from five patients, two of which were taken from 
muco-cutaneous oral lesions and three from healing primary chancres. DGM was performed 
on samples from the healing chancres and spirochetes were seen in two. All five samples 
contained T. pallidum DNA with a mean bacterial load of 303 (std. dev 206) copies/strip. 
When compared, the mean tpp047 DNA copy number was lower in these three healing 
primary chancres (351 copies/strip) than primary chancres (2480 copies/strip) (p=0.219).  
 
Other cases 
 
Latent disease (early or late) was diagnosed in a total of eight patients of whom four were 
HIV-1 infected. All had a positive T. pallidum EIA and four had a positive RPR (two were 
neat, one was 1:16 and one was 1:256). tpp047 DNA was detected in the EDTA whole blood 
of a single patient who was HIV-1 infected, had an RPR titre of 1:256 and had not received 
prior syphilis treatment. The patient had been initially diagnosed with syphilis two years prior 
to study entry (with an RPR of 1:131,072), but had been lost to follow-up. Three patients 
recruited to the study were diagnosed with neurosyphilis. All three had serological results 
consistent with early disease (EIA positive and an RPR 8) together with neurological 
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symptoms and CSF examination typical of central nervous system involvement. None had 
detectable T. pallidum DNA in either their blood or CSF.  
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Figure 3.9 Assessment of the impact of sample storage on T. pallidum bacterial load 
 
A. Primary disease Snostrip samples 
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B. Secondary disease whole blood samples 
 
 
 
Fig. 3.9. A. T. pallidum DNA (tpp047) from primary ulcer snostrip samples was either 
extracted and quantified (using qPCR) immediately following collection, or after sample 
storage at -80C for up to 5 years. B. Whole blood samples collected into EDTA were 
available from patients with secondary syphilis. DNA was extracted and quantified (tpp047 
qPCR) immediately or following long-term storage at -80C. A student’s t-test was used to 
compare mean bacterial loads. 
 
 139 
Figure 3.10 Comparison of T. pallidum ulcer bacterial load with DGM detection 
 
 
 
Fig. 3.10. During a cross-sectional study of early syphilis, ulcers suspected to be primary 
syphilis chancres were examined by DGM prior to sampling for T. pallidum DNA. Following 
T. pallidum qPCR (tpp047 target), the bacterial load in DGM positive and negative ulcers was 
compared. A student’s t-test was used to compare mean ulcer load. 
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3.2.5.5 Impact of HIV infection of T. pallidum load  
 
Of the 14 patients recruited to the study suffering from primary disease, half were HIV-1 
infected and, as demonstrated previously, all 14 ulcer samples collected contained T. pallidum 
DNA. Figure 3.11 demonstrates the difference in T. pallidum bacterial load observed in 
primary disease ulcers according to HIV seropositivity. In HIV-1 infected patients, a mean of 
3772 (std. dev. 4513) tpp047 copies/strip were detected compared with a mean of 1190 (std. 
dev. 1035) for HIV-1 uninfected patients (p= 0.166). The mean CD4 count of the seven HIV-
1 infected patients was 501 (std. dev. 234) and CD4 count did not correlate with T. pallidum 
load.  
 
T. pallidum DNA was detectable in the blood of 11 patients with secondary disease, of whom 
eight (73%) were HIV-1 infected. No statistically significant difference was observed in 
whole blood bacterial load between HIV-1 infected (276 tpp047 copies/ml, std. dev. 344) and 
uninfected (534 tpp047 copies/ml, std. dev. 484) subjects (p=0.343), although it must be 
noted that the standard deviations for both measurements were wide. Across all stages of 
disease, the mean CD4 count of bacteraemic HIV-1 infected patients was 446 (std. dev. 166) 
and not significantly different from those patients without detectable bacteraemia (494, std. 
dev. 183) (p=0.497). 
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Figure 3.11 T. pallidum load in ulcer samples according to HIV-1 infection status 
 
 
 
 
 
Fig. 3.11. T. pallidum DNA (tpp047) was quantified by qPCR in 14 ulcer samples collected 
from patients suffering from primary disease, of whom seven were HIV-1 co-infected. Error 
bars show 95% confidence intervals. 
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3.2.5.6 RPR correlates with bacterial load (tpp047 DNA)  
 
Figure 3.12 demonstrates a moderate correlation (Spearman’s correlation coefficient = 0.354) 
between T. pallidum load detectable in whole blood and baseline RPR results (taken on day of 
recruitment to the study) (p=0.021). This association was not seen when stages of disease 
were analysed separately. 
3.2.5.7 Initial RNA quantification  
 
Tempus™ RNA blood samples were collected from a total of 70 patients. Tubes were stored 
at -80C for an average of 5 years prior to RNA extraction and quantification as described in 
Chapters 2.3.3.1 and 2.12.2. During extraction, 16 samples were noted to be clotted and were 
discarded, leaving 54 samples for analysis by RT-qPCR. A total of 22 samples were from 
patients with syphilis, of which 11 (5 primary, 5 secondary and 1 latent) were found to 
contain T. pallidum 16S rRNA. None of the 32 samples from patients with non-syphilis 
diagnoses contained detectable T. pallidum 16S rRNA. 
Table 3.16 summarises RT-qPCR data for patients with syphilis diagnoses. RNA detection 
was more sensitive than DNA for the correct identification of primary (62.5% vs 25%), 
secondary (55.5% vs 55%) and latent (16.4% vs 0%) syphilis and was equally specific 
(100%). Moreover, the amount of RNA quantified exceeded that of DNA for both primary 
(p=0.086) and secondary (p=0.023) disease.  
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Figure 3.12 Correlation of blood T. pallidum load and baseline RPR titre 
 
 
 
 
Fig 3.12. Baseline (pre-treatment) RPR titres (log
10
) of 19 patients with secondary stage 
syphilis (blue), eight with latent stage (light green) and 12 with primary stage (purple) were 
compared with the results of T. pallidum tpp047 quantification in whole blood samples. 
Spearman’s correlation coefficient was 0.354 (p=0.021, 2-tailed))  
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Table 3.16 Validation of T. pallidum RNA and DNA qPCRs  
 
Disease Stage Patient study 
number  
16S rRNA 
copies/ml blood 
tpp047 copies/ml 
blood 
 
Primary 33 3841 0  
69 0 0  
90 6892 127  
93 0 0  
26 0 0  
32 3015 168  
52 48 0  
89 60 0  
mean (std. dev.) 1732.00 (2600) 36.88 (69) p=0.086* 
sensitivity (%) 62.5 25  
 specificity (%) 100 100  
     
Secondary 29 2437 58  
27 2061 632  
34 1776 495  
45 4376 6  
61 2433 91  
74 0 0  
75 0 0  
77 0 0  
83 0 0  
mean (std. dev.) 1453.67 (1556) 142.44 (243) p=0.023* 
sensitivity (%) 55.5 55  
 specificity (%) 100 100  
     
Latent 44 0 0  
67 82 0  
95 0 0  
59 0 0  
84 0 0  
mean (std. dev.) 16.40 (16.40) n/a  
sensitivity (%) 20 0  
 specificity (%) 100 100  
 
Table 3.16. T. pallidum DNA (tpp047) and 16S rRNA detection and quantification were 
compared in 22 whole blood samples (only samples where both RNA and DNA results were 
available were included). Sensitivity and specificity were calculated by comparing T. 
pallidum detection with patients’ clinic-microbiological diagnosis. Patients included in the 
study with non-syphilis diagnoses (not shown) became negative controls.  
*Statistical significance was calculated with a two-tailed student’s t-test. 
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3.2.6 CDTB samples 
 
Following clinical validation of the tpp047 qPCR, blood and ulcer samples from a a further 
cross-section of patients (described in Chapter 2.14.2) were used to assess modifications made 
to the tpp047 qPCR (Chapter 3.2.3.2); to continue to monitor the prevalence of T. pallidum 
macrolide resistance (Chapter 5), to quantify T. pallidum 16S rRNA in freshly drawn samples 
and to assess T. pallidum load in blood from more patients with latent disease. 
 
3.2.6.1 Demographics 
 
As shown in Figure 3.13, 62 patients were recruited. A total of 58 syphilis diagnoses (nine 
primary, 21 secondary and 28 latent) three cases of genital herpes and one patient with a non-
specific genital ulcer. In contrast to the validation study, patients with neurological signs or 
symptoms were considered to be secondary or latent cases, and sub-divided into those with 
and without neurological symptoms. In this cross-section, seven patients had neurological 
involvement and all were in the secondary stage. Patients with syphilis comprised two women 
(3.4%) and 58 men (96.6%) of whom 52 (89.7%) were MSM and 36 (62.1%) were HIV-1 
infected (with a mean CD4 count of 603.5 (std. dev. 160). Overall, patients had a mean age of 
37.45 (range 43) and the majority (62.1%) were white. 
 
 146 
Figure 3.13 Summary of CDTB sample collection 
 
 
 
 
Fig. 3.13. A total of 62 patients donated samples to the CDTB between January 2011 and 
December 2012 of which 58 patients were diagnosed with syphilis, and four were given an 
alternative diagnosis. 
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3.2.6.2 T. pallidum bacteraemia and disease stage 
 
None of the samples collected from patients without syphilis contained detectable T. pallidum 
nucleic acids. DNA quantification results were available from all 58 patients with syphilis, 
and RNA results from 44 (Tempus™ samples were not collected from the first 10 patients 
recruited and four samples were spoiled). Table 3.17 and Figure 3.14 show quantification data 
from all samples and compare DNA and RNA quantification in the sub-group of patients 
where both samples were available for qPCR. The stage of disease during which both DNA 
and RNA were most frequently detected was secondary (81% and 61.75%), followed by 
primary (55.5% and 40%) and finally latent (25% and 39%). Bacterial load, measured by both 
qPCR and RT-qPCR, was also greatest during the secondary stage and was significantly 
higher than detected in latent disease (p=0.0001).  
 
The standard deviation of mean RNA levels at any stage of disease were seen to exceed those 
of DNA, suggesting that DNA level may be a better predictor of disease stage as it is less 
variable. Figure 3.14 demonstrates that the nine highest tpp047-measured bacterial loads 
(1303 copies/ml and above) were all from patients with secondary disease. When this level of 
1303 copies/ml was taken as a cut-off (i.e. levels above this value indicated secondary 
disease), T. pallidum DNA detection in whole blood had a sensitivity of 0.58 (95% CI 0.33 - 
0.80) and specificity of 1 (95% CI 0.69 - 1) to identify correctly secondary disease. When a 
level of <1303 was used to predict latent disease, the sensitivity was 100% (95% CI 0.84 – 1), 
however specificity was low (33%. 95% CI 0.17-0.52). Binary logistic regression was then 
employed to calculate the predicted probability of both secondary and latent disease at each 
observed level of whole blood T. pallidum DNA. Next, these probabilities were used to plot 
receiver operator characteristics (ROC) curves for both stages (Figure 3.15) comparing the 
true positive rate (sensitivity) on the ‘y’ axis with the false positive rate (1-specificity) on the 
‘x’ axis. The area under the curve for secondary disease was 0.784 (asymptotic significance = 
0.010) signifying that a whole blood sample containing T. pallidum DNA has a 78.4% chance 
of being from a patient with secondary disease. Latent disease, however, had an area under 
the curve (AUC) of 0.569 (asymptotic significance = 0.543) confirming that presence T. 
pallidum bacteraemia cannot be used to predict latent infection. Too few quantification results 
were available from patients diagnosed with primary disease to make detailed analysis of this 
group meaningful.  
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Table 3.17 Comparison of the quantification of T. pallidum DNA and RNA in whole 
blood. 
 
Disease Stage All samples Paired DNA and RNA results* 
 
DNA 
(tpp047) 
16S rRNA 
DNA 
(tpp047) 
16S rRNA 
t-test (2-
sided) 
Primary      
no of positive 
samples (%) 
5/9 (55.5) 
2/5  
(40) 
3/5  
(60) 
2/5  
(40) 
 
mean copies/ml 
(std. dev.) 
205 (388) 
486  
(850) 
248  
(518) 
486  
(850) 
p=0.608 
      
Secondary      
no of positive 
samples (%) 
17/21 
(80.9) 
11/16 
(68.75) 
12/16  
(75) 
11/16 
(68.75) 
 
mean copies/ml 
(std. dev.) 
4776 
(1396) 
2608  
(2969) 
1458** 
(1408) 
2608** 
(2969) 
p=0.171 
Latent      
      
no of positive 
samples (%) 
7/28  
(25) 
9/23  
(39) 
7/23  
(30) 
9/23  
(39) 
 
mean copies/ml 
(std. dev.) 
124 (315) 
796  
(1698) 
151**  
(342) 
796** 
(1698) 
p=0.081 
 
 
Table 3.17. T. pallidum tpp047 DNA and 16S rRNA were quantified in 58 whole blood 
samples collected into EDTA and 44 Tempus™-preserved samples from patients with 
primary, secondary and latent syphilis. 
*Results are only displayed where both DNA and RNA quantification data were available for 
the same patient. 
** RNA and DNA quantification in samples from patients with secondary disease compared 
with samples from latently infected patients. Secondary vs latent (RNA) p=0.02; secondary vs 
latent (DNA) (p=0.0001). 
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Figure 3.14 Comparison of bacterial load in whole blood samples taken from patients 
with different stages of disease 
 
A. tpp047 quantification  
 
B. 16S rRNA quantification 
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Fig 3.14. A. Whole blood from patients with primary (n=5), secondary (n=16) or latent 
(n=23) syphilis was collected into EDTA and T. pallidum DNA (tpp047) quantified by qPCR. 
B. Quantification of 16S rRNA in Tempus™ blood samples collected from the same patients.  
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Figure 3.15 Receiver operator characteristics (ROC) of T. pallidum detection in blood 
for the diagnosis of syphilis. 
 
A. Secondary Disease 
 
B. Latent Disease 
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Fig. 3.15. A binary logistic regression was used to calculate the probability of secondary and 
latent syphilis being correctly identified across a range of whole blood bacterial loads. These 
ROC curves (in blue) compare the sensitivity and 1-specificity for each probability. An area 
under the curve (AUC) of 0.5 (green line) represents the null hypothesis that any association 
between disease and detectable bacteremia is due to chance alone. A. demonstrates the AUC 
for secondary disease to be 0.784 with an asymptotic significance value of 0.010 (95% CI 
0.617-0.952). B. shows the AUC for latent disease is 0.569 with an asymptotic significance 
value of 0.543 (95% CI 0.385-0.754). 
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3.2.6.3 HIV-1 infection is not associated with higher levels of T. pallidum bacteraemia at 
any stage of disease 
 
In total, 62% of patients included in the current study were HIV-1 infected with a mean CD4 
count of 603.5 cells/l. This percentage varied according to stage of syphilis, as demonstrated 
in Figure 3.13. Of note, the percentage of HIV-1 infected patients who presented with 
secondary disease was 85.7% compared with 55.6% and 50% for those diagnosed with 
primary or latent disease, respectively. 
 
Figure 3.16 demonstrates that no significant differences in T. pallidum bacterial load 
(measured with both tpp047 and 16S rRNA) were identified when patients with and without 
HIV-1 infection were compared.  
 
3.2.6.4 Concordance of RNA and DNA detection in samples from both cross-sectional 
studies. 
 
The detection of tpp047 DNA and 16S rRNA in samples collected during the two UK cross-
sectional studies were compared. Only those Tempus™ blood samples which were intact (not 
clotted) were included in this analysis. For patients with secondary disease, there was 100% 
concordance between DNA and RNA detection, with 15/23 (65%) of samples positive for 
both nucleic acids and 8/23 (35%) of samples negative for both. Samples from patients with 
primary disease were 70% concordant and 89% concordance was observed for patients with 
latent disease. RNA detection was the more reliable in primary and latent disease with 3/13 
(23%) and 3/28 (11%) of samples being RNA positive and DNA negative, respectively. A 
single primary sample (7%) and no latent samples were DNA positive, RNA negative. 
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Figure 3.16 T. pallidum quantification in blood according to HIV-1 status 
 
A. 16S rRNA quantification 
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Fig 3.16. B. tpp047 DNA quantification 
 
  
 
Fig 3.16 T. pallidum 16S rRNA (A) and tpp047 DNA (B) and were quantified in Tempus™ 
samples and whole blood collected into EDTA from 58 patients with (green bars) and without 
(blue bars) HIV-1 co-infection.  Error bars define the 95% confidence intervals. 
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3.2.7 Cross-sectional study of T. pallidum in Sri Lanka 
 
A total of 25 exudate samples were collected from 25 patients with microbiologically 
confirmed syphilis between January and August 2012. All subjects except one were male of 
whom 11 (45.8%) were MSM. The mean age of subjects (excluding a neonate with congenital 
disease) was 29.5 (std. dev. 9.7) years and all except two patients were Sinhalese. 
T. pallidum DNA and RNA were detected in 24/25 samples (96% sensitive, 95% CI 76-99%). 
The single negative sample was taken from a female patient who presented with a DGM-
negative labial ulcer and positive syphilis serology (RPR 1:64). Excluding the negative 
sample, 14 samples were from primary chancres, 9 were from secondary lesions and one was 
a skin swab (neonatal sample). A summary of recruitment and samples is given in Figure 
3.17. 
3.2.7.1 T. pallidum quantification according to stage of disease 
 
T. pallidum DNA and RNA were quantifiable in 14 primary chancres. These chancres had a 
mean area of 57.15mm
2
 (std. dev. 36.42) and contained an average of 3.84x10
4
 (std. dev. 
4.78x10
4
) tpp047 copies/strip and significantly more 16S rRNA (6.79x10
6
 (std. dev. 
7.52x10
6
) copies/strip) (p=0.002). Secondary lesions had a mean area of 32.71mm
2
 (std. dev. 
20.50) and contained 8.42x10
3 
(std. dev. 1.08x10
4
) tpp047 copies/strip and 1.41x10
6
 16S 
rRNA copies/strip (std. dev. 2.26x10
6
) (p=0.08). When the quantity of DNA and RNA present 
in primary and secondary lesions were compared (Figure 3.18), it was noted that primary 
chancres contain more of both nucleic acids than secondary lesions, but that only the 
difference in RNA reached significance (p=0.05).  
 
3.2.7.2 Ulcer size correlates with bacterial load in secondary disease 
 
Ulcer area data were available for seven secondary lesions and found to correlate with tpp047 
(DNA) measured in those lesions. Figure 3.19 highlights this association and Pearson’s 
correlation coefficient (for normally distributed data) was calculated to be 0.831 (p=0.021). A 
similar correlation was not observed with primary lesions using Spearman’s rank  (non-
parametric data) (0.006, p=0.986). Ulcer RNA levels showed no correlation with ulcer size 
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for either stage of disease, although there was on overall weak correlation between ulcer load 
measured by DNA and RNA (R
2
 = 0.367) (Figure 3.20) 
 
 158 
Figure 3.17 Recruitment of patients from Colombo, Sri Lanka 
 
 
 
 
 
 
Fig 3.17. Summary of the recruitment of patients diagnosed with early syphilis to a cross-
sectional study between January and August 2012 at the National Centre for STD control in 
Colombo, Sri Lanka.  
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Figure 3.18 T. pallidum bacterial load in primary and secondary lesions 
 
 
 
Fig. 3.18. T. pallidum DNA (tpp047) and 16S rRNA were quantified in 14 primary chancres 
and nine moist secondary lesions by qPCR and RT-qPCR, respectively. The symbols 1, ★5, 
★15, ★19 represent outlying values (the numbers refer to the study number assigned to each 
patient). 
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Figure 3.19 Correlation between ulcer size and ulcer bacterial load 
 
 
 
 
 
Fig 3.19. The area of primary chancres (blue) and moist secondary lesions (green) was 
measured prior to ulcer exudate collection. The quantity of T. pallidum DNA (tpp047) in the 
lesions was then determined by qPCR and compared with ulcer area.  
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Figure 3.20 Correlation between T. pallidum DNA and RNA levels in ulcers 
 
 
 
 
Fig 3.20.  T. pallidum DNA (tpp047) and 16S rRNA were quantified in 23 samples (14 
primary chancres and nine secondary lesions). When compared, a positive correlation was 
observed between DNA and RNA-measured bacterial loads (R
2
 = 0.367).  
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3.2.7.3 Association between duration of symptoms and T. pallidum load in ulcer exudates 
 
Data concerning the duration of symptoms prior to presentation were available for 13 patients 
with primary and nine patients with secondary disease. The mean quantity of T. pallidum 
DNA present in a primary chancre of 4-7 days’ duration was 2.14x104 (std. dev. 1.83x104) 
tpp047 copies/strip, which increased to 3.18x10
4
 (std. dev. 4.94x10
4
) at 8-14 days and 
5.61x10
4
 (std. dev. 5.98x10
4
) if present for longer than two weeks. This trend, shown in 
Figure 3.21, was not statistically significant. RNA levels in primary chancres are seen to rise 
between 4-7 days (7.21x10
6
) and 8-14 days (9.08x10
6
), but then fall after 14 days (5.68x10
6
). 
Only a single sample was available from a secondary lesion within 7 days of onset and both 
DNA and RNA levels in secondary lesions at 8-14 days and over 14 days were similar.  
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Figure 3.21 Duration of symptoms and T. pallidum bacterial load 
 
A. DNA quantification 
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Fig 3.21. B. RNA quantification 
 
 
 
 
Fig 3.21. Duration of symptoms (days since reported onset) was compared with ulcer T. 
pallidum load for 13 patients with primary (blue) and nine patients with secondary disease 
(green). A. shows load according to DNA (tpp047 gene) quantification and B. shows 16S 
rRNA quantification. Error bars depict 95% confidence intervals. 
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3.2.8 Impact of long-term sample storage on T. pallidum nucleic acid detection and 
quantification 
 
The blood and ulcer samples collected for each of the three current studies were the same, but 
the methods for storage, DNA extraction and T. pallidum quantification were not. Differences 
in sample handling are described fully in Chapter 2 and are summarised in Table 3.18. For 
this reason, quantification results for each study have been considered separately. It is, 
however, possible to compare quantification data between studies to assess further the impact 
of long-term sample storage. 
 
Table 3.19 A compares DNA and RNA quantification data from blood samples collected in 
the periods 2006-8 and 2011-12. Combining all stages of disease, T. pallidum DNA was 
detected in 28% of whole blood samples collected in 2006-8, which had been stored long-
term at -80C, compared with 50% of samples from 2011-12. Moreover, a significantly 
higher quantity of DNA was detected in samples collected during the later period. A similar 
pattern was seen when each stage of disease was analysed separately (data not shown). In 
contrast, RNA detection and quantification appeared to be unaffected, with roughly 50% of 
samples from both periods containing detectable RNA and at similar levels. 
 
T. pallidum load in primary disease ulcers and secondary disease lesion samples from all three 
studies are compared in Table 3.19 B. A similar pattern is seen, where samples collected in 
2006-8 and stored at -80C until 2011 contained smaller amounts of DNA. RNA 
quantification data are presented for completeness, but were only available for samples 
collected in Colombo. 
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Table 3.18 Comparison of sampling handling and qPCR methods 
 
 2006-8 
(qPCR validation) 
2011-12 
(CDTB) 
Cross-sectional 
study in Colombo  
    
Snostrips Stored dry at -80C. 
 
Extracted immediately 
or stored for 1-2 months 
in Lysis buffer at -80C 
Stored in 
RNAlater
®
 at -
80C.  
    
Whole Blood  
 
Histopaque separation and 
storage at -80C or divided 
into 400l aliquots and 
stored at -80C 
 
500l added to 500l 
Lysis Buffer and 
extracted immediately 
or stored for 1-2 months 
at -80C 
 
n/a 
Tempus™ Stored at -20C until 2011, 
then -80C until extracted in 
late 2012. 
Stored at -80C for 1-2 
months until extracted. 
n/a 
    
qPCR method SYBR-green based qPCR 
(Roche light-cycler 
instrument). 
Standard curve made from 
whole organism DNA. 
RT-qPCR with 16SrRNA 
TaqMan assay (Biorad 
instrument). Plasmid 
standard (p16SRNA) 
 
TaqMan q-PCR and 
RT-qPCR with plasmid 
standards (pTp47 and 
p16SRNA) 
(Biorad instrument) 
TaqMan q-PCR 
and RT-qPCR 
(Biorad instrument) 
with plasmid 
standards (pTp47 
and p16SRNA) 
 
 
Table 3.18. Summary of sample handling techniques and T. pallidum quantification methods 
in three cross-sectional studies. 
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Table 3.19 Detection and quantification of T. pallidum nucleic acids  
 
A. Quantification in blood samples 
Study  DNA (whole blood) RNA (Tempus™) 
    
2006-8 (qPCR 
validation) 
n (% pos) 21 (28%) 21 (48%) 
 Mean copies/ml 51 1202 
 std. dev. 141 1952 
    
2011-12 (CDTB) n (% pos) 58 (50%) 44 (50%) 
 Mean copies/ml 597 1420 
 std. dev. 1108 2335 
    
 t-test (2-sided) p=0.027 p=0.713 
 
B. Quantification in ulcer samples 
Study  DNA RNA 
    
2006-8 (qPCR validation) n (% positive) 14 (100%)  
 Mean copies/strip 2480  
 std. dev. 3419  
    
2011-12 (CDTB) n (% positive) 4 (75%)  
 Mean copies/strip 18042  
 std. dev. 19668  
    
Cross-sectional study in 
Colombo 
n (% positive) 23 (100%) 23 (100%) 
 Mean copies/strip 26646 4.68x10
6
 
 std. dev. 40168 6.51x10
6
  
    
 
Table 3.19 A. Comparison of T. pallidum DNA (tpp047 gene) and 16S rRNA quantification 
in Tempus™ samples and whole blood collected into EDTA from patients in two separate 
studies. B. Quantification of T. pallidum DNA (tpp047) and 16S rRNA in ulcer samples 
collected during three separate cross-sectional studies. 
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3.3 Discussion 
 
For 20 years, PCR has been used on a variety of clinical and rabbit specimens to detect, type 
and quantify T. pallidum (51, 132, 150, 151, 153). Now PCR reliably detects T. pallidum in 
ulcer specimens, often as part of a multiplex assay, for the diagnosis of primary syphilis 
(132). The more modest success of T. pallidum DNA PCR in other clinical samples has been 
attributed to their lower treponemal load and the presence of PCR inhibitors, especially in 
blood samples (133, 134). There are few data on the quantification of T. pallidum by PCR in 
clinical samples thus the timing of bacteraemia and duration post-treatment, as well as the 
impact of HIV-1 infection on the course of T. pallidum infection, is uncertain. Although 
cross-sectional, the data presented here provide insight into the quantity of T. pallidum 
organisms, measured by qPCR, that are present in blood and ulcer samples taken from 
patients at different stages of syphilis, both with and without HIV-1 infection. 
 
The initial focus of the current study was to establish an efficient method to extract T. 
pallidum nucleic acids from clinical samples. A number of extraction methods exist, which 
are generally solution or column-based, and many have been developed into commercial kits. 
Chomczynski and Sacchi described perhaps the best known solution-based method for 
DNA/RNA/Protein isolation using guanidium thiocyanate-phenol-chloroform (234). Column-
based methods, however, are quicker, do not rely on toxic and irritant chemicals and are not 
subject to problems with phase separation (235). The Roche highpure, Qiagen QiAamp (both 
mini and midi) and Qiagen All-prep kits employed for T. pallidum nucleic acid extraction 
were all solid phase extraction methods using silica-containing micro-centrifuge columns. In 
order to avoid phenol:cholorform-based co-extraction of DNA and RNA from ulcer exudate 
samples, it was initially decided to extract DNA and RNA separately, by dividing the sample 
into two aliquots. When compared, however, the Qiagen all-prep method for DNA/RNA co-
extraction was more efficient at recovering T. pallidum DNA from snotrips stored in 
RNAlater
®
 than a combination of QiAamp and Roche highpure methods. Moreover, all-prep 
was quicker (important to avoid RNA degradation) and had the advantage of not requiring the 
limited material of the ulcer samples to be divided. All extraction processes begin with cell 
disruption/lysis to release nucleic acids, followed by inactivation of nucleases and separation 
of cell debris and salts from the target molecule (DNA, RNA, proteins). Tempus™ tubes 
achieve cell lysis and RNA preservation immediately after blood is drawn and mixed 
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vigorously with the detergent and guanidium thiocyanate inside the tube (236). Moreover, this 
method of blood collection and RNA extraction better preserves RNA (237, 238). When 
compared with alternative methods of T. pallidum RNA extraction from human blood, the 
Tempus™ system was equally effective and required less processing time. Moreover, 
concerns that adequate bacterial lysis would not be achieved with the Tempus™ detergent 
alone were unfounded and an additional proteinase K digestion step resulted in decreased 
RNA yield. Another concern was that the overwhelming majority of human RNA species and 
the presence of other PCR inhibitors (e.g. haem, calcium) in Tempus™ blood samples would 
inhibit the detection of bacterial RNA or result in high levels of non-specific target 
amplification (239). A single attempt was made to deplete human poly-adenylated RNA from 
Tempus™-extracted samples using magnetic bead capture, which was counterproductive in 
improving T. pallidum detection. While it is likely that a proportion of human RNA was 
removed from the samples tested, however, it is equally likely that additional sample handling 
resulted in T. pallidum RNA degradation and negated any benefit thus further exploration of 
the technique was abandoned. 
 
The T. pallidum gene tpp047 is the most commonly used PCR target for T. pallidum 
amplification and had an excellent likelihood ratio for the correct identification of primary 
syphilis in a recent meta-analysis (52, 132, 133, 143, 240). New primers were designed to 
amplify this target in two real-time PCR assays. The first was based on the detection of 
SYBR-green fluorescence and performed in a Roche LightCycler 2.0 instrument. This assay 
was specific for T. pallidum detection with no cross-reactivity to T. denticola or any of the 
common commensal skin flora and sexually transmitted organisms tested. Analytical 
sensitivity was maintained when quantifying T. pallidum DNA extracted from human whole 
blood samples (that have been previously spiked with T. pallidum) with no evidence of 
inhibition from co-extracted human DNA. Absolute quantification of T. pallidum was 
achieved by comparing cycle thresholds of unknown samples to a standard of DNA extracted 
from whole organisms. The limit of detection of this assay was determined to be a single 
organism (genome equivalent) per 10l reaction and inter-assay variance (reproducibility) 
was acceptable. It must be noted, however, that assuming a Poisson distribution and a 95% 
chance of including at least one copy in a given reaction, that the theoretical limit of detection 
for any qPCR is three copies/reaction (241). It is possible that the DNA from a single T. 
pallidum contained more than a single copy of the gene tpp047, although this has no 
foundation in published whole gene sequences of Nichols strain T. pallidum (28). An 
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alternative explanation is inaccuracy of the initial quantification by DGM of spirochetes from 
which DNA for the quantification standard were extracted.   
 
A further goal was to design an internal control that could be co-extracted with T. pallidum 
DNA then co-amplified in a single qPCR. It is not possible using SYBR-green to quantify 
two or more targets in the same qPCR, thus an alternative assay was designed and validated, 
this time with a Biorad real-time PCR instrument. This assay paired the existing tpp047 
amplification primers with a novel hydrolysis (TaqMan) probe and absolute quantification 
was achieved by comparison to an in-run plasmid (pTp47) DNA quantification calibrator. 
Inter-assay variance remained low at <2.35%, intra-assay variance (repeatability) was equally 
low <1.05% and the analytical sensitivity of the new qPCR was determined to be 10 tpp047 
copies/reaction. Multiplex detection of tpp047 and internal control sequences is described in 
Chapter 4. 
 
A recent meta-analysis compared 46 studies aiming to diagnose syphilis using PCR (52) and 
showed the sensitivity of T. pallidum detection in whole blood across all stages of disease to 
be 41.2% (95% CI 26.5 – 57.6%). T. pallidum was most reliably detected in blood from 
neonates with congenital disease (sensitivity 83%) and in adults with secondary disease 
(sensitivity 54.2%). A previous attempt to improve this sensitivity was made by targeting 
bacterial RNA in place of DNA. A 100-fold greater sensitivity of the detection of diluted 
whole T. pallidum organisms was shown using a 16S rRNA target which, based on data from 
other bacterial species, was predicted to be present at 5,000 to 10,000 copies per organism 
(153). Of interest are data from an animal model demonstrating that DNA from heat-killed T. 
pallidum could persist in skin lesions for 15-30 days (155), whereas RNA was predicted to be 
more quickly cleared due to its inherent instability. The potential for more sensitive T. 
pallidum detection with a novel 5’ nuclease (TaqMan) RT-qPCR was, therefore, assessed in 
the current study. The prediction of a more rapid clearance of this RNA target following 
syphilis treatment is addressed in Chapter 5. Following the trial of three probes and four 
primer pairs, assay design settled on the previously published sense primer sequence (153) 
together with a novel anti-sense primer and hydrolysis probe. This combination was specific 
for T. pallidum species detection and did not result in amplification of any member of a panel 
of skin and sexually transmitted bacteria nor of human DNA or RNA. A ‘one-step’ assay 
method, where reverse transcription and PCR take place in a single tube, was selected to 
reduce to potential for contamination with RNAse and cross-contamination between samples 
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(242). Moreover, given that a one-step RT-qPCR uses the same reaction primers for both 
reverse transcription and for qPCR, the potential for non-specific target amplification is 
reduced. An RNA quantification standard was required for the absolute quantification of T. 
pallidum 16S rRNA as despite being more stable and therefore reproducible, a DNA standard 
would not control for reverse transcription (243, 244). RNA for this standard was produced 
from the recombinant nco-1 linearised plasmid (p16SRNA) by the action of T7 polymerase 
and template plasmid DNA subsequently removed with DNAse treatment. The RNA 
transcript was then purified, subject to serial dilution and used to test rigorously the 
amplification characteristics of the assay. The average efficiency of the quantification 
standard curve was established as 87.7%. Analytical sensitivity was 23 copies/reaction with 
an intra-assay variance of 1.12% or less and a maximum inter-assay variance of 3.05%, thus 
demonstrating adequate sensitivity, repeatability and reproducibility. It is likely that the slight 
(1%) increase in inter-assay variability of the RT-qPCR compared with the tpp047 qPCR was 
caused by inherent variation in the efficiency of reverse transcription (245). 
 
With the assays established, attention turned to the validation of T. pallidum quantification in 
clinical samples.  SYBR-green-based qPCR was used to quantify T. pallidum DNA in ulcer 
samples collected from 19 patients with syphilis (15 primary, five secondary) and 35 controls 
in the qPCR validation study and from a further 25 patients (nine secondary, 15 primary, one 
congenital) in the Sri Lankan cross-sectional study. The sensitivities of T. pallidum detection 
in primary chancres were 100% and 96%, respectively and compare favourably to a meta-
analysis comparing 15 studies (mean sensitivity 78.4%, 95% CI 68.2 – 86.0) (52). In the 
qPCR validation study, the mean bacterial load (DNA) in primary chancres was measured at 
2480 organisms/strip. T. pallidum DNA was also detected in samples from secondary syphilis 
lesions with three quarters of genital and two thirds of oral lesions being positive. Fewer 
organisms were detected in these lesions compared with primary chancres (303 
organisms/strip). Although a difference in extraction and PCR techniques does not permit 
direct comparison of quantification data between studies, the same pattern was seen in Sri 
Lankan samples where significantly more 16S rRNA was detected in primary ulcers 
compared with secondary lesions. This observed reduction in T. pallidum load as disease 
progressed from early to latent is supported by studies from the pre-PCR era, which 
demonstrated using DGM and bacterial staining that exudates from primary disease were rich 
in T. pallidum, but treponemes were scant in histological samples from latently infected 
patients (224). Of further note is an assessment of T. pallidum dissemination during 
 172 
experimental rabbit infection when bacterial load in testicular tissue (measured by DGM) rose 
from 1.4x10
6
 treponemes/ml exudate at day 3 post-innoculation to 8.2x10
7
 at day 11 then 
decreased thereafter (246). This parallels the observation in primary chancres from Sri Lanka 
that T. pallidum load increased with the duration of symptoms. However, this study was 
cross-sectional, not longitudinal, and the observed difference was not statistically significant. 
Analysis of DGM results from both studies provides further support for the validity of qPCR 
data. In the hands of a skilled operator, DGM has a sensitivity of approximately 80% for the 
identification of T. pallidum in lesions of both primary and secondary disease (114, 247). In 
the validation study, 71% of primary and 40% of secondary lesions were DGM positive, 
compared with only 53.8% of primary and 57% of secondary Sri Lankan ulcer samples. If 
used as a diagnostic test, qPCR would have identified an additional 16 cases of syphilis in 
these studies. It was further observed that for primary chancre samples collected in London, 
DGM positivity was associated with bacterial load, such that those ulcers with high load were 
more likely to have been DGM positive. To summarise, ulcer PCR is a sensitive and specific 
test for the diagnosis of primary and secondary syphilis. It out-performed traditional DGM, 
although it is not a point-of-care diagnosis. Moreover, the concept of lesion bacterial load, 
measured by qPCR, has been validated and results shown to be biologically plausible.  
 
In the current study, T. pallidum DNA was more frequently detected and at a higher load in 
whole blood than in plasma or PMBC fractions. This finding is similar to a previous 
description of T. pallidum detection in rabbit blood where significantly more organisms were 
recovered from whole blood and plasma compared with serum and PBMCs (51). T. pallidum 
bacteraemia is thought to occur from the outset of the primary infection and to persist at all 
stages of disease thereafter, albeit at markedly different levels (146), and a number of studies 
have attempted to detect T. pallidum in whole blood samples from patients. The mean 
sensitivity of detection in primary disease was previously calculated to be 36.1%, rising to 
54.2% in secondary disease and falling to 20.2% in the latent stage (52). While the stages of 
disease are clinically well defined and the likelihood of detectable bacteraemia is measurable, 
the rate of bacterial dissemination and clearance (both immunological and following 
treatment) in humans is not known. In rabbits inoculated intra-testicularly, a low load of T 
pallidum flaA DNA could be detected in blood after 24 hours and a much higher load was 
detected after 7-10 days. This increased detection after one week also corresponded with 
rising RPR titres and widespread treponemal dissemination into organs (51). In both the 
qPCR validation and CDTB samples, detection rates observed in whole blood samples from 
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patients with any stage of syphilis were lower than for ulcers, but were comparable with those 
previously reported (151, 240). This could be partly explained by the presence of PCR 
inhibitors in blood-extracted samples, however the ulcer is the site of bacterial inoculation, 
multiplication and invasion and would be expected to contain more T. pallidum. Moreover, 
the current data demonstrate that improved detection of bacteraemia during secondary 
syphilis corresponded to higher bacterial load, a similar picture to that reported in the rabbit 
model 7-10 days post-innoculation. Were the difference in ulcer and blood load due to PCR 
inhibition alone, such dynamic change according to stage would perhaps not be expected. 
 
Combining qualitative and quantitative findings a pattern of bacterial dissemination emerges. 
Primary disease is characterized by high numbers of organisms in ulcers, but low-level or 
undetectable tpp047 DNA in blood. In secondary disease, healing ulcers and mucosal lesions 
contain T. pallidum at lower load, but bacteraemia is more frequently detected and at higher 
load than in primary disease. By the latent stage, bacteraemia is less commonly detected and 
when present is at low load.  
 
The greater number of blood samples collected for the CDTB from patients with secondary 
and latent disease enabled more detailed analysis of T. pallidum load during those stages of 
disease. Bacteraemia was associated with a 78.4% probability of being from a patient with 
secondary disease, and only patients in this stage had more than 1303 tpp047 copies/ml whole 
blood. Low bacterial load, however, was equally associated with primary or latent disease and 
could not be used to predict disease stage, although a load over 1303 tpp047 copies/ml 
effectively excluded latent disease.  
 
An assay to quantify 16S rRNA was developed to improve the sensitivity of T. pallidum 
detection and to exploit the inherent instability of RNA in order to follow changes in bacterial 
load more quickly. RNA captured in Tempus™ blood samples from both the qPCR validation 
and CDTB was extracted and quantified with the same quantification standard and the assay 
was 100% specific in both studies. Using the qPCR validation samples, qualitative RNA 
detection identified three additional primary cases and one additional latent case when 
compared with DNA detection. Mean 16S rRNA levels for both these stages were higher than 
those of DNA, although not significantly so. The same number of secondary cases were 
positive by both qPCR and RT-qPCR, but significantly more RNA was detected at this 
disease stage than DNA.  
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When CDTB samples were analysed a similar, although not identical, picture was seen as 16S 
rRNA detection identified two additional latent cases, but one less secondary and one less 
primary case. Again, RNA levels were higher than DNA at all stages, although not 
significantly so for any stage this time. It was predicted that T. pallidum RNA levels in 
clinical samples would far exceed those of DNA, given that each bacterium is expected to 
contain a single copy of the tpp047 gene but many hundreds of 16S ribosomes. While RNA 
levels were undoubtedly higher than DNA, however, this did not translate to a large 
improvement in T. pallidum detection.  
 
The near-parity of DNA and RNA detection for CDTB samples could be explained by 
superior tpp047 detection with a hydrolysis probe compared with SYBR-green, although a 
direct comparison of these assays was not possible (due to insufficient remaining sample 
volumes). The key, however, is likely to be the much longer storage time of samples collected 
for the qPCR validation. Across all stages, T. pallidum DNA was detected in 50% of 
contemporaneously-extracted CDTB whole blood samples compared with 28% of those 
stored for the qPCR validation study. A similar observation was made in a study of secondary 
syphilis where detection of T. pallidum DNA in stored whole blood was 30% compared with 
63% for samples processed within a few hours of collection (151). The maximum interval 
between blood sampling and DNA extraction, which is likely to be short, remains to be 
established.  
 
In contrast to DNA, Tempus™-preserved RNA in the current studies was detected in 50% of 
intact samples and at similar levels, regardless of length of storage, indicating that Tempus™ 
tubes can preserve T. pallidum RNA effectively. RNAlater
®
 solution was also effective at 
preserving both DNA and RNA in ulcer samples that were shipped to the UK at ambient 
temperature (around 48 hours in total) and then stored at -80C. On average, around 100-fold 
more RNA than DNA was detected in ulcer exudates compared with up to 10-fold more RNA 
than DNA in whole blood samples. Differences in assays and potential PCR inhibition aside, 
the most likely explanation for this difference is the metabolic activity of the treponemes 
sampled. During primary infection, T. pallidum are more virulent and have been shown to 
divide more quickly than those observed in latent disease (4). Moreover, studies of the disease 
trachoma have shown that active disease (with clinical signs) is associated with 100-fold 
greater detection of 16S rRNA from its causative organism, C. trachomatis (248). It follows, 
therefore, that once T. pallidum have invaded and are detectable in the blood they become less 
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metabolically active and the difference between quantifiable DNA and RNA falls to between 
two-fold and 10-fold.  
 
Another observation was made possible by comparing RNA quantification in CDTB samples 
from patients with secondary and latent disease. Although the difference measured according 
to stage was significant, the spread of RNA levels measured far exceeded that of DNA and, in 
some ways, made RNA quantification a less useful measure of bacterial load. Although this 
may be explained by variation in metabolic activity, it likely reflects the greater inter-assay 
variance determined for 16S rRNA quantification as a result of differences in reverse 
transcription.  
 
A final observation was made by comparing the qualitative detection of tpp047 DNA with 
that of 16S rRNA from samples collected during both UK cross-sectional studies. In this 
analysis RNA appeared the better sample type identifying an additional two cases of primary 
disease and three cases of latent disease compared with DNA detection alone. Again, this is 
likely to be the result of more effective nucleic acid preservation within RNA Tempus™ 
tubes, especially for those samples collected during the validation study and stored for a 
number of years prior to extraction. It may also indicate that the best method for qualitative T. 
pallidum detection in blood should be based on 16S rRNA detection. 
 
Syphilis and HIV-1 are known to interact in a number of ways. Both HIV-1 transmission and 
acquisition are facilitated by the presence of syphilitic ulcers and there is evidence that those 
ulcers and the clinical course of syphilis can be affected by HIV-1 induced 
immunosuppression (197). In a previous study, 214 patients with genital ulcers were recruited 
and HIV-1 positive men were found to be 11% more likely to have secondary syphilis with a 
concomitant primary chancre (209). Similarly, in the current study HIV-1 infected patients 
with secondary syphilis were more likely to present with unhealed primary ulcers. Moreover, 
HIV-1 positive patients had a higher number of organisms in primary ulcers than patients 
known to be HIV-1 uninfected. Although this association did not reach statistical significance, 
the higher bacterial load suggests HIV-1-positive patients with primary syphilis may be more 
infectious, helping to explain high rates of syphilis-HIV-1 co-infection.  
 
It should also be noted that the cohort of HIV-1 infected patients included in the current 
studies were not significantly immunosuppressed, but had good median CD4 counts. The 
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clinical course of syphilis has also been demonstrated to change in the context of HIV-1 
infection. Patients are more likely to present with secondary disease, bypassing the primary 
stage and some suggest that enhanced syphilis treatment is required in HIV-1 infected patients 
to reduce the risk of treatment failure (249, 250). It may be significant, therefore, that despite 
no observed difference in whole blood bacterial load between HIV-1 infected and uninfected 
patients, the majority of patients (85%) with secondary disease who donated samples to the 
CDTB were HIV-1 infected compared with 50% for both primary and latent. 
 
The studies presented in this chapter demonstrate that T. pallidum qPCR has the potential to 
determine the kinetics of syphilis infection and the impact of a number of factors, including 
HIV-1 co-infection, on those kinetics. They demonstrate that both ulcer and blood samples 
contain quantifiable T. pallidum nucleic acids and that bacterial load varies according to stage 
of disease in a way that is biologically plausible. It is noted that some of the data presented 
are derived from small samples, which limited the statistical significance of associations. It is 
also appreciated that longitudinal sampling of the same patients during the course of their 
infection, as opposed to these cross-sectional data, would more accurately reflect infection 
kinetics but this would not be ethical. Importantly, these data indicate the potential for qPCR 
as a tool for monitoring treatment response in patients with early syphilis – the focus of 
Chapter 5.  
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Chapter 4 
The kinetics of early Syphilis treatment in vivo 
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4.1 Introduction 
 
4.1.1 Background 
 
As long as 50 years ago, researchers were interested in T. pallidum persistence following 
standard syphilis treatment. In one study from that period, lymph nodes taken from two 
prisoners who had been previously treated for syphilis with penicillin were disturbingly found 
to contain viable T. pallidum by rabbit inoculation testing (RIT) (221). It is noteworthy that 
both of these patients had VDRL results that would be consistent with cure by today’s 
standards. More recently, by combining PCR and RIT in an animal model it was 
demonstrated that viable treponemes could persist in untreated animals for more that 120 days 
(155). Of course, RIT and surgical lymph node removal are impractical for the routine 
diagnosis of cure, thus, current clinical practice relies on serological testing, however 
inefficient, as a marker of treatment efficacy (104). PCR has given us the capability to detect 
micro-organisms in clinical specimens without the need for culture (251). However, the 
process required for this detection is complex and dependent on, not only the efficiency of 
PCR, but also that of nucleic acid extraction and, in the case of RNA quantification, reverse 
transcription. Internal controls for these processes, often added to samples at the start of 
nucleic acid extraction, have become commonplace and are now commercially available 
(228).  
 
This Chapter describes the progress of four patients with early syphilis following treatment of 
their disease with benzathine penicillin. Each patient is monitored with both standard 
serological tests and by qPCR detection of bacterial load in their blood and for one patient, 
ulcer exudate. Additionally, it presents the construction of an internal control for the T. 
pallidum bacterial load assay and an initial clinical validation of its utility.  
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Results  
4.2.1 Assay Development 
 
Assays for the quantification of T. pallidum DNA (targeting tpp047) were described in 
Chapter three. In order to control for differences in bacterial load as a result of inefficiencies 
in extraction, an internal control was designed. Initially, splice-overlap PCR was used to 
produce a 178bp section of tpp047 containing an alternative probing sequence complementary 
to a new TaqMan probe that was labelled with a different fluorescent dye to the T. pallidum 
probe TPP. Both the mutated and original probe-site sequences were flanked with the primer-
binding sites TP1 and TP2 so that both would be amplified in a multiplex qPCR. An 
alternative internal control was also assessed. This time, a section of a gene was taken from a 
tomato plant virus and amplified in a multiplex PCR containing two primer pairs and two 
differently labelled TaqMan probes (one set for the virus and the other for T. pallidum). 
Finally, control sequences were cloned into recombinant plasmids and, together with T. 
pallidum bacteria, were spiked into whole blood samples in order to assess the utility of this 
approach as an internal control in vitro. 
 
4.2.1.1 Splice-overlap PCR to produce an internal control of tpp047 amplification 
 
The method for site directed mutagenesis of the T. pallidum tpp047 gene is described in 
Chapter 2.8. It proceeded with three separate rounds of PCR using six different primers to 
produce a mutated 178bp section of the gene that contained a 19bp sequence complementary 
to the TaqMan probe TPP-QC. As pictured in Figure 4.1, the first step was to PCR-amplify 
the tpp047 gene with the primers TP3 and TP4. Two separate reactions produced amplicons 
that were 5’-tailed with the sense and anti-sense sequence of the TPP-QC binding site. During 
the final step, these two tails were allowed to anneal and the outer primers (TP3 and TP4) 
employed a second time to fill in the sequence either side. The region of interest, containing 
the new probe site, was then amplified with the tpp047 qPCR primers TP1 and TP2, gel 
extracted and quantified (4.44x10
10
 copies/l) with spectrophotometry. Gene sequence 
analysis was then performed to confirm both the sequence and position of the TPP-QC probe 
site within tpp047. 
 
 180 
Once the sequences were confirmed, the specificity of each of the probes TPP and TPP-QC 
was assessed by qPCR. Two 1:10 dilution series from 10
6
 to 10 copies of the TPP-QC 
amplicon and Nichols strain DNA (extracted from whole organisms) were constructed. All 
four series were then subject to qPCR with the amplification primers TP1 and TP2 and either 
the probe TPP or TPP-QC (Figure 4.2). Across the range of dilutions, only Nichols strain 
DNA amplification was detected by the probe TPP and TPP-QC DNA with the probe TPP-
QC.   
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Figure 4.1 Production of an internal control for T. pallidum extraction and qPCR 
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Fig 4.1. Panel A. DNA was extracted from Nichols strain T. pallidum organisms and primers 
TP3 and TP4 were used to amplify a 1357bp section of the tpp047 gene. Panel B. The 
purified product of step A was amplified in two separate PCRs with the primer pairs TP3 
(outer sense) & TP5 (inner anti-sense) and TP4 (outer antisense) & TP6 (inner sense). One 
amplicon was 5’-tailed with the 19bp internal control sense sequence and the other with the 
anti-sense internal control sequence. Panel C. Equimolar concentrations of the two products 
from ‘B’ were annealed, then extended with the primers TP3&4 to produce a 1357 bp section 
of tpp047 in which the TPP probing site was replaced with TPQC. Next, the diagnostic 
primers TP1 and TP2, which flank the probing site, amplified a 178bp section which was gel-
extracted and purified. Panel D. Gene sequence analysis of the product from step C using the 
primers TP1&2 confirmed the location and sequence of the alternative probing site. NB. In 
panels B and C, the gels were pictured after the desired DNA had been cut from them. 
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Figure 4.2 Assessment of TaqMan probe specificity  
 
A. Amplification Curves 
 
B. Detection cycle thresholds 
 FAM (TPP) detection 
(PCR cycles) 
VIC (TPP-QC) detection 
(PCR cycles) 
   
T. pallidum (Nichols) DNA 
genome equivalents/reaction 
  
   
1.0x10
6
 19.72 -ve 
1.0x10
5
 23.24 -ve 
1.0x10
4
 26.53 -ve 
1.0x10
3
 29.79 -ve 
1.0x10
2
 33.19 -ve 
10.0 37.15 -ve 
NTC (water) -ve -ve 
   
Purified TPP-QC amplicon 
copies/reaction 
  
   
4.4x10
6
 -ve 14.72 
4.4x10
5
 -ve 17.92 
4.4x10
4
 -ve 21.26 
4.4x10
3
 -ve 24.39 
4.4x10
2
 -ve 27.91 
44.0 -ve 31.20 
NTC (water) -ve -ve 
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Fig. 4.2. Two 1:10 dilution series from 10
6
 to 10 copies of both a TPP-QC amplicon and 
Nichols strain DNA (extracted from whole organisms) were constructed. Panel A. All four 
series were subject to qPCR with the amplification primers TP1 and TP2 and either the probe 
TPP for T. pallidum DNA detection (blue) or TPP-QC for internal control detection (green). 
Panel B. Cycle thresholds for PCR product detection. 
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4.2.1.2 Construction of the recombinant plasmid pTpQC and its concurrent detection with 
tpp047 DNA 
 
Following the successful production and qPCR detection of the TPP-QC oligonucleotide, it 
was cloned into the vector pCR4-TOPO to produce the plasmid pTpQC and amplified in E. 
coli according to the method in Chapter 2.9. Following extraction, the plasmid was linearised 
with the restriction enzyme ncoI (pictured in Figure 4.3 A) for use as a T. pallidum DNA 
extraction control. 
 
In order for pTpQC to be a reliable internal control it needed to be detected consistently in a 
multiplex qPCR without impacting on the detection of tpp047. Initially, 70 copies of pTpQC 
were spiked into a 1:10 dilution series of T. pallidum DNA extracted from whole organisms 
(Figure 4.3 panel B and Table 4.1). Cycle thresholds for the detection of tpp047 at starting 
concentrations from 10
5 
to 10 T. pallidum genome equivalents were similar both with and 
without the addition of pTpQC. However, whereas a single genome equivalent was detectable 
in the single-target qPCR, it was not detected in the multiplex. The detection of pTpQC 
showed a different pattern with no amplification when T. pallidum DNA concentrations were 
above 10
3
 genome equivalents/reaction. Then, as the Nichols DNA concentration decreased, 
so did the cycle threshold for pTpQC detection, which fell from 33.64 to 32.08 cycles. 
Subsequently, two further concentrations of pTpQC (14 and 35 copies per reaction) were 
assessed and the results are compared in Table 4.1. Both concentrations were seen to impair 
the detection of tpp047 in reactions containing DNA from between one and 10 T. pallidum 
genome equivalents. Moreover, pTpQC could not be detected at higher starting quantities of 
T. pallidum DNA. In summary, detection of tpp047 was impaired at <10 T. pallidum genome 
equivalents at all concentrations of pTpQC and pTpQC detection was unreliable when DNA 
from more than 1000 T. pallidum organisms was present. The functional range of this assay, 
assuming that amplification of both targets was required, was thus between 10 and 1000 
organisms.  
 
The possibility that co-detection of the fluorescent dyes FAM and VIC were impairing the 
detection of one-another was explored by assessing an alternative TaqMan probe for pTpQC 
detection that was labeled with the dye ROX (TPP-QCR) (sequence and structure are given in 
Appendix 2). A dilution series of DNA extracted from 10
5
 to one T. pallidum Nichols strain 
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organisms was quantified by qPCR using the probe TPP (FAM detection) and the primers 
TP1 and TP2 (Table 4.2). This was compared with the detection of either TPP (FAM) or TP-
QC in a multiplex qPCR containing the same dilution series of T. pallidum plus 35 copies of 
the plasmid pTpQC using the primers TP1 and TP2 and the probes TPP (FAM) and TP-QCR. 
pTpQC could not be detected in reactions containing more than 100 genome equivalents of T. 
pallidum although T. pallidum detection appeared unimpaired by the co-amplification of 
pTpQC.  
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Figure 4.3 Construction and quantification of a recombinant plasmid 
 
A. Plasmid linearisation 
 
B. Multiplex qPCR 
 
 
 
 
 
Fig 4.3. Panel A. ncoI-linearisation of the recombinant plasmid pTpQC. Lane 1: undigested 
plasmid separated into open conformation (A) and super-coiled (C) species. Lane 2: 
Linearised plasmid (B) (5314bp). Panel B. Nichols strain T. pallidum DNA spiked with 70 
copies of internal control plasmid (pTp47) was amplified in a TaqMan qPCR with the primers 
TP1&TP2 and the probes TPP (tpp047 detection) and TPPQC (pTpQC detection). Samples 
were assayed in quadruplicate and amplification is shown in blue (tpp047) and green 
(pTpQC). 
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Table 4.1 Multiplex qPCR of T. pallidum and an internal control 
 
 
 
Table 4.1. Plasmid (pTpQC) was added to Nichols strain T. pallidum DNA in one of three 
concentrations: 14 copies (columns 3,4), 35 copies (columns 7,8) and 70 copies (columns 
11,12). Cycle thresholds shown are the mean of two experiments and four technical replicates 
of each PCR were performed. 
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Table 4.2 Detection of an internal control with an alternative TaqMan probe 
 
T. pallidum (Nichols) 
DNA/reaction 
(genome equivalents) 
Mean* cycle threshold of detection 
 Condition one Condition two Condition three 
10
5
 23.93 neg 23.92 
10
4
 27.12 neg 27.08 
10
3
 30.50 neg 30.57 
10
2
 33.78 43.34 34.27 
10 37.03 37.03 36.96 
1 41.33 37.46 39.80 
 
 
Table 4.2. A 1:10 dilution series from 10
5 
to a single genome equivalent of DNA extracted 
from Nichols strain T. pallidum were added to 35 copies of the internal control plasmid 
pTpQC and quantified in a multiplex qPCR. All reactions included the T. pallidum detection 
probe, TPP. In addition, reactions in condition one included the FAM-labelled TaqMan probe 
(TPP-QC) for pTpQC detection and those in condition two included an alternative ROX-
labelled TaqMan probe (TP-QCR). Condition three was a control including only the probe 
TPP and to which pTpQC was not added. 
* Denotes the average of three replicas in a single experiment. 
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4.2.1.3 Assessment of an alternative internal control of T. pallidum amplification  
 
Whilst an analytical sensitivity of 10 T. pallidum organisms in the multiplex assay was 
considered acceptable, failure to detect the internal control pTpQC when over 1000 organisms 
were present was unacceptable. A new assay was required with separate amplification primers 
for the internal control sequence and tpp047 to avoid competition in the reaction. In order to 
avoid cross-reactivity with any human or T. pallidum gene, a sequence from the plant 
germinivirus TYLCV gene was selected as the alternative internal control (Chapter 2.1.4). 
The design of the new assay settled on the previously described amplification primers 
TYLCV_F3 and TYLCV_R3 (226) and a new Yakima Yellow-labelled TaqMan probe 
(P_TYLCV) (Appendix 2). A 100bp section of the TYLCV genome was amplified with the 
primers TYLCV_F3 and TYLVC_R3 and cloned into the pCR-4TOPO plasmid vector 
(Chapter 2.9). Following amplification in transformed E. coli, the new plasmid (pTYLCV) 
was linearised with the restriction enzyme ncoI and quantified, firstly by spectrophotometry 
and then by limiting dilution qPCR (Figure 4.4). Next, the multiplex detection of tpp047 and 
pTYLCV was assessed taking note of the following observations: 
 the maximum bacterial load seen in whole blood during the cross-sectional studies 
(Chapter 3) was 4770 tpp047 copies/ml. 
 low-level tpp047 detection was impaired by the co-amplification of pTpQC. 
 high starting tpp047 concentrations impaired the detection of pTpQC. 
 
DNA extracted from 100 Nichols strain T. pallidum was spiked with 10, 50, 100, 500 or 1000 
copies of pTYLCV and both targets detected simultaneously in the multiplex qPCR (Table 
4.3 A). It was established that a minimum of 100 pTYLCV copies were needed in order to be 
detected reliably and that tpp047 detection of 100 T. pallidum organisms was not affected by 
the addition of up to 1000 copies of pTYLCV. This observation was confirmed in a second 
experiment where the detection of both 100 and 10 T. pallidum genome equivalents was not 
impacted by the addition of 500 pTYLCV copies (Table 4.3 B). 
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Figure 4.4 Limiting dilution and quantification of an alternative internal control 
plasmid  
 
A. Constructing a standard curve 
 
 
B. Limiting dilution series  
Starting concentration 
(pTYLCV 
copies/reaction) 
Number of replicas 
positive 
Mean* (std. dev) cycle 
threshold 
10
6 
+ + + + 18.62 (0.024) 
10
5 
+ + + + 21.92 (0.098) 
10
4 
+ + + + 25.38 (0.079) 
10
3
 + + + + 28.72 (0.247) 
10
2
 + + + + 32.36 (0.189) 
10
 
+ + + + 35.26 (0.965) 
1
 
+ + +  - 38.66 (2.308) 
0.1
 
+  -  -  - **38.19 
 
Fig 4.4. A. Following linearisation with the restriction enzyme ncoI, the plasmid pTYLCV 
was quantified by spectrophotometry and diluted to a concentration of 1x10
6
 copies/l. A 1:10 
dilution series was then made (dilution factors displayed) and quantified by qPCR with the 
primers TYLCV_F3 and TYLCV_R3 and the probe P_TYLCV. B. Mean cycle thresholds 
and the number of PCR-positive replicas at each dilution. 
* The mean of four replicas in a single experiment  ** Only a single replica was positive at 
this dilution. 
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Table 4.3 Multiplex PCR detection of T. pallidum and pTYLCV 
 
A.  
 pTYLCV copies added to each reaction 
 1,000 500 100 50 10 (0) control 
T. pallidum 
detection  
      
mean cycle 
threshold 
29.87 29.96 30.05 30.20 30.09 30.04 
std. dev. 0.142 0.160 0.031 0.057 0.102 0.030 
TYLCV 
detection 
      
mean cycle 
threshold 
33.51 33.22 35.77 35.79* neg neg 
std. dev. 1.993 0.920 0.101 n/a   
 
B.  
Nichols strain  
T. pallidum DNA (copies/reaction) 
100 100 10 10 
pTYLCV (copies/reaction) 500 0 500 0 
     
T. pallidum detection      
mean* cycle threshold 30.05 29.90 33.08 33.59 
std. dev. 0.137 0.231 0.412 0.332 
TYLCV detection     
mean* cycle threshold 33.51 neg **34.74 neg 
std. dev. 1.993 n/a n/a n/a 
 
Table 4.3. T. pallidum and TYLCV DNA were co-quantified in a multiplex qPCR.  
A. Nichols strain T. pallidum DNA (100 genome equivalents) were added to either 1,000, 
500, 100, 50, 10 or 0 copies of pTYLCV. Cycle thresholds are displayed for both the 
detection of T. pallidum and TYLCV.  
*only a single technical replica was positive  ** two of three of replicas were positive.  
B. pTYLCV (500 copies) was added to either 100 or 10 T. pallidum genome equivalents and 
both targets quantified. Additionally, the potential impact of pTYLCV amplification on the 
ability to detect T. pallidum was assessed by including two no-pTYLCV controls.  
* The mean of two technical PCR replicates each for two separate samples ** Only a single 
replica PCR-positive. 
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It was predicted that the process of DNA extraction from blood was not 100% efficient. It 
was, therefore, necessary to assess the amount of pTYLCV that was to be added to whole 
blood samples in order to be reliably detected by qPCR. Aliquots of 500l of whole blood 
were spiked with 5000 T. pallidum genome equivalents and either 500, 1000 or 5000 copies 
of pTYLCV followed by DNA extraction (Chapter 2.3.1) and multiplex qPCR. Table 4.4 A 
demonstrates that starting concentrations of pTYLCV of less than 5000 copies/reaction were 
undetectable, and that while cycle thresholds for tpp047 detection were variable, differences 
were not significant. A second experiment was conducted with the same conditions to confirm 
that the recovery and detection 5000 pTYLCV copies was reproducible. Four separate blood 
samples were spiked with 5000 T. pallidum organisms, two were then spiked again with 5000 
copies of pTYLCV. The mean cycle threshold for pTYLCV detection was 38.18 cycles, 
which was significantly different from the previous experiment (Table 4.4 B). However, the 
cycle thresholds for the two replicas in this experiment were similar (std. dev. 0.432).  
 
The internal control selected for the quantification of tpp047 DNA was 5000 copies of 
pTYLCV. The final method is described in Chapter 2.12.1.3. 
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Table 4.4 Co-extraction of T. pallidum and an internal control  
A. 
Nichols strain T. 
pallidum (genome 
equivalents/reaction) 
5,000 5,000 5,000 5,000 0 
pTYLCV 
(copies/reaction) 
5,000 1,000 500 0 0 
T. pallidum detection      
mean* cycle threshold 36.25 37.03 37.87 35.75 neg 
std. dev 0.344 1.017 0.342 0.354 /a 
TYLCV detection      
mean* cycle threshold 40.08 neg neg neg neg 
std. dev 1.159 n/a n/a n/a n/a 
 
B.  
Nichols strain T. pallidum (genome 
equivalents/reaction) 
5000 5000 0 LB only 
pTYLCV (copies/reaction) 5000 0 0 LB only 
T. pallidum detection     
mean** cycle threshold 36.80 35.75 neg neg 
std. dev 1.19 0.354 n/a n/a 
TYLCV detection     
mean** cycle threshold 38.18 neg neg neg 
std. dev 0.432 n/a n/a n/a 
 
Table 4.4. A. Whole blood collected into EDTA (500l) was spiked with 5,000 T. pallidum 
bacteria and either 5,000, 1,000, 500 or 0 copies of pTYLCV. Following DNA extraction, 
both T. pallidum (tpp047) and TYLCV were quantified in a multiplex qPCR (three technical 
replicates of each sample). A negative control of unspiked blood was also included.  
* The mean of three PCR technical replicas for a single spiked sample. B. Whole blood 
(500l) was spiked with 5,000 T. pallidum genome equivalents and with 5,000 or 0 copies of 
pTYLCV. DNA was extracted and both targets amplified in a multiplex qPCR (three 
technical replicates of each sample). Two negative controls were included, the first was un-
spiked blood and the second was lysis buffer.  
* The mean of three PCR technical replicas for a single spiked sample. **DNA was extracted 
from two separate spiked whole blood samples.  
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4.2.2 Longitudinal clinical study of T. pallidum clearance in four patients with early 
syphilis 
 
As described in Chapter 2.14.4, regulatory and ethical approvals were obtained to recruit four 
patients with early syphilis to a longitudinal study that aimed to monitor the clearance of T. 
pallidum from blood and, where present, ulcer exudates following standard treatment. Briefly, 
patients were required to have a microbiologically confirmed (DGM or serology) diagnosis of 
primary or secondary syphilis; to have been prescribed benzathine penicillin as treatment and 
to have not received anti-treponemal antibiotics in the three months prior to study recruitment.  
 
4.2.2.1 Patient recruitment and characteristics 
 
A total of four patients, three with secondary and one with primary disease, were recruited to 
the study. All four patients were homosexual men and three were HIV-1 co-infected. The 
presentations and clinical course of each of the subjects are as follows and standard 
serological results for each patient are presented in Table 4.5. 
 
Case one (STS1) 
 
A 48 year-old white British and HIV-1 infected homosexual man presented with a two week 
history of rash. His HIV-1 infection was well controlled on combination anti-retroviral 
therapy (Lopinavir/Ritonavir/Tenofovir) and his latest CD4 count (one month prior to syphilis 
diagnosis) was 640 cells/mm
3
. On examination, the rash comprised discrete erythematous 
macules over his trunk, and more diffusely involved his face, arms and legs. The palms of his 
hands were affected, but the soles of his feet were not.  An area of dry healing skin was noted 
on glans penis, which he described as being an ulcer when it had first appeared four weeks 
previously. Examination was otherwise normal, with no apparent signs of central nervous 
system involvement. Syphilis serology had been negative one month prior to presentation, but 
was now positive (EIA positive, TPPA positive, RPR 1:64). He was diagnosed with 
secondary syphilis and his physician selected three once-weekly injections of intra-muscularly 
(IM) administered benzathine penicillin (2.4 megaunits) as treatment. The patient described 
feverish symptoms during the night after his treatment (at around eight hours post-dose) and 
his rash was noticed to deepen at 24 hours, before starting to improve at day 5.  
 196 
Case two (STS2) 
 
A 45 year-old homosexual white Brazilian man presented with a two day history of rash. He 
was HIV-1 infected, but well controlled on combination anti-retroviral therapy 
(Tenofovir/Emtricitabine/Efavirenz) with a CD4 count of 776 cells/mm
3 
(measured two 
weeks prior to study enrolment). On examination, the patient had a feint, erythematous, 
macular rash over his trunk, arms and legs that spared his face, palms and soles (Figure 4.5 
A). Examination was otherwise unremarkable and he gave no history of recent mucosal (oral, 
genital or peri-anal) ulcer. The patient described the rash as identical to one present during a 
previous diagnosis of syphilis three years before. Serological testing revealed a rise in RPR 
titre from negative to 1:32 and the patient was diagnosed with secondary syphilis. His 
physician selected treatment with a single dose of IM benzathine penicillin (2.4 megaunits). 
Approximately 16 hours after treatment the patient experienced feverish symptoms, which he 
did not report at the time and, thus, temperature was not recorded. His rash was noticed to 
deepen over 48-72 hours (Figure 4.5 B) before beginning to improve at day 5. 
 
Case three (STS3) 
 
A 26 year-old black British homosexual man presented with a four-week history of a painless 
penile ulcer. He had initially presented to a different genito-urinary medicine service, where 
blood for syphilis and HIV serology had been taken. He had been contacted and informed of a 
negative HIV-1 antibody/antigen test, but positive syphilis serology (EIA positive, RPR 1:32) 
and attended for treatment. He had no previous history of syphilis. On examination he had a 
firm, painless penile ulcer on the coronal sulcus anteriorly measuring 14x8mm at its widest 
points, which was associated with bilateral inguinal lymphadenopathy. Physical examination 
was otherwise unremarkable with no signs of secondary syphilis. A diagnosis of primary 
syphilis was confirmed with DGM and treatment with a single dose of IM benzathine 
penicillin (2.4 megaunits) was selected. Six hours following treatment, the patient felt unwell 
and was found to be pyrexial at 38.9C. Physical examination revealed a tachycardia at 110 
beats/minute and blood pressure of 145/85. No further physical signs of infection, other than 
the unchanged penile chancre were elicited. The patient continued to spike fevers over the 
following 24 hours. Blood chemistry revealed a C-reactive protein of 37 IU/ml at 6 hours, 
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which rose to 87 IU/ml at 30 hours and two sets of blood cultures were negative. At 48 hours, 
the patient was fully recovered. 
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 Figure 4.5 Clinical presentations. 
 
 
 
Fig 4.5. Panel A. Right forearm of patient STS2 at the time of presentation. Panel B. Right 
forearm of patient STS2 taken 48 hours after administration of benzathine penicillin. Panel C. 
Penile chancre of patient STS3 photographed at the time of presentation. 
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Case four (STS4) 
 
A 35-year-old white Brazilian homosexual man was recalled to the HIV clinic for the 
investigation of an RPR of 1:64 and a rise in the liver enzyme alanine aminotransferase 
(ALT) to 89IU/L (upper limit of normal 40 IU/L). Syphilis serology six months prior had 
revealed a positive EIA, but a negative RPR. The patient was known to be HIV-1 infected and 
was stable on combination therapy (Darunavir/Ritonavir/Tenofovir/Emtricitabine) with an 
undetectable HIV-1 viral load (<50 copies/ml) and a CD4 count of 820 cells/mm
3
. The patient 
described no rash or mucosal ulcers over the last few weeks, but mentioned that his regular 
sexual partner had developed a strange rash one month previously. He did complain of a 
headache on and off for the previous ‘few’ weeks, which was like a migraine, but no other 
neurological symptoms. On examination, he was noted to have a diffuse erythematous 
macular rash over his back and chest (pictured in Figure 4.6 A&B). The patient was uncertain 
how long this had been present. He was also noted to have a 5mm diameter red macule on 
glans penis (Figure 4.6 D), which had the appearance of a healing ulcer. The patient had 
noticed ‘something’ but had felt it to be traumatic in origin. Neurological and cardiovascular 
examinations were normal. It was felt that the patient had secondary syphilis with potential 
neurological involvement. He underwent a CT brain scan, which was normal, and a lumbar 
puncture was performed. CSF microscopy revealed 5 white blood cells per mm
3
 (no 
differential given) and no red blood cells together with a protein of 0.47g/L (range 0.01-0.40) 
and a glucose of 3.1mmol/L. Bacterial culture and a CSF syphilis RPR were negative. A 
single dose of IM benzathine penicillin (2.4 megaunits) was selected as treatment. The patient 
was then transferred to the inpatient study unit for monitoring and sample collection. The 
patient described no symptoms of a JH reaction and no pyrexia was recorded. Any change in 
his rash (Figure 4.6 C) following treatment was modest. 
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Figure 4.6 Clinical presentation 
 
 
Fig 4.6. Clinical presentation of patient STS4. Panel A. shows the rash on patients back at 
time of presentation and a close-up is show in Panel B.. Panel C. depicts a close-up of same 
shoulder at 48 hours after treatment. Panel D. shows a healed ulcer present on glans penis at 
the time of presentation. 
 201 
Table 4.5 Serological follow-up  
 
 Rapid Plasma Reagin titre 
 Baseline One month Three months Six months 
Case 1 1:64 1:4 negative negative 
Case 2 1:32 1:4 1:1 1:4 
Case 3 1:32 1:2 DNA* negative 
Case 4 1:64 unavailable 1:4 1:2 
 
Table 4.5. Following the end of the study, patients were followed up with syphilis serological 
tests according to local guidelines. RPR titres, a measure of disease activity, were determined 
at one, three, six and 12 months following treatment. A two-dilution (four-fold) decrease in 
RPR titre confirmed treatment success.  
*Result is missing as the patient did not attend for phlebotomy. 
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4.2.2.2 Patient management and sample handling 
 
Following informed written consent, initial blood (and ulcer) samples and medical 
photographs were taken and patients then received a single dose of 2.4 mega-units of 
benzathine penicillin by deep intramuscular injection. Following transfer to an inpatient study 
facility, an intravenous cannula was inserted and blood samples (1x Tempus™ blood tube and 
1ml EDTA whole blood) were collected according to the sample schedule in Appendix 7. 
Samples were immediately placed on dry ice prior to transport to the laboratory. Patient three 
(STS3) had a sample of penile ulcer exudate absorbed onto a snostrip at each sampling time 
point. These were placed into cryovials containing 1.3ml RNAlater solution and then stored 
on dry ice. T. pallidum DNA extraction and quantification proceeded in batches of up to eight 
samples. A positive (5000 Nichols organism-spiked blood or snostrip) and negative (2x lysis 
buffer) control were included with each batch. DNA was extracted from 500l whole blood 
samples without the addition of 5000 pTYLCV copies. Following the end of sample 
collection from the fourth and final patient, a second 500l aliquot of EDTA whole blood 
from each patient time-point was spiked with 5000 pTYLCV copies and DNA extracted 
according to the same method as unspiked samples.  
 
Samples were taken from patient one (STS1) for the entire sampling schedule (a total of 22 
samples over 150 hours). It was noted that once undetectable in two consecutive whole blood 
samples, T. pallidum qPCR remained negative in all subsequent samples. Allowing for 
sample batching, blood collection from patients two, three and four ended once a minimum of 
two consecutive blood samples were tpp047 negative.  
 
RNA from Tempus™ tube-collected blood samples was also extracted in batches of up to 
eight samples with a positive (syphilis seronegative blood in a Tempus™ tube spiked with 
5000 T. pallidum) and a negative (PBS) control. Tempus™ tube-collected sample extraction, 
and likewise DNA/RNA co-extraction from ulcer samples was performed after sample 
collection from all patients was complete. All qPCR (tpp047 quantification) and RT-qPCR 
(16S rRNA quantification) assays included three technical replicates of each sample. 
Insufficient whole blood and ulcer exudate were available to perform more than one 
biological replicate for each assay at each time point. 
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4.2.2.3 Kinetics of T. pallidum clearance from whole blood 
 
All four of the patients recruited to the study had detectable T. pallidum bacteremia and it was 
possible to document a fall in the bacterial load, measured by both DNA and RNA, over time.  
The fourth patient recruited, STS4, had only low-level traces of T. pallidum nucleic acids in 
his blood. Indeed the first two time-points (pre-treatment and 2 hours post-treatment) were 
negative for both. tpp047 was subsequently detected at hours 10, 18, 26 and 30 (maximum 
was 49 copies/ml at 18 hours) and 16S rRNA at hours 18 and 30 only (maximum was 237 
copies/ml at 30 hours) (Figures 4.7 D and 4.8 D). It must be noted that Tempus™ samples 
from times one to six (0-14 hours) were spoiled, thus 16S rRNA may have been detectable 
prior to 18 hours. Both DNA and RNA were undetectable at hours 34 and 38, after which 
sample collection ended.  
 
Samples from patients STS1, STS2 and STS3 showed a different pattern (Figures 4.7 A,B&C 
and 4.8 A,B&C). The average peak tpp047 level was 1626 copies/ml (std. dev. 652), which 
did not occur pre-treatment, rather two to 10 hours post-treatment. Peak 16S rRNA levels 
(8879 copies/ml, std. dev. 11109) were detected at similar time-points (Table 4.6) and while 
the peak of tpp047 DNA was similar for all three patients, that of 16S rRNA for patient STS3 
was a log higher than for STS1 and STS2. Following peak bacteraemia, the level of both 
RNA and DNA was then seen to fall quickly with neither detectable in any patient after 56 
hours. The decline in DNA and RNA levels for patients STS1 and STS2 is seen to oscillate 
rather than to fall smoothly as is the case for STS3. The magnitude and frequency of these 
oscillations appears greater for DNA than for RNA.  
 
The time elapsed from the administration of treatment to halfway between the first of the 
consecutively negative samples and last detectable sample was referred to as ‘time to 
clearance’ (Table 4.6). For samples STS1, STS2 and STS3, the mean time to tpp047 DNA 
clearance was 34 hours (std. dev. 8) and for 16S rRNA is was 29 hours (std. dev. 23.86). The 
greater variability of time to 16S rRNA clearance is explained by the 56-hour clearance time 
measured for STS3, which was the result of low-level (35 copies/ml) 16S rRNA detection at 
56 hours following two negative samples at 42 and 46 hours. This 16S rRNA amplification at 
56 hours was observed in two of three technical replicates during two separate experiments. 
Furthermore, both the negative Tempus™ extraction control and the two no-template PCR 
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negative controls were negative. In order to account for both the difference in time of peak 
bacteraemia and for outliers, clearance half-lives were calculated. Half-life is defined as the 
time it takes for a substance undergoing decay to decrease to half its initial quantity and 
usually describes exponential decay. Taken from the peak in bacterial load onwards, the plots 
of mean 16S rRNA and tpp047 levels in blood and ulcers (Panel E in Figures 4.7 and 4.8) 
appeared to fall exponentially over time. In order to determine whether this relationship was 
truly exponential, regression lines for linear, quadratic, logarithmic and exponential 
relationships were fitted to the data (Figure 4.9). By measuring the coefficient of variation 
(R
2
) for each regression line (where values of zero and one indicate no fit and perfect fit 
respectively) the decay of RNA and DNA in both ulcer and blood samples were deemed to be 
exponential, thus half-life was an appropriate measure of clearance. The calculation of half-
life used was based on the exponential decay equation: 
 
 
 
where: 
N(t) = the quantity that still remains and has not yet decayed after a time t 
N0 = the initial quantity of the substance that will decay 
t
1/2 
= the half-life of the decaying quantity  
 
The mean half-life of T. pallidum tpp047 DNA clearance from blood was determined to be 
5.68 hours (std. dev 0.53) and was significantly longer than the 3.89 hours (std. dev. 0.84) 
calculated for 16S rRNA (p=0.035).  
 205 
Figure 4.7 Clearance of T. pallidum DNA from blood  
 
A. STS1 B. STS2 
  
C. STS3 D. STS 4 
 
 
E.  
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Fig 4.7. Four patients with microbiologically confirmed early syphilis were treated with a 2.4 
megaunit dose of benzathine penicillin at time zero. Blood samples were collected into EDTA 
immediately pre-treatment, at two hours post-treatment and then four hourly for up to 50 
hours. T. pallidum DNA was extracted from whole blood and quantified by qPCR (tpp047 
gene). Each of the Panels A to D represents a different patient and Panel E shows the average 
of tpp047 quantification for patients STS1, STS2 and STS3. Error bars depict 95% confidence 
intervals 
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Figure 4.8 Clearance of T. pallidum RNA from blood  
 
A. STS1  B. STS2 
  
C. STS3 D. STS4 
  
E.   
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Fig. 4.8. Four patients with microbiologically confirmed early syphilis were treated with a 2.4 
megaunit dose of benzathine penicillin at time zero. Blood samples were collected into RNA 
preservation tubes immediately pre-treatment, at two hours post-treatment and then four 
hourly for up to 50 hours. T. pallidum RNA was extracted from whole blood and quantified 
by RT-qPCR (16S rRNA target). Each of the Panels A to D represents a different patient and 
Panel E shows the average of 16S rRNA quantification for patients STS1, STS2 and STS3. 
The first six time-points for STS4 are missing as the Tempus™ samples were spoiled during 
RNA extraction. Error bars represent 95% confidence intervals. 
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Figure 4.9 Decay of T. pallidum DNA and RNA following treatment  
 
A. Blood DNA B. Blood RNA 
  
 R
2
 sig  R
2
 sig 
Linear 0.363 0.001 Linear 0.218 0.007 
Exponential 0.470 0.001 Exponential 0.70 0.001 
  
  
C. Ulcer DNA D. Ulcer RNA 
  
 R
2
 sig  R
2
 sig 
Linear 0.698 0.010 Linear 0.332 0.050 
Exponential 0.878 0.001 Exponential 0.839 0.001 
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Fig 4.9. The quantity of T. pallidum DNA (Panel A) and RNA (Panel B) detected in blood 
samples from four separate patients with early syphilis were plotted against time elapsed since 
treatment. Linear and exponential regression lines were then fitted to the data to assess the 
nature of the observed decay in bacterial load. The correlation coefficient, R
2
 provides a 
measure of ‘fit’ of the data with the regression line where a value of one indicates a perfect fit 
and zero represents no fit. The significance of the R
2
 values are also given. Panels C and D 
show the same analysis for DNA and RNA quantification in a penile ulcer from a single 
patient.  
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Table 4.6 Measurement of T. pallidum clearance following treatment. 
 
  
STS1 STS2 STS3 Mean Std. dev. 
Blood DNA 
     
 
t
1/2 
(hours) 5.79 6.15 5.11 5.68* 0.53 
 
Peak bacteraemia  
(tpp047 copies/ml) 
2151 895 1832 1626.00 652.85 
 
Peak Bacteraemia (hours) 2 0 2 1.33 1.15 
 
Time to clearance (hours) 40 24 32 32.00 8.00 
       
Blood RNA 
     
 
t
1/2
 (hours) 3.87 3.07 4.75 3.89* 0.84 
 
Peak bacteraemia  
(16S rRNA copies/ml) 
3635 1363 21640 8879.33 11109.30 
 
Peak bacteraemia (hours) 2 10 6 6.00 4.00 
 
Time to clearance (hours) 32 20 53 35.00 16.70 
      
Ulcer DNA 
     
 
t
1/2
 (hours) x x 3.19 x x 
 
Peak ulcer load (tpp047 
copies/strip) 
x x 67400 x x 
 
Time of peak load (hours) x x 14 x x 
 
Time to clearance (hours) x x 50 x x 
      
Ulcer RNA 
     
 
t
1/2
 (hours) x x 4.08 x x 
 
Peak ulcer load (16S rRNA 
copies/strip) 
x x 7.08e7 x x 
 
Time of peak load (hours) x x 2 x x 
 
Time to clearance (hours) x x 56** x x 
 
Table 4.6. Three patients were treated for early syphilis with benzathine penicillin. Following 
injection of the drug, T. pallidum DNA and RNA clearance from the blood of all three 
patients and the penile ulcer of a single patient was measured and used to calculate time to 
clearance and the half-life for clearance.  
*p=0.035 (2-sided t-test of t
1/2
(RNA clearance) vs t
1/2
(DNA clearance) 
** The last sample collected was the first negative sample. 
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4.2.2.4 Relationship between DNA and RNA clearance 
 
A direct comparison of DNA-measured and RNA-measured whole blood bacterial load 
revealed a positive correlation between these levels for each of the patients STS1 (R
2
 = 0.69), 
STS2 (R
2
 = 0.44) and STS3 (R
2
 = 0.64) (Figure 4.10 A). It is also noteworthy that for a given 
level of DNA the amount of RNA detected in the blood of patient STS3 was higher than that 
of patients STS 2 or STS 1. When expressed as a ratio of RNA:DNA and plotted against time 
since treatment (Figure 4.10 B) the decay of bacterial load was similar to that observed for 
DNA or RNA considered individually. The mean RNA:DNA ratio over all time periods was 
7.19 (std. dev. 6.22) for STS3 compared with 1.44 (std. dev. 1.36) for STS1 and 3.66 (std. 
dev. 3.62) for STS2. Only the difference between STS1 and STS3 ratios was significant 
(p=0.002). 
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Figure 4.10 T. pallidum nucleic acid levels in blood during early syphilis 
 
A. RNA vs DNA 
 
B. DNA:RNA ratio vs time 
 
 
 
 
 
Fig 4.10. Panel A. Comparison of tpp047 DNA and 16S rRNA levels detected in the blood of 
three patients (STS1 in red, STS2 in blue and STS 3 in green) with early syphilis measured 
over a 40-hour period following treatment. Regression lines are shown and were used to 
calculate the following correlation coefficients: STS1 R
2
=0.686; STS 2 R
2
=0.435 and STS 3 
R
2
=0.637 Panel B. The ratio of 16S rRNA:tpp047 DNA quantity measured in the blood of 
three patients over 40 hours following treatment for early syphilis. Trendlines are shown with 
colour coding as for panel A. 
 214 
4.2.2.5 Kinetics of T. pallidum clearance from a penile chancre 
 
A single subject presented with a DGM positive genital ulcer that was suitable for sampling. 
Samples were taken at the same time-points as for blood samples, however, nucleic acid 
extraction and quantification was not performed in parallel with blood samples. Figure 4.11 
demonstrates an initial ulcer tpp047 load of 34000 copies/strip, which peaked at 67400 
copies/strip at 14 hours and remained high until 26 hours when it began to fall rapidly. At 50 
hours following treatment, tpp047 was no longer detectable. The decay of tpp047 DNA fitted 
an exponential regression line (R
2
 = 0.878) (Figure 4.11) and the t
1/2 
(clearance) was 
calculated to be 3.19 hours (Table 4.6). Quantification of 16S rRNA followed a similar 
pattern, although started from a level 1000 times greater than that seen for DNA (1.28x10
7
 
copies/strip) and peaked earlier at two hours post-treatment (7.08x10
7 
copies/strip). After 40 
hours, the level was seen to decrease 10-fold every four hours until becoming undetectable at 
56 hours. It must be noted that no ulcer samples were taken beyond the 56 hour time-point as 
the end of sample collection was informed by whole blood DNA results (which were negative 
after 34 hours). Again, the decay of 16S rRNA was deemed to be exponential (R
2
 = 0.839) 
and t
1/2 
(clearance) was 4.08 hours.
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Figure 4.11 Ulcer bacterial clearance 
 
A. tpp047 quantification B. 16S rRNA quantification 
  
C. tpp047 curve estimation D. 16S rRNA curve estimation 
  
 
Fig 4.11. A patient presenting with a DGM positive penile ulcer (primary syphilis) was 
administered a 2.4 megaunit dose of benzathine penicillin at time zero. Ulcer samples for T. 
pallidum DNA and RNA quantification were collected pre-treatment and then four hourly for 
56 hours. Panel A. presents DNA (tpp047) decay and Panel B. shows 16S rRNA decay. 
Panel C. depicts the fit of tpp047 clearance data to linear (R
2 
=0.66) and exponential (R
2
 = 
0.78) regression lines. Panel D. shows the fit of 16S rRNA data to exponential (dotted line) 
(R
2 
=0.83) and linear  (solid line) (R
2 
=0.29) regression lines. 
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4.2.2.6 Further observations of T. pallidum quantification at two or more time points from 
samples collected in a cross-sectional study  
 
During the cross-sectional study described in Chapter 2.14.2 four patients from whom pre-
treatment samples were taken were subsequently admitted to hospital for the investigation and 
treatment of suspected neurosyphilis. All four patients were HIV-1 infected MSM with a 
mean age of 38.25 years (range 9) and a mean CD4 count of 689 cells/ml (range 712). 
Moreover, all received treatment, at least initially, with 6-hourly intravenous infusions of 
aqueous benzylpenicillin. Patient TP124 had two blood draws (at baseline and 36 hours post-
treatment) expressly for T. pallidum quantification, which included Tempus™ samples. Pre-
treatment samples for the remaining three patients were also taken for T. pallidum qPCR, 
however subsequent EDTA whole blood samples were left over full blood count (EDTA 
whole blood) samples which had been stored in the haematology department at 4C. Three of 
the four patients attended for syphilis follow-up and all met the serological criteria for cure 
(Table 4.5). 
 
Table 4.7 summarises the T. pallidum quantification data obtained for each of these four 
patients. It is noteworthy that none of the samples taken from patient TP103 at 7, 10, and 13 
days post-treatment or the samples donated by patient TP105 at 12 and 14 days following 
treatment contained detectable T. pallidum DNA. A t
1/2
 (clearance) of 9.97 hours has been 
calculated for patient TP140 as four samples over 86 hours were available for tpp047 
quantification. However, this calculation is based on the peak DNA being that which was 
recorded at baseline as a second sample was not available until 41 hours into treatment. 
Finally, patient TP 124 was shown to have cleared T. pallidum DNA by 36 hours, but not 16S 
rRNA, which remained detectable at 36 copies/ml. 
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Table 4.7 Clinical characteristics and T. pallidum qPCR results  
 
Patient Study 
Number 
TP 103 TP 105 TP124 TP140 
Age (years) 44 44 35 36 
CD4 count 
(cells/mm3) 
460 540 880 590 
Anti-retroviral 
treatment 
naive naive naive 
Darunavir 
Ritonavir 
Tenofovir 
Emtricitabine 
Syphilis treatment 
received 
notes 
unavailable 
2.4g IV 
benzylpenicillin 
4-hourly for 14 
days 
2.4 megaunits 
IM benzathine, 
and  
11 x 2.4g IV 
benzylpenicillin, 
and 3 once-
weekly injections 
of benzathine 2.4 
megaunits IM 
2.4g IV 
benzylpenicillin 4-
hourly for 14 days 
Steroids therapy 
administered 
notes 
unavailable 
none none 
3x 40mg 
prednisolone on 1st 
3 days of treatment 
HIV-1 viral load 
(copies/ml) 
79092 75 496936 <50 
CSF results 
WCC (cells/mm3) 
RBC (cells/mm3) 
protein (g/L) 
TPPA 
RPR 
 
3 
4 
no result 
positive 
no result 
 
 
<1 
<1 
<0.4 
positive 
negative 
 
 
6 
18 
0.27 
no result 
no result 
 
 
4 
<1 
0.52 
positive 
not done 
 
tpp047 DNA 
(copies/ml blood) 
Days Load Days Load Hours Load Hours Load 
Sample 1 0 679 0 30 0 105 0 2335.2 
Sample 2 7 0 12 0 36 0 41 135.36 
Sample 3 10 0 14 0 
  
62 0 
Sample 4 13 0 
    
86 0 
t 1/2 (tpp047 
clearance)  
n/a n/a n/a 9.97 hours 
16S rRNA 
(copies/ml blood) 
n/a n/a 
  
Sample 1 0 3404 0 7470.4 
Sample 2 36 34 
  
RPR titre 
Pre-treatment 128 512 32 64 
1 month 64 128 
Did not attend 
follow-up 
16 
3 months 2 16 2 
6 months 4 4 - 
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Table 4.7. Characteristics of four HIV-1 infected patients admitted to hospital for the 
treatment of suspected neurosyphilis.  At least two whole blood (EDTA) samples were 
obtained from each patient for T. pallidum quantification and were stored in the CDTB at -
80C prior to DNA extraction. One or two Tempus™ blood samples were also available for 
T. pallidum 16S rRNA quantification from patients TP124 and TP140.  
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4.2.2.7 Multiplex results 
 
The design of an internal control is described in Section 4.2.1 and was intended to measure 
the efficiency of DNA recovery from clinical samples and its subsequent amplification by 
PCR. It was to be spiked into whole blood samples and co-‘extracted’ with T. pallidum DNA, 
then co-amplified in a multiplex qPCR. In order to assess the feasibility of this process, 30 
whole blood samples from patients STS1, STS2 and STS3 were selected and 500l aliquots 
were spiked with 5000 copies of ncoI-linearised pTYLCV DNA. The samples chosen were 
those in which tpp047 DNA was previously detected and the first two T. pallidum negative 
samples from each of the patients. 
DNA extraction proceeded in batches of eight samples (Chapter 2.3.1) and was followed by 
tpp047 and pTYLCV quantification in a multiplex qPCR (Chapter 2.12.1.3), which included 
three technical replicates of each sample, a no-template control and positive tpp047 and 
pTYLCV controls. The cycle thresholds for detection of both targets were determined and 
compared with the two absolute quantification standards included in each run.  
 
Panel A of Figure 4.12 and Table 4.8 describe the clearance of tpp047 DNA, measured by the 
multiplex assay, from the blood of all three patients. On average, peak bacteraemia was 
detected at 0.7 hours (std. dev 1.15) and bacterial clearance was achieved by 28 hours (std. 
dev. 6). Panel B of Figure 4.12 and Table 4.9 summarise the quantity of pTYLCV DNA 
‘recovered’ from whole blood samples. The average, across all patients and time points was 
1949 copies (std. dev 3108). The efficiency of DNA extraction (E) was calculated by dividing 
the number of pTYLCV copies ‘recovered’ from a given sample (R) by the number spiked 
(5000) and expressing the result as a percentage, i.e. 
 
  (
 
    
)       
 
Next, in order to adjust the quantity of tpp047 DNA detected in a given sample (Q) for the 
DNA extraction efficiency of that sample (E), the copy number was multiplied by E
-1
, i.e 
 
                        (
 
     ⁄
)    
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Table 4.9 demonstrates that the efficiency of DNA extraction from the whole blood samples 
included in this assessment was, on average, 39% (min seven, max 338%). Analysed 
separately, the extraction efficiency of STS 3 samples (extracted as a single batch) was 
significantly lower than that for STS1 (p=0.033) or STS 2 (0.056). Of course, the observed 
extraction efficiency was also subject to the performance of the multiplex qPCR used to 
quantify pTYLCV. To minimise variation, DNA from all sample time-points for a given 
patient was quantified during the same experiment using the same ‘master’ dilution as the 
starting concentration for each standard curve. The performance characteristics of each of 
these absolute quantification standard curves are described in Table 4.10 and are broadly 
similar. 
 
Figure 4.12 and Table 4.8 also provide a comparison of tpp047 quantification with and 
without adjustment for extraction efficiency. Moreover, they demonstrate the impact of 
multiplex detection on tpp047 quantification by providing a comparison with the single-target 
qPCR. Panel C demonstrates that the patterns of clearance for each of these three 
measurement methods (single-target assay, multiplex, and adjusted multiplex) are similar 
although the overall levels of tpp047 measured are different. Table 4.8 allows closer 
inspection of the differences and demonstrates that while there is a trend towards higher 
tpp047 levels following adjustment for extraction efficiency and lower levels in the single 
target assay these differences are not significant. t
1/2(clearance) measured by the ‘multiplex’ 
method is seen to be 9.38 and 7.74 hours longer than ‘single-target’ and ‘adjusted’ methods of 
tpp047 quantification. Again, this difference did not reach statistical significance. Finally, 
when analysed separately, extraction efficiency-adjusted levels of tpp047 for patient STS3 are 
markedly higher than for patients STS2 and STS1  
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Figure 4.12 Efficiency of T. pallidum DNA extraction  
 
A. tpp047 quantification B. pTYLCV quantification 
 
 
C. Singleplex vs multiplex tpp047 quantification  D. Adjusted tpp047 quantification 
  
 
 222 
Fig 4.12. Multiplex qPCR detection of tpp047 and pTYLCV DNA in the whole blood of three 
patients treated for early syphilis with single-dose benzathine penicillin at time zero. Each 
500l whole blood sample was spiked with 5000 pTYLCV copies prior to DNA extraction 
and qPCR. Panels A and B show tpp047 and pTYLCV quantification for patients STS1 (red), 
STS2 (blue) and STS3 (green), respectively. Panel C compares the mean tpp047 detection for 
all three patients at each time-point in both single-target (tpp047) (red) and multiplex (tpp047 
and pTYLCV) (blue) qPCRs. Additionally, quantification of tpp047 was adjusted for DNA 
extraction efficiency (green) Panel D compares tpp047 quantification adjusted for DNA 
extraction efficiency for each of the three patients (STS1 in red; STS2 in blue and STS3 in 
green) separately. 
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Table 4.8 T. pallidum clearance with and without adjustment for DNA extraction 
efficiency 
  
Patient 
  
 
  STS1 STS2 STS3 Mean Std. dev. t-test* 
A. Single-target tpp047 
detection      
 
 
t
1/2
 (hours) 5.79 6.15 5.11 5.68 0.53  
 
Peak bacteraemia  
(tpp047 copies/ml) 
2151 895 1832 1626 653 
 
 
Peak Bacteraemia 
(hours) 
2.00 0 2.00 1.33 1.15 
 
 
Time to clearance 
(hours) 
42 26 34 34 8 
 
B. Multiplex detection of 
tpp047      
 
 
t
1/2
 (hours) 22.4 14.84 7.94 15.06 7.23 0.089 
 
Peak bacteraemia  
(tpp047 copies/ml) 
5160 2832 7608 5200 2388 0.067 
 
Peak Bacteraemia 
(hours) 
0 0 2.00 0.66 1.15 0.002 
 
Time to clearance 
(hours) 
34 22 30 28 6 0.357 
C. tpp047 detection adjusted 
for DNA extraction efficiency      
 
 
t
1/2
 (hours) 12.37 5.77 3.82 7.32 4.48 0.56 
 
Peak bacteraemia  
(tpp047 copies/ml) 
11481 13605 83587 36224.33 41031.02 0.22 
 
Peak Bacteraemia 
(hours) 
18 2 10 10.00 8.00 0.14 
 
Time to clearance 
(hours) 
34 22 30 28.67 6.11 0.41 
 
Table 4.8 Whole blood was collected into EDTA from three patients with early syphilis 
before administration of 2.4 megaunits of benzathine penicillin. Samples were then taken 
four-hourly post-treatment and T. pallidum DNA (tpp047 gene) quantified at each time point. 
The level and time of peak bacteraeamia were determined in addition to the total time and 
half-life required for its clearance (A). A second aliquot of blood from each time-point was 
spiked with 5000 copies of pTYLCV and both tpp047 and pTYLCV were quantified in a 
multiplex qPCR (B). DNA extraction efficiency were determined by calculating the fraction 
of spiked pTYLCV recovered and tpp047-measured T. pallidum load adjusted accordingly 
(C) *comparison of single-target and either multiplex or adjusted tpp047 results. 
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Table 4.9 Efficiency of pTYLCV extraction  
 
Patient Study Number 
(number of samples) 
pTYLCV copies 'recovered' 
(copies/reaction) 
Extraction efficiency (%) 
 
mean std. dev mean min max 
STS 1 (n=12) 3602 4476 72 11 338 
STS 2 (n=8) 1059 671 21 10 47 
STS 3 (n=10) 678 370 13 7 31 
All patients (n=30) 1949 3108 39 7 338 
 
 
Table 4.9. Linearised internal control plasmid (pTYLCV) (n=5,000 copies) were spiked into 
500l whole blood collected during a longitudinal study of T. pallidum clearance following 
treatment. The quantity of pTYLCV recovered following DNA extraction was determined in 
a multiplex qPCR. All samples for a given patient were extracted in the same batch and 
quantified in a single qPCR experiment (comprising three technical replicates of each 
sample). pTYLCV copy numbers and extraction efficiencies presented are the mean of all 
samples collected from each patient.  
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Table 4.10 Multiplex qPCR efficiency for T. pallidum and pTYLCV amplification 
 
Patient PCR Target Efficiency R
2
 (linearity) Slope (cycles) 
STS1 pTYLCV 1.98 0.98 -3.46 
 tpp047 1.43 0.95 -4.27 
STS2 pTYLCV 1.63 1.00 -3.85 
 tpp047 1.64 1.00 -3.83 
STS3 pTYLCV 2.18* 1.00 -3.45 
 tpp047 1.90 1.00 -3.45 
 
Table 4.10. A multiplex qPCR was used to quantify pTYLCV and tpp047 by comparing the 
cycle thresholds for detection in samples with that of two absolute quantification standard 
curves. The PCR instrument software calculated reaction efficiency and plotted cycle 
threshold vs cycle number to calculate the number of PCR cycles between each 10-fold 
dilution of standard curve DNA. Finally, R
2 
was calculated which denotes how well the 
experimental standard curve line fits a theoretical regression line.  
*It is noted that this result is above the theoretical limit of PCR efficiency. 
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Discussion 
 
qPCR is used routinely in clinical practice to monitor patient responses to HIV-1 and hepatitis 
C therapy and for both diseases an undetectable ‘viral load’ has become synonymous with 
treatment success (252, 253). In both cases, RNA is extracted from patients’ blood and 
subject to reverse transcription and quantification in one of a number of commercially 
available assays. The principal aim of the current study was to replicate this approach for 
early syphilis by measuring bacterial load following treatment. It has previously been shown 
that qPCR can quantify T. pallidum in blood and ulcer samples taken from patients with early 
disease (131, 151). Moreover, in Chapter three it was demonstrated that T. pallidum bacterial 
load in both blood and ulcers varies according to stage of disease in a way that is both 
biologically plausible and potentially clinically useful.  
 
4.3.1 Controlling for the efficiency of DNA recovery with an internal control 
 
Both the T. pallidum qPCR for tpp047 DNA quantification and RT-qPCR for 16S rRNA 
quantification described in Chapter two include internal calibration with an in-run absolute 
quantification standard. By observing for changes in the amplification characteristics of these 
standards, the overall efficiency of the PCR was controlled. It was also important, especially 
in a quantitative assay, to control for the efficiency of DNA recovery, which can be variable 
(254). This is most often achieved by adding an internal control to samples prior to processing 
which is then co-extracted with the same efficiency as target DNA. Both targets can then be 
quantified in the resultant DNA mixture with separate or multiplex qPCR (228, 255, 256). Of 
course, it is not possible to control for the efficiency of bacterial lysis using this method as the 
control plasmid is not contained within intact T. pallidum organisms. The first of two internal 
control plasmids assessed in the current study (pTpp047) was produced using site-directed 
mutagenesis of the tpp047 gene. The rationale for this method was that both tpp047 and 
control DNA could be amplified with a single primer pair, thus reducing the potential for one 
or other target to dominate the reaction. Three concentrations of pTp47 were assessed and 70 
copies/reaction appeared to be optimal. However, the utility of this multiplex qPCR proved 
limited as competition in the qPCR prejudiced against the detection of low bacterial loads 
(<10 T. pallidum genome equivalents), which had previously been detectable in the singleplex 
tpp047 qPCR. Moreover, at higher (>1000 genome equivalents/reaction) starting quantities of 
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T. pallidum DNA, pTpp047 was not detected. This effect is thought to result from earlier 
amplification of the higher concentration target exhausting PCR reagents such that the 
reaction has plateaued before the lower concentration target has been amplified beyond the 
threshold of its detection. For example, a similar pattern was described for the Roche Cobas 
AMPLICOR multiplex assay, which detects Neisseria gonorrhea, Chlamydia trachomatis and 
an internal control. When one or both of the organisms were present at a high starting quantity 
they would be amplified in preference to the low-level internal control DNA and the assay 
reported as a failure despite correctly identifying the target organism (257). Another 
consideration was the potential for interference between the detection of the two fluorescent 
dyes in the reaction. This was easily assessed by replacing the VIC fluorophore on the probe 
TPP-QC with ROX and observing no demonstrable change in the detection of either target 
over a range of T. pallidum DNA starting concentrations. One approach to removing 
competition in multiplex qPCRs is to limit the concentration of one target’s primer pair (258). 
In this way amplification of that target will reach plateau phase earlier and allow time (and 
reagents) for the second target, which is not primer concentration-limited, to amplify. To put 
this in context, at low starting amounts of T. pallidum DNA a reduction in the internal control 
primer concentration should allow both targets to amplify adequately before other reaction 
substrates (magnesium, taq polymerase, DNTPs) become limited. Of course, this approach is 
only possible for multiplex qPCRs using two distinct primer pairs thus a new internal control 
was constructed from a section of the TYLCV genome. By having two sets of primers the 
concentration of both could be varied to optimise the detection of both targets. During an 
initial assessment, the detection of neither 100 nor 10 T. pallidum genome equivalents was 
affected by the addition of 500 pTYLCV to the multiplex qPCR, even without limiting 
TYLCV reaction primer concentrations.  
 
The next step was to determine the optimal amount of pTYLCV to be added to whole blood 
samples prior to DNA extraction. When samples were spiked with 500 copies, the amount of 
DNA recovered was below the threshold of detection in the qPCR and it was ultimately 
demonstrated that spiking with 5000 pTYLCV copies was required. Again, tpp047 detection, 
this time from 1000 T. pallidum organisms, was unaffected by co-recovery and qPCR 
amplification of pTYLCV. The DNA extraction efficiency of Qiagen’s QIAamp method has 
been shown previously to have variable efficiency. In one study, the recovery of marker DNA 
(a familiar 500 copies/ reaction of a linearised plasmid target) was 38%. However, another 
assessment of 12 DNA extraction methods favoured the QIAamp technique, not only for a 
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DNA recovery rate of 55.7%, but additionally for the higher purity and integrity of the DNA 
extracted (255, 256, 259). In the current study an ex vivo assessment of DNA recovery 
efficiency and the performance of the multiplex qPCR was made using blood collected during 
the longitudinal treatment study. The overall efficiency of DNA recovery, according to the 
average fraction of pTYLCV recovered, was 39%, with a range of over 300%. Potential 
explanations for the unexpectedly high variation of DNA recovery lie in the spiking and DNA 
extraction methods. Firstly, pTYLCV was diluted to a concentration of 1000 copies/l and 
each sample was spiked separately with 5l. The potential existed therefore, for variation in 
the amount of DNA spiked into each sample and adding pTYLCV to the lysis buffer used 
during the first step of the process may have improved consistency. Secondly, following DNA 
elution into 400l of water, a DNA precipitation step was performed. The last step of this 
process required the DNA pellet to be dried (ethanol allowed to evaporate) and then re-
suspended in 60l of water. Any remaining ethanol would have likely affected the qPCR and 
over-drying led to difficulty in re-suspending the pellet. It may have been preferable, in the 
context of a quantitative and not qualitative PCR, to replace this step with an alternative 
method. Finally, the measurement of extraction efficiency also relied on the efficiency of the 
qPCR used to detect the extracted DNA. All samples from a given patient were quantified in 
triplicate during a single multiplex qPCR run and compared with the same absolute 
quantification standard. Variation in efficiency of the calibration curves between runs was 
noted (1.98, 1.63, 2.18) and would have contributed to the reported variation in extraction 
efficiency to some extent. This may also explain the higher DNA-measured bacterial loads 
detected with the multiplex assay compared with the single-target tpp047 assay. 
Unfortunately, repeating the extractions to produce the average extraction efficiency for each 
time point was not possible as insufficient sample remained. Despite these limitations, a 
similar pattern of T. pallidum clearance was observed for tpp047 single-target detection; 
tpp047 mutliplex detection and tpp047 detection adjusted for DNA recovery efficiency. 
 
4.3.2 T. pallidum clearance as a marker of anti-microbial efficacy 
 
T. pallidum persistence after syphilis treatment has been the subject of research for more than 
50 years. Prior to the description of PCR, these studies relied on DGM examination and RIT 
of clinical and animal specimens (221, 224). In the first description of penicillin use for the 
treatment of syphilis, four men with DGM positive chancres were given four-hourly IM 
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penicillin injections and ulcers sampled with each injection. By the 16
th
 hour, no spiral forms 
were observed in any of the ulcers (18). PCR has since provided a tool for sensitive detection 
of bacterial DNA and has been used in rabbits to demonstrate that T. pallidum injected intra-
testicularly were cleared two weeks after the animals were treated with penicillin and 
probenecid (155). In a more recent clinical study, PCR detection revealed that T. pallidum in 
the CSF of patients with asymptomatic neurosyphilis could persist for up to 36 months after 
treatment (144). By serially sampling blood following treatment the current study 
demonstrates, in four patients, that it is possible to monitor the treatment of early syphilis with 
qPCR and that bacterial clearance (to below the level of detection) can be observed within 
three days of treatment. All three patients were also shown, by following their RPR titres, to 
be ‘cured’ following treatment according to the currently recognised definition of serological 
cure (104). Of course, a far greater number of patients would be needed to prove definitively 
that DNA clearance equates with cure and further assessment should include patients with 
both serological failure and those with serofast treatment outcomes in addition to serological 
successes. Moreover, it could be argued that RIT is the current gold standard for T. pallidum 
detection and should be used in future studies to diagnose cure, however impractical. 
 
The ultimate goal of establishing the kinetics of T. pallidum clearance is to develop a speedy 
and robust way of predicting patient treatment outcomes without the need for months of 
serological follow-up. It was important for this pilot study to select patients who were likely 
to have detectable bacterial loads at baseline. Therefore, patients with early syphilis, 
specifically those with late primary or early secondary disease, were selected as they were 
previously shown in the cross-sectional data (Chapter 3.2) to have more frequently a 
detectable blood bacterial load. This strategy proved successful as all of the four patients 
recruited were found to be bacteraemic. It must be noted, however, that patient STS4 had a 
much lower blood bacterial load than the other three recruits, and while data from this patient 
were of interest; they were excluded from many of the analyses. Overall, the half-life for 
blood clearance of T. pallidum DNA following the administration of a single dose of 
benzathine penicillin was 5.68 hours and for RNA was 3.89 hours. All patients had an 
undetectable blood bacterial load (DNA and RNA) 56 hours after treatment. Importantly, this 
correlated with serological cure, defined as a two-dilution fall in RPR titre, measured at either 
one or three months following treatment. It is also significant that patient STS1, whose blood 
was sampled until 150 hours (6.25 days) post-treatment continued to have an undetectable 
bacterial load following clearance. Moreover, inpatients undergoing treatment for 
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neurosyphilis who had detectable bacteraemia pre-treatment had consistently negative 
bacterial loads following treatment up to 14 days after treatment. This time period more than 
adequately covers the 32-hour replication time of T. pallidum and the theoretical potential for 
a late recrudescence in bacterial load (4). It could be envisaged, therefore, that for patients 
with active PCR-positive syphilis at baseline, a clearance half-life of under six hours and/or a 
negative bacterial load at three days would be adequate to indicate cure and could potentially 
be a measure of treatment success in a trial comparing syphilis treatments. Of course, the 
results presented in the current study would need to be replicated in a much larger study in 
order to validate this strategy. 
 
A further question arises when considering the use of bacterial load as a marker of T. 
pallidum clearance (and syphilis cure): Is DNA or RNA the superior measure of bacterial 
clearance? If time is of the essence, then RNA may be deemed superior as the clearance half-
life for DNA was significantly longer than RNA (5.68 hours vs 3.89 hours). Of course, the 
number of samples taken in a study assessing the efficacy of a syphilis treatment will be 
limited, and sampling points could easily be tailored to the marker being used, which makes 
the five-hour difference between DNA and RNA clearance less important. If laboratory time 
and costs are also considered then RNA, which can be extracted in 50 minutes, is the clear 
favourite. The DNA extraction method requires two three-hour incubations and a DNA 
precipitation step that, as discussed previously, may contribute to a wide variability in 
extraction efficiency. It must be noted, however, that an internal control of the RNA 
extraction process has not been assessed. One final consideration is the effect that bacterial 
metabolic activity has on RNA levels detected, which has been predicted to be substantial. 
Again, if clearance half-life is to be the measure of anti-microbial efficacy then DNA may 
prove the superior measure as it is less variable. However, if a qualitative approach is 
favoured, then the greater sensitivity offered by RNA detection may be preferable. 
 
All four subjects in the current study presented within one month of the onset of symptoms 
and had serological results consistent with early disease, however they were not an 
homogenous group. Most notable is patient STS4 who had only low-load T. pallidum 
bacteraemia, similar to levels seen for latent disease in Chapter three. Moreover, he was the 
only one of the four not to exhibit a marked worsening of his rash or other symptoms of a 
JHR following treatment. It is possible, therefore, that he had already progressed to the early 
latent stage by the time he was recalled for treatment and enrolled into the study, which may 
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explain the significantly lower level of T. pallidum bacteremia recorded. If this is indeed the 
case, it may indicate a role for testing the blood of patients with suspected latent disease on 
more than one occasion in order to increase the sensitivity of T. pallidum detection. Also of 
interest, is patient STS3 who presented with a primary chancre of 4 weeks’ duration, which 
was still strongly DGM positive. Measured by DNA, his blood bacterial load at presentation 
was not significantly higher that that of patients STS1 or STS2. The RNA-measured load, 
however, far exceeded that of the other three patients. When expressed as a ratio of 
RNA:DNA and plotted against time since treatment a similar pattern of clearance was noted 
for patients STS1, STS2 and STS3. It is notable, however, that patient STS3’s blood had a 
higher RNA:DNA ratio than that of patients STS1 or STS2. This could simply represent 
differences in extraction and PCR efficiency for samples collected for this patient, however, it 
may well represent increased metabolic activity of T. pallidum organisms actively invading 
the patients blood stream from his primary chancre (which contained 1000 times more RNA 
than DNA pre-treatment).  
 
Three of the four patients in the study developed symptoms and signs consistent with a JHR 
in the hours following their treatment with benzathine penicillin. A reported 40-80% of 
patients experience a JHR following treatment and it has been associated with younger age 
(maximal at 27 years); early disease (primary or secondary) and with previous penicillin 
administration (190, 218, 260, 261). Furthermore, increased risk of JHR has been associated 
with RPR titres greater than 1:32 compared with less than 1:32 (82.1% vs 55.6%, p=0.001) 
(261). It is also of note that in a recent post-hoc multivariate analysis of a randomised syphilis 
treatment trial, younger patients who experienced a JHR following treatment had two-fold 
greater odds of cure than those who did not (218). In the current study, patient STS3, a 26 
year-old with primary disease experienced the most severe JHR, which resulted in 24 hours of 
fever, malaise and headache. Of interest, this patient had the highest RNA-measured blood 
bacterial load; a baseline RPR titre of 1:32; was the youngest patient recruited and had 
achieved serological cure at one month. Patient STS4, a 35 year-old with secondary disease 
and who had the lowest blood bacterial load was the only patient not to develop the JHR 
despite a baseline RPR titre of 1:64. One might conclude, therefore, that higher bacterial loads 
are associated with both increased risk and greater severity of JHR although a much larger 
number of patients would be needed to prove this association. It is also of note that in a study 
measuring inflammation (CRP and complements C3 and C4) following early syphilis 
treatment the only patient not to experience a JHR was one with early latent disease (192). A 
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further interesting observation is that a peak in RNA bacterial load was noted between two 
and 10 hours after treatment in patients STS1, STS2 and STS3. A similar peak was noted in 
DNA levels at two hours post-treatment for patients STS1 and STS3 and a peak in neither 
DNA nor RNA was noted for patient STS4. This phenomenon was initially suspected to be 
the result of variations in extraction and PCR efficiency, but became harder to explain when it 
was noted in three patients’ blood and for both nucleic acids. A possible explanation would be 
that the rapid killing of T. pallidum following the administration of penicillin results in the 
release of bacterial nucleic acids, proteins (including ribosomes) and other cellular 
components into the bloodstream. Indeed, the peak plasma concentration of penicillin does 
not occur until 13-24 hours after the administration of benzathine thus the drug and nucleic 
acids levels may peak simultaneously. This transient increase in the amount of detectable T. 
pallidum nucleic acids in the circulation also coincides with the JHR and may explain its 
aetiology. (100). Of course, at a higher pre-treatment bacterial load (patient STS3 had the 
highest pre-treatment levels of both DNA and RNA) this effect would be magnified and at 
lower loads (such as documented for patient STS4) it may be absent. 
 
In summary, it has been demonstrated in a prospective longitudinal study of four patients that 
qPCR can be used to monitor decay in T. pallidum load following treatment and that bacterial 
clearance correlates with both resolution of clinical symptoms and serological cure. RNA 
decay is the quicker measure both in terms of laboratory processing time and time taken for 
blood clearance, and may be subject to less variation during the extraction process. A larger 
study is now proposed, using time points selected on the basis of these data, to show 
definitively that qPCR is superior to serology as a measure of T. pallidum clearance and thus 
to diagnose cure in early syphilis. These data will then be used to inform to design of new 
clinical trials comparing syphilis treatments in which cure or treatment failure can be quickly 
diagnosed.  
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Chapter 5 
 
Molecular characterisation of T. pallidum strains 
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5.1 Introduction 
5.1.1 Background 
 
The British and Sri Lankan guidelines for the management of syphilis include macrolide 
antibiotics as alternative treatments for early disease. (104) In Britain, this advice comes with 
the caveat that intrinsic macrolide resistance is present in some strains of T. pallidum, 
although until now the prevalence of such strains in either country was unknown. Following 
clinical trials showing comparable efficacy to benzathine penicillin (161, 164, 219, 220, 262), 
there was enthusiasm for treating incubating and early disease with single-dose azithromycin 
(160). Unfortunately, this introduction was shortly followed by treatment failures in some 
patients (mostly MSM), which was attributed to a single point mutation in the 23srRNA gene 
(168, 169). Macrolide antibiotics are not widely used in Sri Lanka and the level of resistance 
in another bacterium, Streptococcus pneumoniae, is reported to be low. It is predicted that T. 
pallidum macrolide resistance, if present, will be equally low-level (263)  . 
 
Molecular studies of T. pallidum go beyond the identification of resistance and can also be 
used to reveal a number of strains based on analysis of the acidic repeat protein (arp); T. 
pallidum repeat (tpr) subfamily 1 genes and the T. pallidum 548 gene (tpp0548) (82, 86). 
Population studies have shown that whilst there are common types, there is also considerable 
strain diversity within epidemics (87, 147). These data have led to theories regarding the 
origin of macrolide resistant strains. Previous studies have reported partial strain-typing data 
due to a low success rate of amplifying the arp gene by PCR (89, 264). There are also 
reported differences in the success of typing according to the clinical samples from which T. 
pallidum DNA is extracted. Finally, the original CDC method for T. pallidum strain-typing 
did not include tpp0548 sequence analysis which may improve strain discrimination. (86)  
 
In this study, macrolide resistance and strain-typing data from St Mary’s Hospital, London, 
UK and the central clinics of the National STD/AIDS control programme in Colombo, Sri 
Lanka are presented. Additionally, an assessment is made of the addition of tpp0548 gene 
sequence analysis to the standard CDC typing together with discussion of optimal PCR 
conditions for arp gene amplification and the most appropriate samples for strain-typing. 
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5.2 Results  
 
5.2.1 Assessment of assay modifications to improve amplification of the T. pallidum arp 
gene  
 
Successful amplification of DNA targets containing repeated sequences and a high proportion 
of guanine and cytosine bases can be troublesome. (265) In order to optimise the 
amplification of the T. pallidum arp gene, which contains a variable number of 60bp repeats 
and has a high GC content, four optimisation steps were assessed. 
Initially, the concentration of the amplification primers ARP F and ARP R were increased 
from 0.2M to 0.4M and the amount of taq polymerase per reaction increased from one to 
two units. Figure 5.1 A demonstrates the superior PCR efficiency with the higher enzyme and 
primer concentrations. Moreover, that the limit of detection for this assay is approximately 
10
3
 genome equivalents of DNA. Secondly, the addition of betaine to the reaction (Figure 5.1 
B) resulted in inferior arp-amplification at each of the three concentrations assessed. 
Likewise, the addition of GC-rich solution to the reaction (Figure 5.1 C) failed to enhance 
amplification, regardless of concentration. Finally, reaction efficiency was unaltered by the 
variation of magnesium concentration from 1-4 mM per reaction(data not shown). 
On the basis of these results, the final reaction mixture selected for arp amplification 
contained: 0.4M of each primer; 2 units of taq polymerase; 2mM magnesium (as supplied in 
PCR reaction buffer) and no betaine or GC-rich solution. Failed reactions were repeated with 
10L extracted T. pallidum DNA in place of the standard 5L. 
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Figure 5.1 Optimisation of T. pallidum PCR amplification  
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Fig. 5.1. T. pallidum strain typing required amplification of the gene arp. Different PCR 
conditions were assessed with the aim of improving arp amplification efficiency. Panel A 
shows PCR amplification in reactions with different concentrations of taq polymerase and 
reaction primers. Reactions in lanes A-D contained one unit taq polymerase and 0.2M of 
ARP_F2 and ARP_R2 primers. Reactions in lanes E-H contained two units taq polymerase 
and 0.4μM of the primers ARP_F2 and ARP_R2. The impact of T. pallidum DNA starting 
concentration was also assessed for both conditions. Accordingly, 10
4 
genome equivalents 
were added to reactions in lanes A&E; 10
3
 in lanes B&F and 10
2
 in lanes C&G. Reactions 
shown in lanes D&H were no template (water) controls. Panel B demonstrates the effect of 
adding betaine on the amplification of arp DNA extracted from 10
4
 Nichols strain T. 
pallidum. The concentration of betaine added to reactions was either 40mM (lane E); 35mM 
(lane D); 30mM (lane C); 25mM (lane B) or none (lane A). Panel C assessed in impact of 
‘GC-rich solution’ (Roche, Germany) at final concentrations of 0.4x (lane B); 0.6x (lane C) or 
0.4x (lane B). Lane A contained no GC-rich solution. 
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5.2.2 Patient Recruitment and Demographics 
London 
Samples were collected from patients attending the sexual health department at St Mary’s 
Hospital in London during two separate periods (described in sections 2.14.1 and 2.14.2). A 
total of 99 patients were recruited for the qPCR validation study between July 2006 and 
March 2008 and a further 62 patients donated samples between January 2011 and November 
2012. In total, 102 patients had a clinic-microbiological diagnosis of syphilis and at least one 
sample (blood or ulcer) from 58 of these patients contained T. pallidum DNA. Following 
initial tpp047 quantification by real-time PCR, any remaining DNA was subject first to 
mutation analysis, and then to strain-typing. Blood-extracted DNA was used only when ulcer-
extracted DNA was unavailable.  
Mutation analysis was achieved for 41 samples and a full or partial strain type subsequently 
identified in 23. All 41 samples were from men, of whom 38 (92.7%) were MSM and 26 
(63.4%) were HIV-1 infected. The mean age of patients was 37.34 years (std. dev. 9.47) and 
the majority were of white British (22, 53.7%) or white ‘other’ (13, 31.7%) ethnic origin. A 
total of 16 (39%) patients were diagnosed with primary disease, 21 (48.8%) with secondary 
and 5 (12.2%) were latently infected. Patient recruitment and available samples are 
summarised in Figure 5.2. 
 
Sri Lanka 
Exudate was collected from the primary and secondary syphilis lesions of 25 patients 
attending the clinics of the centre for STD/AIDS control in Colombo, Sri Lanka between 
January and August 2012. All patients had a microbiological diagnosis of syphilis following 
dark-ground microscopy or serological testing. The presence of T. pallidum DNA was 
confirmed by PCR (tpp047 gene) in 24 of the 25 samples of which 14 were from primary 
chancres, nine were from moist secondary lesions (or healing ulcers still present in secondary 
disease) and one was a skin swab. In total, 11 patients had self-referred to the service and 13, 
including a neonate with congenital syphilis, were referred from general practice or another 
hospital department. The majority of patients were Sinhalese (88%) and the remainder (12%) 
Sri Lankan Tamil. Excluding the neonate, patients had a mean age of 29.52 years (std. dev. 
9.70). All patients were male and 11 (47.8%) identified as MSM (including seven identifying 
as bisexual). The majority (91.3%) reported no previous travel outside Sri Lanka. 
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Figure 5.2 Molecular characterisation of T. pallidum strains in London 
 
 
 
Fig. 5.2. T. pallidum strain-type and antibiotic resistance mutation analysis was performed on 
samples collected in London during two cross-sectional studies.  
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5.2.3 Sensitivity of T. pallidum strain-typing techniques  
 
In London, 27 samples were subjected to strain type analysis resulting in the identification of 
five full and 19 partial subtypes. It was not possible to amplify any of the three typing genes 
in the remaining three samples. Figure 5.3 summarises these data and compares the success of 
strain-type identification from blood and ulcer specimens. The five full subtypes identified 
were all from ulcers with an average of 1798 tpp047 copies/strip (std. dev. 1104) and of the 
19 partial sub-types, 11 were from ulcers (mean 8789 copies/strip, std. dev. 14429) and eight 
from blood samples (mean 729 copies/strip, std. dev. 905). The difference in ulcer bacterial 
load between those yielding a full or a partial sub-type was not statistically significant 
(p=0.302). Ulcer samples taken in Sri Lanka allowed identification of 13 full and 11 partial 
strain types and a significant difference in bacterial load was observed between those samples 
yielding a partial (8482 tpp047 copies/strip, std. dev. 17745) or a full subtype (44643 
copies/strip, std. dev. 46255) (p=0.023). 
 
tprEGJ MseI restriction digest patterns were identified in 5/19 (26.3%) samples from London 
and 13/24 (54.1%) of samples from Colombo. The only DNA samples from either country for 
which this technique was successful were ulcer-derived. A tpp0548 gene sequence was 
identified in all 24 Sri Lankan samples analysed. As shown in Figure 5.4, tpp0548 sequence 
analysis was successful in 20/24 (83%) samples from London. Of the four samples for which 
PCR amplification failed, two were low-load blood samples (six and 234 copies/ml) and a 
further sample was a low-load ulcer (113 copies/strip). The fourth sample was a high load 
(36720 copies/strip) ulcer sample. The size of the arp amplicon was established in 23/24 
(95.8%) Sri Lankan strains and 13/24 (54.2%) of London strains. In London samples, arp 
amplification was achieved in 11 ulcer samples with a mean of 9444 tpp047 copies/strip 
(st.dev. 14039) and failed in five ulcer samples (357 copies/strip, std .dev. 182) (p=0.178). 
Bacterial load in the failures did not exceed 648 copies/strip, whereas in all but two of the 
successes, bacterial load was in excess of 1024 copies/strip. Successful arp amplification was 
achieved in only A total of two blood samples containing an average of 1165 tpp047 
copies/ml (std. dev. 1475) yielded and arp type, and amplification failed in a further eight 
(mean 446 copies/ml, std. dev. 708) (p=0.312). Unlike ulcer samples, there was no clear cut-
off above which successful arp amplification was more likely. 
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Finally, 23S rRNA mutation analysis was achieved in all 24 tpp047-positive Colombo samples 
and 41/58 London samples (16 ulcer and 25 blood). The 41 samples on which the assay was 
successful included five blood-extracted and two ulcer-extracted samples for which all three 
strain-type analysis PCRs failed.  
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Figure 5.3 T. pallidum strain-type analysis from different sample types 
 
 
 
Fig. 5.3. T. pallidum strain type analysis requires analysis of three genes. Successful 
amplification of all targets yielded a ‘full’ subtype and identification of one or two targets, a 
‘partial’ subtype. Partial or full T. pallidum strain-types were identified in 27 samples, 
comprising 16 ulcers (blue) and 11 blood samples (green). PCR amplification failed for all 
targets in three samples. 
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Figure 5.4 Assessment of an additional target for T. pallidum strain type analysis  
 
 
 
 
 
Fig. 5.4. The T. pallidum gene tpp0548 was PCR-amplified and subject to gene sequence 
analysis to better discriminate between molecular sub-types.  In total, tpp0548 was 
successfully sequenced in 20 samples and three strains (‘d’. ‘f’ and ‘g’) were identified. 
Amplification failed in four samples. 
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5.2.4 Mutation analysis and strain-typing in London 
5.2.4.1 T. pallidum macrolide resistance in London is of high and increasing prevalence 
 
23S rRNA mutations conferring macrolide resistance were identified in 73% (30/41) of T. 
pallidum strains collected between July 2006 and November 2012. Whilst a single A2059G 
substitution was identified, the majority (29/30) of mutations were A2058G. 
An increase in the prevalence of resistant T. pallidum strains from 66% (12/18) in 2006-8 to 
78% (18/23) in 2011-2012 was observed but this was not statistically significant (p=0.50) 
(Figure 5.5). 
 
All resistant strains were identified in samples from MSM of whom 62.1% (18/29) were HIV-
1 infected and 86.6% (26/30) were of white British or white ‘other’ ethnic origin (Figure 5.6). 
The demographics of patients infected with resistant strains matched the overall study 
population. Therefore, while white ethnicity, sexual orientation and HIV status are seemingly 
associated with risk of T. pallidum infection, they cannot be analysed as risk factors 
associated with macrolide resistance. 
 
Data concerning the use of antibiotics in the three months prior to syphilis diagnosis were 
available for 51.2% (21/41) patients. Of these, two had received macrolide antibiotics 
(clarithromycin or azithromycin) and both had genotypic evidence of resistance. One further 
patient with resistance had received the fluoroquinolone ofloxacin. None of the four patients 
infected with wild-type strains (and for whom antibiotic use data were available) had received 
antibiotics. However, mutant strains were identified in 14 patients who had not received 
antibiotics prior to their diagnosis. 
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Figure 5.5 Prevalence of macrolide resistant T. pallidum strains  
 
 
 
Fig 5.5. Blood and ulcer samples containing T. pallidum were subject to a point mutation 
assay for the identification of macrolide resistance conferred by A2058G and A2059G base 
substitutions in the 23S rRNA gene. Samples were collected at St Mary’s Hospital, London 
during two separate periods (July 2006 to March 2008 and January 2011 to December 2012) 
and the frequency of resistant and wild-type strains were determined. Blue bars depict wild-
type strains; green bars show A2058G mutants and beige bars are wild-type strains. Sample 
numbers for each type are displayed within bars.  
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Figure 5.6 T. pallidum macrolide resistance according to demographic factors  
 
A. Ethnic origin 
 
B. HIV-1 co-infection C. Sexual orientation 
  
Fig 5.6. 23S rRNA mutation analysis was performed on a total of 41 T. pallidum strains. 
Results are presented here according to patients’ ethnic origin (Panel A); HIV-1 status (Panel 
B) and sexual orientation (Panel C). Blue bars depict wild-type strains; green bars show 
A2058G mutants and beige bars are wild-type strains. Sample numbers for each type are 
displayed within bars. 
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5.2.4.2 Analysis of T. pallidum strain types  
 
All strain types identified in London, including 23S rRNA analysis are listed in Table 5.1 and 
summarized in Figure 5.7. A total of three unique complete (ie. successful amplification and 
analysis of the genes arp, tpp0548 and trpEGJ) strain types (two 14d/g, one 14d/f and two 
14g/g) and a further seven partial strain types were identified. All 13 samples for which arp 
amplification was possible had 14 tandem repeats and of the five identifiable tprEGJ digest 
patterns three were ‘d’ and two were ‘g’.  
 
The 23S rRNA A2058G mutation was found in each of the three unique full sub-types. No 
sub-type analysis was possible from the single A2059G mutant strain. The A2058G 23S 
rRNA mutation was found in all 10 samples with the tpp0548 ‘g’ sequence and in only one 
third of type ‘f’ strains with the remainder being wild-type. 
 
All full and the majority of partial strain types identified include a tpp0548 gene sequence. 
Figure 5.4 demonstrates sequences ‘f’ and ‘g’ to be the most prevalent at 45% and 50% 
respectively, and that a single strain was found to have sequence ‘d’ (5%). No demographic 
differences were noted between patients with tpp0548 ‘f’ or ‘g’ gene sequences and HIV-1 
status, ethnic origin, gender, sexual orientation. 
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Table 5.1: T. pallidum strain-typing and mutation analysis in London 
 
Study ID Disease Stage Sample Type Macrolide Type Strain Type 
Patients recruited from qPCR validation study (2006 to 2008) 
23 Primary Ulcer Swab A2058G 14d/g 
24 Primary Ulcer Swab A2058G 14d/g 
26 Primary Ulcer Swab wild-type ++/+ 
32 Primary Ulcer Swab A2058G 14g/g 
33 Primary Ulcer Swab A2058G xx/g 
52 Primary Ulcer Swab A2058G 14d/f 
62 Primary Ulcer Swab wild-type 14x/f 
69 Primary Ulcer Swab A2058G xx/g 
89 Primary Ulcer Swab A2058G 14g/g 
90 Primary Ulcer Swab wild-type 14x/f 
93 Primary Ulcer Swab wild-type xx/f 
22 Secondary Ulcer Swab A2058G xx/g 
34 Secondary Ulcer Swab wild-type xx/f 
27 Secondary Whole Blood A2058G ++/+ 
45 Secondary Whole Blood A2058G xx/x 
53 Secondary Whole Blood wild-type ++/+ 
61 Secondary Whole Blood A2058G ++/+ 
81 Secondary Whole Blood A2059G ++/+ 
Samples from patients recruited to the CDTB (2011 to 2012) 
109 Primary Ulcer Swab A2058G 14x/g 
108 Primary Whole Blood wild-type xx/f 
127 Primary Whole Blood A2058G 14-/- 
129 Primary Whole Blood A2058G 14-/x 
107 Secondary Ulcer swab A2058G 14x/d 
100 Secondary Whole Blood A2058G xx/f 
103 Secondary Whole Blood A2058G xx/g 
105 Secondary Whole Blood A2058G xx/g 
106 Secondary Whole Blood wild-type xx/f 
110 Secondary Whole Blood A2058G xx/f 
115 Secondary Whole Blood A2058G --/- 
124 Secondary Whole Blood wild-type --/- 
134 Secondary Whole Blood A2058G 14-/- 
138 Secondary Whole Blood A2058G --/- 
140 Secondary Whole Blood A2058G --/- 
151 Secondary Whole Blood A2058G --/- 
154 Secondary Whole Blood A2058G --/- 
155 Secondary Whole Blood A2058G --/- 
113 Latent Whole Blood wild-type xx/x 
123 Latent Whole Blood wild-type --/x 
128 Latent Whole Blood A2058G 14-/- 
136 Latent Whole Blood A2058G --/- 
142 Latent Whole Blood A2058G --/- 
     
 
Table 5.1. Blood and ulcer samples collected during two cross-sectional studies in London 
were subject to molecular analysis to identify 23S rRNA mutations associated with macrolide 
resistance and T. pallidum strain types. Strain types are presented in the order: arp repeats, 
tprEGJ digest pattern (tpp0548 sequence). E.g. 14d/d. The symbol ‘x’ denotes a typing target 
which failed to amplify; ‘+’ indicates that insufficient sample was available for the analysis 
and ‘-’ signifies that amplification was not attempted. 
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Figure 5.7 T. pallidum sub-types identified in London 
 
 
 
 
Fig 5.7. Molecular analysis of 24 T. pallidum DNA samples identified five full and 19 partial 
sub-types. The four components of the sub-type are presented in the order: arp repeats; 
tprEGJ digest pattern; tpp0548 sequence and 23S rRNA mutation analysis. Eg. 14d/d 
A2058G. Missing components replaced with ‘x’ 
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5.2.5 Strain-typing and mutation analysis in Sri Lanka 
 
A total of 24/25 samples collected from the central STD clinics of Colombo, Sri Lanka 
contained T. pallidum DNA sufficient for mutation and strain type analysis. T. pallidum DNA 
was not detected in one sample, collected from a female patient with a DGM positive labial 
ulcer and serology consistent with a diagnosis of early syphilis. PCR amplification of tpp047 
and RT-PCR of 16S rRNA both failed. 
 
In total, 11 partial and 13 full strain-types were identified and are listed in Table 5.2. The full 
sub-types comprised a single 13b/f strain and twelve (92.3%) 14b/f strains. Similarly, of the 
partial sub-types characterised, the majority (10/11, 90.0%) were 14x/f and a single 13x/f 
strain was found. When analysed for 23S rRNA mutations, neither substitution (A2058G or 
A2059G) was identified in any of the 24 strains. 
 
Two patients were infected with a strain containing 13 arp tandem repeats, whereas the 
majority of strains had 14 (Figure 5.8). These two strains were otherwise similar, both 
possessing a tpp0548 ‘f’ sequence and neither having a mutated 23S rRNA gene. The patients 
were both men of a similar age and Sinhalese (Table 5.3). Patient eight gave a history of 
travel to Saudia Arabia and Germany and of sex with other men. Patient 13 had never left Sri 
Lanka and was heterosexual.  
 251 
Figure 5.8 Determination of the size of T. pallidum arp amplicons in Sri Lankan strains 
 
 
Fig 5.8. The arp gene from Sri Lankan T. pallidum strains was PCR-amplified and visualised 
with SYBRsafe stain and agarose gel electrophoresis. Using a molecular marker and 
LabWorks Image Acquisiton Software sample band sizes were determined and compared 
with that of the Nichols reference strain. L=Ladder, N=Nichols (reference) T. pallidum strain.  
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Table 5.2 Molecular analysis of T. pallidum strains in Sri Lanka 
 
Study ID Disease Stage Macrolide Type Strain Type 
1 Primary wild-type 14b/f 
2 Primary wild-type 14x/f 
3 Primary wild-type 14b/f 
4 Secondary wild-type 14x/f 
5 Secondary wild-type 14b/f 
6 Secondary wild-type 14x/f 
7 Secondary wild-type 14b/f 
8 Primary wild-type 13b/f 
9 Secondary wild-type 14b/f 
10 Secondary wild-type 14x/f 
11 Primary wild-type 14x/f 
12 Secondary wild-type 14x/f 
13 Primary wild-type 13x/f 
14 Primary wild-type 14b/f 
15 Secondary wild-type 14b/f 
16 Primary wild-type 14b/f 
17 Primary wild-type 14b/f 
18 Primary wild-type 14b/f 
19 No T. pallidum DNA was detected in sample  
20 Primary wild-type 14b/f 
21 Primary wild-type 14b/f 
22 Primary wild-type 14x/f 
23 Secondary wild-type 14x/f 
24 Secondary wild-type 14x/f 
25 Primary wild-type xx/f 
 
Table 5.2. Ulcer samples were collected from patients with early syphilis in Colombo, Sri 
Lanka. The presence of T. pallidum (tpp047) DNA was confirmed and samples were then 
subject to molecular analysis for strain-type identification and to determine the prevalence of 
23S rRNA mutations which confer macrolide antibiotic resistance. Strain Types data is  
presented in the order: arp repeats, tprEGJ digest pattern and tpp0548 sequence. Eg. 14d/d.  
‘X’ denotes amplification failure of target to amplify. 
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Table 5.3 Clinical details of two Sri Lankan patients  
 
 Patient 8 Patient 13 
   
Age 27 25 
Gender Male Male 
Ethnic Origin Sinhalese Sinhalese 
Disease Stage Primary Primary 
Sexual Orientation Bisexual Heterosexual 
Travel outside Sri Lanka (ever) Saudi and Germany None 
Referral Source GP referral Self-Presentation 
   
 
Table 5.3. Two patients were found to have been infected with T. pallidum strains containing 
13 arp gene tandem repeats, whereas the remaining 22 strains identified contained 14 repeats. 
Demographic data collected for these two patients is presented including history of travel 
outside Sri Lanka. 
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5.3 Discussion 
 
The data presented in this chapter are the first description of T. pallidum macrolide antibiotic 
resistance in both the United Kingdom and Sri Lanka and have implications for syphilis 
treatment guidelines. Associated strain-typing data both enhances understanding of the origins 
of macrolide resistance and helps to inform the choice of samples and techniques for T. 
pallidum molecular characterisation.  
 
Several studies have presented T. pallidum macrolide resistance data since 2004 when a 23S 
rRNA point mutation (A to G at position 2058) was linked definitively with phenotypic 
macrolide resistance (168-172, 176, 266). In London, T. pallidum samples were collected 
during two separate studies. The first (qPCR validation) was conducted in 2006-8 and the 
second (CDTB sample collection) in 2011-12. In the three years between studies, the 
prevalence of macrolide resistance, which was already 66% in 2006, increased by 14% to near 
80%. This increase was not statistically significant but similar prevalence data have been 
reported in San Francisco, where resistance rose from 4% to 56% percent between 2000-2002 
and 2004, and British Columbia where a temporary fall in syphilis cases following an 
azithromycin intervention in 2001 was not sustained. (171, 176). The populations affected by 
syphilis on both sides of the Atlantic are also similar, being predominantly white MSM with 
high (30%) rates of HIV-1 co-infection (1, 171). Patients with syphilis sampled in Sri Lanka 
also bore a resemblance to their North American and British counterparts being mostly male 
and 50% MSM. In stark contrast however, no macrolide resistant strains were identified in 
any samples collected in Colombo during this study. 
 
Two theories have been suggested to explain the rapid spread of macrolide resistance in T. 
pallidum (266). The first is that a strain with a pre-existing 23S rRNA mutation is introduced 
into a small and well-defined population and becomes endemic. The strain ‘street 14’, which 
carries the 23S rRNA mutation A2058G, was isolated from a patient in San Francisco in 1977 
and despite multiple passages in rabbits (in the absence of antibiotic pressure) the mutation 
has remained stable (167, 266). It is conceivable that this strain, or another like it, spread 
within the city’s MSM population during the 80s and 90s and resulted in treatment failure 
among patients treated with azithromycin following inclusion of the drug in clinical 
guidelines in 2000 (168, 171). The prevalence of resistance then increased as selection 
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pressure singled out this clone. According to this theory a mutant strain would have been 
introduced into the London MSM population (8% of infections are thought to be acquired 
abroad) and would have come to predominate under selection pressure from wide-spread 
azithromycin use in this population for genital Chlamydia trachomatis infection and non-
specific urethritis treatment (1). By the same analysis, the absence of a resistant strain in 
Colombo, and the relative seclusion of the Sri Lankan population (only two patients in our 
study had ever been outside Sri Lanka) could explain why no macrolide-resistant strains were 
identified. Further support for this theory is found in Madagascar, where none of 141 strains 
studied contained macrolide resistance mutations, and where sexual networks in which 
syphilis is transmitted are distinct from those of North America and Europe where MSM 
predominate (175). 
 
Strain-typing data available from this and other studies support a second theory on the origins 
of macrolide resistance. If the result of endemic spread of a mutant clone in a given sexual 
network, then a single resistant strain-type would be expected within that population. It has 
been demonstrated widely, however, that epidemics comprise several strains both with and 
without resistant genotypes (96). More specifically, when 20 resistant strains collected in 
King County, Washington, USA were examined for the presence of an insertion in the 
tpp0126-tpp0127 intergenic spacer it was only present in 80%, signifying at least two clones 
(266). The results of strain-type analysis in the current study showed three full sub-types 
(14d/g, 14g/g and 14d/f), which were all A2058G mutants. This indicates that resistance is not 
the result of a single endemic clone, rather a number of resistant strains circulating in 
London’s MSM population, and that resistance may be developing de novo as a result of 
selection pressure. Regarding antibiotic use, two patients in this study had received a 
macrolide antibiotic in the three months prior to their syphilis diagnosis, and both were 
infected with a resistant strain. Moreover, of the four patients with wild-type strains for whom 
antibiotic use data were available, none had recently received a macrolide. This association is 
supported by a previous observation that the relative risk of harbouring a resistant strain was 
2.2 in patients who had received a macrolide in the year prior to a diagnosis of syphilis. Given 
that the prevalence of resistant strains is now 80%, and knowing that the mutant 23S ribosome 
is stable enough to persist in the absence of antibiotic pressure, the majority of patients with 
resistance in this study were likely infected with an already resistant strain, of which at least 
three are currently circulating. In order to assess the true impact of resistance developing de 
 256 
novo, samples prior to 2006 would be required to demonstrate much lower resistance 
prevalence in the context of similar strain diversity. 
In addition to helping identify the origin of antibiotic resistance in a population, strain-typing 
data are useful to map epidemics and to identify populations at risk of disease. The data 
presented here are the first to describe T. pallidum subtypes in England. Data from Scottish 
samples collected in 2006-7 revealed six subtypes among 58 typeable specimens, the majority 
of which (80%) were collected from white MSM. The commonest subtype was 14d (76%), 
followed by 14e (12%), 14j (5%), 14b (3%), 14p and 14k (2% each) (87). Given that the 
population sampled was relatively homogenous, the authors felt the strain diversity surprising, 
although no other epidemiological data were available to explain it. The predominance of 
syphilis among MSM in Scotland is reflected more generally in the UK and in other high 
income countries. The London study population presented here is a relatively homogenous 
group of white MSM thus the majority of patients infected with resistant strains are also white 
MSM. UK national data demonstrate that 27% of syphilis diagnoses of any stage are found in 
men with HIV-1 co-infection (1). Moreover, a phenomenon known as, ‘sero-sorting’ has been 
described where people choose sexual partners of the same HIV serostatus in order to engage 
in unprotected sex resulting in a 61% increase in risk of STI transmission (267). The potential 
exists, therefore, to identify different T. pallidum strains from HIV-1 infected and un-infected 
men as their sexual networks are relatively discrete. However, no evidence was found in this 
study for such a separation as strains identified from both groups were similar across all three 
strain-typing targets and were equally likely to harbour 23S rRNA mutations.  
 
In contrast to London, T. pallidum strain-diversity in Colombo was limited. Just two strain 
types were identified (14b/f and 13b/f) neither being macrolide resistant. This limited strain 
diversity may be a reflection of the limited population sampled, which was similarly-aged 
Sinhalese men. Moreover, whilst half of the patients identified as MSM the majority were 
bisexual, not homosexual, making sexual networks less distinct. It is also of note that only 
two patients gave a history of any foreign travel, so the potential for the introduction of new 
strains is limited. By contrast, the population sampled in London was ethnically diverse with 
around half of patients describing non-British ethnicity, which could explain the increased 
diversity of T. pallidum strains observed. A recent meta-analysis compared strain-types 
identified in eight countries and found between four and fourteen circulating strains. The 
majority of strains worldwide carry 14 arp tandem repeats and strain type 14d, thought to be 
the original circulating subtype in many parts of the world, predominates (83). Whilst this is 
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true of the London strains identified, all containing 14 arp tandem repeats and being either 
tprEGJ ‘d’ or ‘g’, strains from Colombo were more unique. The most common of the two 
types identified was 14b and while less frequent world-wide it has been reported previously in 
China, South Africa, Madagascar and Scotland (82, 87, 89). Type 13b, however, was 
described in this study for the first time. Further examination of the two infections caused by 
type 13b and 13x strains in Colombo revealed a history of foreign travel (to Germany and 
Saudi Arabia) in one patient but not the other and different sexual networks (one homosexual 
and the other heterosexual). No typing data are available from Germany or Saudi to 
demonstrate that this strain was imported from either of those countries, but this remains a 
possibility. It may also be the case that strain 13b is more prevalent in Colombo than the small 
number of patients sampled for this study can demonstrate. 
 
The discussion of T. pallidum strain-types has focussed mainly on the CDC typing method 
which characterises two typing targets (arp and tprEGJ) (82). Addition of tpp0548 gene 
sequence analysis to the typing algorithm was recently shown to improve discrimination 
between sub-types, turning 14 CDC types into 25 ‘enhanced’ sub-types (86) and this study 
presents the first enhanced typing data in Europe. Whilst tpp0548 sequence analysis did not 
identify any additional strains in Colombo, it sub-classified two 14d types into 14d/f and 
14d/g in London and identified a unique partial strain-type which possesses a tpp0548 ‘d’ 
sequence, adding further to the correlation between population and strain diversity observed 
in both countries.  
 
An additional typing target, especially one requiring gene sequence analysis, adds both time 
and expense to strain identification. This study demonstrates, however that the success of 
tpp0548 PCR-amplification and sequencing far exceeds that of the original two CDC typing 
targets. For example, if arp and tpp0548 analysis alone were used to identify strain types, an 
additional 10 full types would have been described in Colombo. Moreover, the success of 
tpp0548 amplification from whole blood samples matched that from ulcer samples making it 
useful in latent and secondary disease. Of the four tpp0548 amplification failures across all 
studies, two were from low-load blood samples and one from a low-load ulcer sample. The 
final amplification failure was from a high-load ulcer sample, perhaps inhibited by the high 
starting DNA concentration (143). tpp0548 sequence analysis is therefore validated in these 
studies as a useful and effective T. pallidum strain-typing target.  
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Far less successful was the amplification by PCR of arp and particularly of tprEGJ genes. 
Several previous studies have reported partial strain type results as a result of arp 
amplification failure, which is unsurprising given its high GC content and the presence of a 
number of tandem repeats (264, 265, 268). Efforts made here to improve the amplification of 
arp were generally unsuccessful. The addition of betaine and Roche GC rich solution which 
aim to reduce secondary structure in the T. pallidum template DNA failed to improve reaction 
efficiency, and likely inhibited it further. Increasing the concentration of the reaction primers 
and of taq polymerase, however, was found to increase PCR efficiency. MseI restriction 
digest analysis of tprEGJ was found to be the least reliable typing target and was successful in 
26.3% and 54.1% of samples from London and Colombo, respectively. All of these strains 
were derived from ulcer samples, which were also found to be the best sample type for arp 
amplification. An observation made previously and confirmed here is that the improved 
detection of T. pallidum typing targets in ulcer samples is likely the result of higher bacterial 
load (83). tpp047 copies in ulcer samples were 26 times more numerous for arp amplification 
successes compared with failures. It was also demonstrated that arp amplification from blood-
extracted samples was more successful at higher bacterial loads. Overall, full strain-types 
were only identified from ulcer samples, and the majority of partial strain types from blood 
samples tended to be only a tpp0548 sequence. The identification of macrolide resistance 
from blood samples was more successful than strain-typing and results are available for five 
patients with latent syphilis. This is perhaps unsurprising as amplification of the two 23S 
rRNA alleles proceeds with two rounds of PCR in a ‘nested’ reaction which can theoretically 
detect a single gene copy. 
 
There are two main avenues of future research to go down in this field. The first is to 
recognise the power of next-generation sequencing techniques (e.g Illumina/Solex and 
ABISOLiD paltforms) for the identification of T. pallidum strain types. Whole genome 
sequences of strains would allow sequence-based analysis of bacterial strains which would 
enhance both strain-discrimination and the ability to correlate strain types with clinical 
phenotypes, such as the association made between subtype 14d/f and neurosyphilis (86). The 
second, is to be vigilant for the development of T. pallidum resistance to other antibiotics, 
specifically tetracyclines. T. pallidum has a small genome which most likely does not include 
plasmid DNA, thus the only mechanism available to the organism for developing resistance is 
to mutate genes encoding targets antibiotic targets (28). Resistance to macrolides was 
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conferred in this way, and 16S rRNA mutations have been shown to cause tetracycline 
resistance in other bacterial species (160). 
 
In summary, 23srRNA mutations conferring macrolide resistance in T. pallidum have been 
discovered to be common in MSM in London and caution is recommended in the use of 
macrolides for the treatment of incubating or early syphilis in the MSM population as well as 
for other populations. Although limited, typing data suggests that the epidemic in London is 
not a single clone of resistant T. pallidum, raising the possibility that resistance mutations are 
developing de novo, secondary to the selective pressure of macrolide use for other indications. 
There is currently no evidence of T. pallidum macrolide resistance strains in Colombo, Sri 
Lanka and strain-diversity there is limited. Given the rapid spread of macrolide resistance in 
other populations and the small sample size of this study, caution in using single dose 
azithromycin for the treatment of early syphilis in Sri Lanka would seem prudent. The 
identification of macrolide resistance is possible in both blood and ulcer samples in early 
disease, but also in latently infected patients with detectable bacteremia. Ulcer samples, which 
generally contain more DNA, are better for T. pallidum strain type analysis than blood and 
tpp0548 gene sequence has been shown to be a reliable typing assay, which enhances strain 
discrimination.  
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Chapter 6 
Discussion 
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General conclusions 
 
In 1943 penicillin was discovered to be an effective treatment for syphilis and its widespread 
use over the following decade led to near-eradication of the disease (18). However, 70 years 
on syphilis is resurgent in the UK in an epidemic characterised by male-to-male transmission 
in urban centres that is paralleled in a number of high-income countries (1). In the post-
penicillin years, the field of syphilis research made slow but steady progress despite 
continuous culture of T. pallidum remaining elusive. Specific antibody tests for clinical use 
have been developed; the enigmatic bacterial surface is beginning to yield its secrets and 
provide insight into the organism’s success in evading the immune response and the genome 
of several T. pallidum strains are now available and providing the answers to key questions 
about the organism’s metabolism and pathogenicity (14, 72, 247). Molecular strain type 
analysis has also shown the potential to identify neuro-invasive phenotypes and is providing 
useful information to the syphilis epidemiologist (95). Other antibiotic classes, namely 
macrolides, tetracyclines and cephlasporins have also been demonstrated to have activity 
against T. pallidum and are used as syphilis treatments (160). A recent shortage of benzathine 
penicillin, however, highlighted the fragility of current syphilis treatment strategies given that 
the evidence for using cephalosporins is weak; macrolide resistance is now widespread and 
doxycycline cannot be used in pregnancy or for treating children with congenital disease (104, 
269). Moreover, the new syphilis epidemic is closely related to that of HIV-1, each disease 
impacting on the clinical course of the other and 30% of those with syphilis being HIV-1 co-
infected (199). Two randomised controlled trials have compared standard benzathine 
penicillin syphilis treatment with oral azithromycin and both demonstrated equivalent 
efficacy. However, in the absence of a speedier alternative both trials were reliant on standard 
serological outcomes to diagnose cure, one at six months and the other at nine months 
following treatment (161, 219). This thesis sought to describe an alternative method for the 
assessment of treatment success in patients with early syphilis. 
 
The first step was to design assays capable of detecting and quantifying T. pallidum DNA and 
RNA and to validate these assays using clinical samples. This required the selection of robust 
methods for nucleic acid extraction; identification of the best sample types and sensitive 
assays for their detection. Early attempts at T. pallidum PCR recognised the need for efficient 
DNA extraction, given the potential for PCR inhibition by haem, proteins and other biological 
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molecules contained in clinical samples (130). DNA extraction from blood was found to be 
efficient with a proprietary DNA extraction kit modified by adding a proteinase K digestion 
step to ensure sufficient bacterial lysis. For blood RNA extraction the Tempus™ system was 
selected, on account of ease, speed and extraction efficiency. There is currently no consensus 
on which blood fraction is the most reliable for T. pallidum detection (52). The bacterium is 
known to bind to many nucleated cell types and is extracellular, thus could potentially be 
detected equally well in cellular and non-cellular blood fractions (59). The current validation 
study identified whole blood as the best sample type and was supported by data from both 
RIT testing (reliant on the presence of viable organisms), prior to the discovery of PCR, in 
which whole blood has been found more likely to harbor T. pallidum than plasma and an ex 
vivo experimental model where viable T. pallidum were spiked into blood and their 
distribution among fractions assessed (51, 126). The current study describes the development 
of four qPCRs: two for tpp047 DNA detection, a multiplex assay targeting TYLCV and 
tpp047 simultaneously, and an RT-qPCR for 16S rRNA quantification. Each assay was 
deemed to have an acceptable analytical sensitivity, all were specific for Treponema pallidum 
subspecies and quantified target DNA by comparison with in-run absolute quantification 
standards with acceptable efficiency. Furthermore, the assays were assessed according to 
published guidelines for the minimum information for publication of quantitative real-time 
PCR experiments (MIQE) and all except two of the essential criteria for publication were met 
(254). The two unmet criteria resulted from non-measurement of nucleic acid concentration 
and purity following extraction and prior to qPCR. The MIQE guidelines also recommend the 
use of internal controls of DNA recovery and PCR efficiency thus an attempt was made to use 
a recombinant plasmid containing TYLCV sequence in this role. While results were 
encouraging, the technique would benefit from further optimisation to improve inter-assay 
reproducibility. The use of PCR has also been described for the diagnosis of a number of 
other bacterial infections and is now used widely for the rapid identification of 
Mycobacterium tuberculosis (270, 271). The particular advantage of PCR is that it can detect 
very small amounts of bacterial DNA without the need for weeks of bacterial culture. 
 
T. pallidum DNA detection in samples from two cross-sectional studies was found to have a 
sensitivity and specificity similar to previously described assays. In ulcer samples, collected 
both in the UK and Sri Lanka, detection sensitivity was 100% and 96%, respectively. 
Compared with DGM, PCR identified an additional 16 cases of syphilis (using final clinical 
diagnosis as the gold standard). It is important to note, however, that in the hands a skilled 
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operator DGM will correctly identify T. pallidum in 80% of primary chancres and provides a 
point-of-care diagnosis in minutes whereas PCR takes at least four hours, and given 
laboratory logistics, potentially days (247). PCR may have a role in the diagnosis of early 
syphilis when DGM is not available, or there is concern of contamination by commensal 
treponemes, but should not, be considered a replacement for DGM. The quantity of DNA 
detected in lesions correlated with both ulcer area and duration, thus larger and earlier ulcers 
should potentially be considered more infectious to sexual partners. It was also notable that 
ulcers containing greater amounts T. pallidum by PCR were more likely to be DGM positive, 
further validating the quantitative capability of the technique. The level of RNA in ulcer 
samples far exceeded that of DNA, thought to be the result of increased metabolic activity of 
organisms in the primary chancre thus a greater number of 16S ribosomes. A trend was also 
noticed towards patients with HIV-1 co-infection having higher T. pallidum bacterial loads 
(DNA) in primary chancres. This fits well with previous observations that HIV-1 infected 
patients are more likely to present with multiple and deeper chancres. Moreover, that chancres 
take longer to heal in the context of HIV-1 infection (209).  
 
The sensitivity of tpp047 DNA detection in blood samples during primary, secondary and 
latent syphilis was also similar to previously published data (52, 83). Sensitivity was greatest 
in secondary disease and a PCR-positive blood sample in the current study had a 78.4% 
chance of coming from a patient in the secondary stage. It was also notable that only patients 
diagnosed with secondary syphilis had blood bacterial loads in excess of 1303 copies/ml. Of 
course, a number of patients with secondary disease had an undetectable blood bacterial load, 
thus the assay could not function as a diagnostic test. It is likely, although difficult to prove, 
that these patients had a longer duration of symptoms and were progressing towards T. 
pallidum immune clearance and disease latency. It was also noteworthy that a quarter of 
asymptomatic patients diagnosed with latent disease had low-level bacteraemia. This may 
represent patients with early latent disease who are either poised to clear the bacteraemia, or 
are heading towards disease relapse, which is common within a year of latency (103). The 
current rationale behind latent disease treatment is that those patients in late latency receive a 
three-week course of penicillin as a longer duration of infection results in attenuated, slow-
growing T. pallidum which take longer to kill. Those in early latency receive a single dose of 
penicillin. The cut-off between early and late latent disease is an arbitrary year in the USA 
and two years in the UK (104, 272). A potential role for T. pallidum qPCR in latent disease 
could therefore be in defining which patients require single-dose or multi-dose treatment, 
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although this strategy would need confirmation in a larger clinical study. T. pallidum qPCR 
cannot help, however, to differentiate between patients with latent non-bacteraemic infection 
and those with previously treated disease as both patient groups will have serological tests 
comprising a positive treponemal antibody and a negative or ‘serofast’ non-treponemal test 
result. In current clinical practice, this question is often addressed by differentiating between 
IgM and IgG antibodies with EIA assays. Whereas IgG persists into late disease, IgM is often 
negative thus differentiating between these two antibody types can help to determine disease 
stage (104). Another potential strategy to address this problem is detailed in the future work 
section below.  
 
Analysis of blood bacterial load in patients with and without HIV-1 co-infection revealed no 
trend towards HIV-1 infected patients having higher-load disease. It is noteworthy that HIV-1 
infected patients in this cross-section had a mean CD4 count of 603 cells/mm
3
 (std. dev. 160) 
thus could not be considered to be highly immunosuppressed. Previous studies of HIV-1 and 
syphilis co-infection have noted that CSF abnormalities are more frequent at CD4
+
 T-
lymphocyte counts under 350 cells/mm
3
 and that while changes to the presentation of early 
disease were more common, there were no significant differences in syphilis treatment 
outcomes between HIV-1 infected and HIV-1 uninfected patients (212, 262). Moreover, the 
majority of case reports describing more severe syphilis in HIV-1 infected individuals 
appeared in the pre-anti-retroviral era in the context of (sometimes profound) 
immunosuppression. It is still the case, however, that syphilis results in a transient fall in 
CD4
+
 T-cell count and rise in HIV-1 plasma viral load, even in patients with suppressed virus 
on anti-retroviral treatment and genital ulcer disease remains a risk factor for both HIV-1 
transmission and acquisition thus the interaction between the two disease cannot be 
considered insignificant (214, 273). 
 
The quantification of T. pallidum RNA in both blood and ulcers was described in the current 
study for the first time. When compared, RNA levels were greater at all stages of disease than 
DNA. This is not surprising considering a great many more copies of the 16S rRNA target are 
present in each organism that the single copy of tpp047 DNA (153). The greater abundance of 
the RNA target also improved the sensitivity of T. pallidum detection in blood for primary 
and secondary disease where three samples from each stage were positive for 16S rRNA, but 
negative for tpp047. In only one case (a patient with primary disease) was a blood sample 
RNA negative but DNA positive. Detection during secondary disease, where bacterial load is 
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higher, was equal for both DNA and RNA. The variability of RNA levels was high, explained 
partly by differences in the efficiency of reverse transcription, but also in the metabolic 
activity of bacteria. This effect was most marked in primary disease ulcers from the Sri 
Lankan cross-sectional study where RNA levels greatly exceeded those of DNA.  
 
These observations raise the question of how disease stage should be classified in the absence 
of symptoms but, in the presence of increased bacteraemia, especially given that RPR results 
did not correlate with blood bacterial load. Current dogma dictates that latent disease is a less 
active stage, characterised by slowly dividing bacteria and requiring prolonged treatment 
(three doses of benzathine penicillin over three weeks). By contrast, secondary disease 
requires only a single dose of benzathine penicillin (104). It could be argued, therefore, that 
asymptomatic, yet bacteraemic, disease is a different disease entity, with greater similarity to 
the secondary than the latent stage. It remains to be proven, however, that this new stage 
would respond adequately to a single dose of penicillin. It is also important to note that 25% 
of patients with early disease in the Oslo study were noted to develop relapses of secondary 
disease and that a further quarter of relapsers experienced more than one relapse (103). An 
alternative hypothesis, therefore, is that those patients with latent disease and detectable 
bacteraemia would, if left untreated, relapse. In these cross-sectional studies, patients with 
latent disease were, by definition, asymptomatic and all were treated on or around the time of 
sample collection.  
 
It was also demonstrated that levels in primary ulcers were much higher than those in 
secondary lesions reflecting a smaller number of bacteria, diminished metabolic activity, or, 
in the latter, both. It must be noted, however, that ulcer sampling with the SnoStrip technique 
is somewhat operator dependent, despite attempts to standardise collection. Overall, it seems 
that the qualitative detection of T. pallidum is improved using the 16S rRNA target. 
Moreover, the Tempus™ system makes sample collection and RNA extraction quick and 
simple. For quantification, however, the greater variability of RNA levels must be weighed 
against improved sensitivity of detection.  
 
Following validation of T. pallidum quantification in blood and ulcer samples, the techniques 
were applied to a longitudinal study to assess the clearance of T. pallidum following 
treatment. Patients with symptomatic early disease were selected, and the rate of bacterial 
clearance from blood and ulcer samples monitored following the injection of benzathine 
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penicillin. After a mean of 35 hours, none of the four patients studied still had detectable T. 
pallidum bacteraemia, measured by either qPCR or RT-qPCR. The increased variability of 
RT-qPCR was reflected in a standard deviation of RNA levels twice that observed for DNA, 
however, by calculating the half-life of clearance RNA was shown to clear significantly more 
quickly. This confirmed the hypothesis that the instability of RNA would make it the more 
dynamic measure of clearance despite much larger starting quantities. Ulcer T. pallidum 
clearance occurred over a similar period although the difference between DNA and RNA-
measured clearance was not significant. Two other important observations were made. Firstly, 
all four patients had serological results consistent with cure, supporting the hypothesis that 
bacterial clearance can predict cure. Secondly, through longitudinal sampling of an additional 
four patients for up to 14 days it was evident that once cleared, there was no recrudescence in 
detectable bacteremia. Finally, the ability to observe patients during treatment also made 
observation on the JHR possible. Anecdotally, the patient with the lowest blood bacterial load 
was the only one not to experience a JHR and the strongest reaction was in a patient with a 
high blood bacterial load (and a very high ulcer load). This observation, correlating strength 
of JHR with bacterial load remains to be proven in a larger observational study of bacterial 
loads, although JHR is known to occur with greater frequency and severity in early disease 
compared with late (190).  
 
The identification of genetic differences between T. pallidum strains, including those that 
confer macrolide resistance allowed comparison of syphilis cases in London and Colombo 
with those described elsewhere in the world. It was of interest that the predominant strain 
types in London were identical to the predominant circulating strains in much of the 
developed world, whereas those in Sri Lanka were unique (83). This was thought to represent 
relative isolation of the Colombo population compared with the melting pot of London. It was 
also of interest that macrolide resistance is of an increasingly high level in London, similar to 
San Francsico or Seattle, but that it was not detected in Sri Lanka, much as has been described 
in two other small island populations: Taiwan and Madagascar (84, 91, 175). The absence of 
resistance in Tawian is of particular interest given its proximity to China where resistant 
strains represent over 90% of circulating strains (90). Strain-typing in London was enhanced 
by the addition of a third typing target, helping to discriminate the predominant 14d subtype 
in two separate types. Other T. pallidum genes (tpp0138, tpp0326, tpp0488) also have 
variability that may make them suitable for strain-typing targets (14). Moreover, given the 
recent association of strain-type 14d/f with neuro-invasion it will be of great interest to 
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identify additional typing targets, which may predict other clinical phenotypes (86). Finally, 
previous studies have stated that ulcer samples are superior to blood for strain type 
identification (83). In the current study, those samples with highest bacterial load were the 
most suitable and were predominantly ulcer samples, thus it appears that DNA quantity is 
key, not necessarily the sample type.  
 
Syphilis is a complex disease caused by an organism that does not yield its secrets easily. 
While clinicians deliberate on how best to diagnose and treat patients at each stage of disease, 
scientists work to establish how such a genetically simple bacterium is so remarkably invasive 
and evasive. The lack of a system for continuous culture is undoubtedly one of the greatest 
impediments to T. pallidum research, but modern molecular microbiological techniques are 
now answering previously unanswerable questions and informing clinicians on appropriate 
management strategies. With time, it is hoped that the technique for monitoring treatment 
described in this thesis will be a useful tool to assess new treatment strategies for this ancient, 
resurgent and fascinating disease. 
 
Plan for future work 
 
This work has demonstrated that qPCR and RT-qPCR can be used to monitor the treatment 
response of patients with early syphilis to treatment with benzathine penicillin injection. 
However, prior to concluding that qPCR is a suitable tool to monitor treatment efficacy in 
new clinical trials the following questions must be answered: 
 
1. Are the results presented here for four patients reproducible in a larger study? 
2. Do patients who are subsequently identified as treatment failures, either serological or 
clinical, exhibit the same qPCR treatment response as treatment successes? 
3. Is there a difference in the rate of clearance according to the antibiotic used. For example, 
does clearance following orally administered doxycycline follow the pattern seen for 
injected penicillin? 
4. Can treatment monitoring by qPCR be applied to the rabbit model of syphilis such that 
candidate antibiotics can be assessed using the tool in animals before human clinical 
trials? 
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5. Can ear lobe samping be used as a quick and easy method for sample collection and does 
capiliary blood contain enough T. pallidum DNA to be detected reliably? 
 
In addition to developing the qPCR method for measuring treatment efficacy, two parallel 
avenues of research also warrant exploration. The first is to better characterise the JHR both 
by correlating propensity to develop the reaction with bacterial load and by characterising the 
inflammatory response in patients who experience it. To date, no studies have associated T. 
pallidum bacterial load with risk of developing a JHR nor shown whether the JHR accelerates 
bacterial clearance despite an association between serological syphilis cure at 6 months and 
developing a JHR (218). Secondly, the ability to discriminate untreated latent and treated 
syphilis, which often have identical serological findings, would significantly improve disease 
management. Acquired immunity to T. pallidum appears to increase as disease progresses 
towards latency, despite the resolution of clinical signs. Whilst the partial immunity to re-
infection induced during early disease wanes after treatment. (100) T-cells derived from 
experimental models of syphilis react strongly to several T. pallidum lipoproteins in the outer 
cytoplasmic membrane leaflet (TpN47, TpN17, TpN15) and the flagellar sheath (TpN37, 
TpN35, TpN33, TpN30) (274). There is also evidence from both humans and rabbits that 
IFN-gamma produced by both CD4
+
 and CD8
+
 T-cells may be integral to bacterial clearance 
from primary ulcers, despite T. pallidum being an extra-cellular pathogen (187). An ELISpot 
assay is one means of quantifying the ex vivo response by enumerating T-cells or B-cells in 
peripheral blood from patients which recognise and respond to specific pathogen antigens by 
secreting antibody or, for example, IFN-gamma (124, 275). It is envisaged, therefore, to 
stimulate either B-cells or T-cells taken from patients with both treated and latent syphilis 
with T. pallidum peptides in order to measure a clinically relevant difference in cytokine or 
antibody secretion. Prior to ELISpot assay development it is also envisaged that the most 
appropriate effector cytokine will be determined in a series of flow cytometry experiments 
measuring the acitivity of cells seperated from the blood of patients with both early and latent 
disease. 
 
Experimental Design and Methods 
 
Animal study experimental plan 
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It is impossible to control the moment of infection in humans, moreover to assess differences 
in bacterial load and immune response between subjects and untreated controls is unethical. 
Rabbits will be used, therefore, to map both bacterial load and immunological response 
during infection and treatment. These results will establish an alternative animal model for the 
assessment of future candidate antibiotics using qPCR at the same time as characterizing the 
inflammatory response to T. pallidum infection and treatment, and correlating this with 
bacterial load. Taken together, these findings will inform further the choice of immune 
markers to be measured in the proposed human study.  
 
It is envisaged that T. pallidum clearance and cytokine response will be measured in three 
groups of animals, which have been infected with T. pallidum by intradermal injection. One 
receiving single-dose benzathine penicillin, a second being given multi-dose oral doxycycline 
and a third group of both uninfected and infected but untreated controls. Blood and ulcer 
biopsy samples will be taken for measurement of IFN-gamma, IL-2, IL-4, IL-10, IL1-beta, 
IL-22, IL-6 and TNF-alpha and both 16S rRNA and tpp047 DNA quantification. 
 
Human pilot study  
 
A three-site clinical study will recruit 100 patients from sexual health clinics in Colombo (Sri 
Lanka), Kampala (Uganda) and London (UK). Participants will be given standard syphilis 
treatment, as selected by their doctor, and their blood monitored with both the novel RT-
qPCR and standard serology. Time points at 0 (pre-treatment), 2 (peak bacteraemia), 24 
(approaching clearance) and 38-48 hours (cleared) have been selected based on previous pilot 
data. A further sample will be taken at 72 hours to cover adequately the 33-hour generation 
time of T. pallidum and potential for a late recrudescence in DNA. Initial sample processing 
will be performed locally prior to shipping samples to the Jefferiss Trust Laboratories, 
Imperial College London for cytokine and T. pallidum nucleic acid quantification. The long-
term goal is to use these data to inform the design of clinical trials comparing syphilis 
treatment efficacy with current and novel antibiotics in patients both with and without HIV-1 
infection.Development of an ELISpot assay 
 
Samples 
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Samples will be needed for the initial development of an ELISpot assay to differentiate 
patients with latent infection (requiring treatment) and those with previously treated disease. 
The following patients will be approached and asked to donate 30ml EDTA blood (We aim to 
recruit 25 patients per group): Those with latent disease (no symptoms or signs and a positive 
T. pallidum EIA); previously treated patient with no symptoms or signs (positive T. pallidum 
EIA, negative or low and stable anti-cardiolipin antibody titre) and finally syphilis negative 
controls (asymptomatic; negative T. pallidum EIA; no sexual contact within the last 3 month). 
At each time point, patients will also have a capillary blood sample collected from their ear 
lobe for the assessment of T. pallidum quantification in capillary blood. This sample type has 
been shown previously to be rich in T. pallidum DNA and may be a quick and easy method 
for serial blood sampling (133). 
 
Assay development 
 
Over-lapping peptides spanning the length of the TpN47 protein will be purchased (to ensure 
that T-cell responses are not restricted to or biased by patient HLA haplotypes). The best 
peptides will be selected for future use. ELISpot plates pre-coated with monoclonal antibodies 
will be purchased from Mabtech and standard ELISpot assay conditions will be employed. 
The following will be determined: 
 
Background number of spot-forming cells (SFC) per million PBMC for buffer-only negative 
controls (if any). 
Background SFC/million PBMC for syphilis negative controls.  
SFC/million PBMC for latently infected patients (clinically asymptomatic) 
SFC/million PBMC for previously treated patients. 
 
Once the working parameters of the assay have been established, a larger clinical validation 
study will be designed.  
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Appendix 1: List of Organisms used to assess species specificity of assay 
 
Gram 
Characteristics 
Organisms 
 
Gram positive 
bacteria 
 
-haemolytic streptococci, Streptococcus milleri, Streptococcus 
pneumoniae, Streptococcus pyogenes, Streptococcus mitis, Streptococcus 
agalacticae, Streptococcus faecalis, Micrococcus luteus, Diptheroids, 
Coagulase-negative Staphylococci, Staphylococcus aureus, Methicillin-
resistant Staphylococcus aureus, lactobacilli 
 
Gram negative 
bacteria 
Neisseria gonorrhoeae, Neisseria meningitidis, Campylobacter jejuni, 
Coliforms, Proteus sp, Escherichia coli, Klebsiella sp, Haemophilus sp, 
Enterobacter, enterobacteracae, Chlamydia trachomatis, Treponema 
denticola, Treponema pallidum subspecies pertenue (Gauthier strain) 
 
Viruses Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus, HIV-1, HTLV-
1 
 
Yeast Candida albicans 
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Appendix 2: Primers and Probes 
 
Primer  Target 
gene 
Sequence (5’-3’) Method Product 
Size (bp) 
TP1 and TP 2 tpp047 TP1 (sense)  CGAGGAATACAAGATTACGAACG 
TP2 (anti-sense) 
ACGTGCAGAAAAACTATCCTCAG 
qPCR 178 
TP3 and TP4 tpp047 TP3 (sense) CCCTCTATACGGAGGTGTAAT 
TP4 (anti-sense)  
TTAAGACACACGGGATAGGAC 
Splice-overlap 
PCR 
 
1357 
TP5 tpp047 CGCATTCTGTGACTACTCTACCCAGACAAAC
TTCATACCGTGAA 
Splice-overlap 
PCR 
577 
TP6 tpp047 CTGGGTAGAGTAGTCACAGAATGCGAAAGG
GATTGCAAAGGAGA 
Splice-overlap 
PCR 
805 
Tpnest4F and 
Tpnest4R 
tpp047 Tpnest4F (sense)  ATGGTGCGTGCCTCTGCGTC 
Tpnest4R (anti-sense) 
AGGTCGTGCGGGCTCTCCAT 
pTp47 
construction 
326 
A2058G_F and 
A2058G_R  
(169) 
23S 
rRNA  
A2058G_F  (sense) GTACCGCAAACCGACACAG 
A2058G_R (anti-sense) 
AGTCAAACCGCCCACCTA 
pTp2058 and 
pTp2059 
construction  
2
nd
 round 
amplification in 
23S rRNA 
mutation analysis 
629 
TP0226_F and 
TP0226_R 
(169) 
23S 
rRNA 
(copy 1) 
TP0226_F  GTACCGCAAACCGACACAG 
TP0226_R  GCGCGAACACCTCTTTTTAC 
 
1
st
 round 
amplification of 
23SrRNA copy 1 
1593 
TP0267_F and 
TP0267_R 
(169) 
23S 
rRNA 
(copy 2) 
TP0267_F  GTACCGCAAACCGACACAG 
TP0267_R GAACCGTCCCTGAAAACTCA 
1
st
 round 
amplification of 
23SrRNA copy 2 
1593 
ARP F and 
ARP R (82) 
arp ARP_F  CAAGTCAGGACGGACTGTCC 
ARP_R GGTATCACCTGGGGATGC 
arp amplification 
for strain-typing 
variable 
TP548 AS_3 
and TP548_S 
(86) 
tpp0548 TP548AS_3  CGTTTCGGTGTGTGAGTCAT 
TP548_S       GGTCCCTATGATATCGTGTTCG 
tpp0548 
amplification for 
strain-typing 
300 
TP548_AS 
(274) 
tpp0548 TP548_AS GTCATGGATCTGCGAGTGG tpp0548 gene 
sequence analysis 
300 
EGJ_F and 
EGJ_R (82) 
tpr EGJ_F  CAGGTTTTGCCGTTAAGC 
EGJ_R  AATCAAGGGAGAATACCGTC 
tpr amplification  
for strain typing 
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16s_F(seattle) 
(153) 
16s_R7 
16S 
rRNA  
16s_F(seattle)   
CTCTTTTGGACGTAGGTCTTTGAG 
16s_R7 TCACCCTCTCAGGTCGGATA  
16S rRNA 
amplification and 
quantification 
131 
16S_P3  
Probe  
16S 
rRNA 
FAM -CGGCCTCGCTCAGAGATGAGC -TAMRA 16S rRNA qPCR  - 
16srRNA_F2 
16srRNA_R2   
16S 
rRNA 
AAGCGAATTTTCGTTTCT 
GTCGGATACCCATCGA 
16S rRNA qPCR 225 
16S_P2  TCTTTTGGACGTAGGTCTTTGA   
FLAB2_F 
FLAB2_R 
flaB2 FLAB2_F  GCGCTATGTTCTCTCAAA 
FLAB2_R  TTCAGAAACTGCAAGACC 
flaB2 qPCR 128 
FlaB2 _P Probe flaB2 FAM-ACATTGAGAAGTTGTCTTCAGG-TAMRA flaB2  qPCR - 
TP_P  
Probe 
tpp047 FAM-CCCAGTTGCGGTTCCTCATGAATTA-
TAMRA 
tpp047 qPCR  
TPP-QC probe 
(228) 
modified 
tpp047 
Yakima Yellow-
CTGGGTAGAGTAGTCACAGAATGCG-BHQ-1 
pTpQC detection 
and quantification 
 
TPP-QCR 
probe 
modified 
tpp047 
ROX-CTGGGTAGAGTCGTCACAGAATGCG-
BHQ1 
pTpQC detection 
and quantification 
 
TYLCV_F3 
and 
TYLCV_R3 
TYLCV TYLCV_F3 
CGTCCGTCGATCTGGAAAGT 
TYLCV_R3  
 TAGCTCCCTGAATGTTCGGAT 
Internal control of 
T. pallidum DNA 
extraction and 
quantification 
100bp 
P_TYLCV TYLCV Yakima Yellow-
TTGTCGATATAGGACTTGACGTCGGAGC-
BHQ1 
TYLCV detection 
and quantification 
 
 
Primers and probes were synthesised either by Eurogentec, Seraing, Belgium; Invitrogen, 
Paisley, UK or Sigma, Gillingham, UK.  
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Appendix 3: Restriction endonucleases used in the project 
 
Enzyme Used for Recognition Sequence Conditions 
Nco-I 
(New England 
Biolabs, Ipswich, 
MA) 
Linearisation of 
plasmids pTpQC, 
pTp47, p16SRNA, 
pTYLCV  
 
5’…C∨CATGG…3’ 
3’…GGTAC∧C…5’ 
 
1 hour at 37C 
NEB Buffer 3   
Eco-RI 
(New England 
Biolabs, Ipswich, 
MA) 
Excision of T. 
pallidum sequence 
from pTp2058, 
pTp2059 and pTp47 
5’…G∨AATTC…3’ 
3’…CTTAA∧G…5’ 
 
 
1 hour at 37C 
NEB Buffer 1 
Mbo-II 
(New England 
Biolabs, Ipswich, 
MA) 
A2058G mutation 
analysis 
5’…GAAGA(N)8 
∨…3’ 
3’…CTTCT (N)7 ∧…5’ 
 
1 hour at 37C 
NEB Buffer 4 
Bsa-I 
(New England 
Biolabs, Ipswich, 
MA) 
 
 
A2059G mutation 
analysis 
5’…GGTCTC(N)1 
∨…3’ 
3’…CCAGAG (N)5 ∧…5’ 
 
1 hour at 50C 
NEB Buffer 4 
1x BSA 
Mse-I  
(New England 
Biolabs, Ipswich, 
MA) 
  
Strain-typing. tpr 
sub-family 2 gene 
analysis. 
 
5’…T∨TAA…3’ 
3’…AAT∧T…5’ 
 
1 hour at 37C 
NEB Buffer 4 
1x BSA 
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Appendix 4: Map of pCR4-TOPO cloning vector 
 
 
 
Structure map of the 3956 bp cloning vector used for the construction of the quantification 
standards for 16SrRNA; tpp047 (wild-type and mutated) and TYLCV in addition to plasmids 
containing the mutated T. pallidum 23S rRNA sequences A2058G and A2059G. The cloning 
site (bases 294-295) is marked as ‘PCR product’ and is flanked by EcoRI restriction sites. The 
T7 priming site is at bases 328-347 and the Ampicillin (bla) resistance gene and promoter are 
located at bases 2203-3160. 
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Appendix 5: Case definitions for cross-sectional studies of T. pallidum quantification 
 
Stage/Disease Definition 
 
HSV 
 
Typical single or multiple genital ulcers from which HSV-1 or HSV-2 
DNA is isolated using an in house PCR. 
 
Primary 
syphilis 
Diagnosis requires the presence of a chancre on examination and 
microbiological confirmation of T. pallidum with any of the following: 
dark ground microscopy; polymerase chain reaction provided by the 
sexually transmitted bacteria reference laboratory, Health Protection 
Agency, London or positive treponemal serology (as per national 
guideline) (104). Primary diagnoses to include dark ground negative 
ulcers and initially negative serology, which becomes positive up to 3 
months later with no sign of secondary disease. 
 
Secondary 
syphilis 
Defined as syphilis within the first two years of infection and 
characterised by both clinical and microbiological findings. Clinical 
findings include: typical rash; condylomata lata; muco-cutaneous 
lesions; generalised lymphadenopathy; anterior uveitis; hepatitis and 
splenomegaly. Microbiological findings must include serological tests 
consistent with secondary disease and may, if available, include PCR of 
secondary lesions (104). If ano-genital examination reveals persisting 
chancres, the case is still counted as secondary.  
 
Other syphilis Latent syphilis 
Positive serological tests in the absence of any symptom or sign. 
Classified as early within the first 2 years of infection and late 
thereafter.  
  
Symptomatic late syphilis 
Positive serology including a negative or low and unchanging RPR titre 
together with symptoms and clinical signs of cardiovascular or 
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gummatous disease. Late disease with neurological involvement is 
classed as neurosyphilis. 
 
Neurosyphilis 
 
Any stage of disease with: clinical neurological involvement
†
 (including 
meningitis, cranial nerve palsies, parenchymatous general paresis, tabes 
dorsalis); serological findings consistent with the stage of disease and a 
relevant CSF abnormality (as per national guidelines) (104).
 
NB. For analysis, cases with neurological involvement were counted as 
neurosyphilis not by stage. 
 
†
Patients without neurological symptoms do not routinely undergo CSF 
examination at our centre. 
Asymptomatic 
contact of 
syphilis 
 
Patient reports sexual contact with a suspected or confirmed case of 
syphilis. Examination reveals no sign of disease and serological results 
(baseline, 6 weeks and 3 months after exposure) are not consistent with 
current infection. 
Non-specific 
genital 
ulceration 
 
Genital ulceration is present on examination, but no microbiological 
diagnosis is made. PCR for HSV is negative; DGM is negative; syphilis 
serology is not consistent with current infection and diagnostic T. 
pallidum PCR (if performed) is negative. 
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Appendix 6: Standard clinical investigation and study results for all participants  
Final Diagnosis Patient 
HIV-1 
Status 
CD4 
count 
DGM 
result
§
 
HSV PCR 
Result
§
 
Syphilis EIA result 
at enrolment 
RPR result at 
enrolment 
Timing of DNA 
extraction 
WB tpp047 
(copies/ml whole 
blood) 
Ulcer tpp047 Copy 
Number (copies/strip) 
Primary Syphilis (n=14) 6 - - + - + 8 immediate 0 620 
9 + 390 +   + 16 immediate 127 2108 
11 + 480 +   + 16 immediate 0 12440 
18 + 270 - - + 0 immediate 0 757 
23 - - +   + 4 immediate 0 2742 
24 - - +   - 16 immediate 0 2577 
26 + 920 +   -   immediate 0 7426 
32 + 720 -   + 4 immediate 168 14244 
33 - - - - + 64 immediate 0 427 
52 + 320 +   + 2 later 0 2115 
69 - - + - + 32 later 0 251 
89 + 420 +   -   later 0 1555 
90 - - -   + 4 later 127 1064 
93 - - + - + 4 later 0 648 
                     
Secondary Syphilis (n=19) 3 + 660 unavailable   + 64 immediate 0 2 
16 + 240 - - + 128 immediate 886 630 
17 - - + - + 128 immediate 1026 422 
22 - - +   + 64 immediate 518 211* 
27 + 680     + 8 immediate 632   
29 - -     + 16 immediate 58   
34 + 390 unavailable - + 128 immediate 495 251* 
45 + 350     + 64 later 6   
46 + 330     + 16 later 0   
47 - -     + 256 later 0   
49 + 630     + 128 later 10   
53 + 400     + 64 later 28   
61 + 470     + 512 later 91   
63 + 790     + 32 later 0   
74 + 410     + 128 later 0   
75 + 470     + 256 later 0   
77 + 370     + 32 later 0   
81 + 430     + 128 later 65   
83 + 420     + 128 later 0 unavailable 
                     
Other Syphilis (latent or 
symptomatic late) (n=8) 
1 - -     + 0 immediate 0   
12 + 400     + 1 immediate 0   
28 + 220     + 256 immediate 70   
44 - -     + 16 later 0   
59 + 610     + 0 later 0   
67 - -     + 0 later 0   
84 + 570     + 0 later 0   
95 - -     + 1 later 0   
                     
Asymptomatic Contact of 
Syphilis (n=17) 
2 - -     + 1 immediate 0   
4 - -     -   immediate 0   
8 - -     -   immediate 0   
15 + 730     -   immediate 0   
25 - -     -   immediate 0   
30 + 320     -   immediate 0   
38 + 490     + 0 immediate 0   
51 - -     -   later 0   
57 - -     -   later 0   
58 + 470     + 0 later 0   
65 + 490     -   later 0   
73 - -     -   later 0   
76 + 670     + 0 later 0   
78 + 510     -   later 0   
88 + 320     + 0 later 0   
94 + 640     -   later 0   
99 - -     -   later 0   
                     
HSV Infection (n=19) 10 - - - + -   immediate 0 0 
19 - - - + -   immediate 0 0 
20 - - unavailable + -   immediate 0 0 
31 - - - + -   immediate 0 0 
37 - - - + -   immediate 0 0 
39 - - - + -   immediate 0 0 
40 - - - + + 0 later 0 0 
41 - - - + -   later 0 0 
42 + 780 - - -   later 0 0 
43 - - - + unavailable   later 0 0 
55 + 550 - - -   later 0 0 
70 - - - + -   later 0 0 
71 + 680 - + -   later 0 0 
72 - - - + -   later 0 0 
79 - - - + -   later 0 0 
86 - - - + -   later 0 0 
91 + 370 unavailable + -   later 0 unavailable 
92 - - + + -   later 0 0 
98 - - + + -   later 0 0 
                     
Non-specific genital 
ulceration (n=19) 
5 - - - - -   immediate 0 0 
7 + 540 +   + 0 immediate 0 0 
13 - - - - -   immediate 0 0 
14 - - - - -   immediate 0 0 
21 - - - - -   immediate 0 0 
35 - - - - -   immediate 0 0 
48 - - - - -   later 0 0 
50 - - + - + 0 later 0 0 
54 + 210     -   later 0   
60 + 750 - - -   later 0 0 
62 + 400 - - -   later 0 46Ψ 
64 + 130     + 0 later 0   
66 + 590 - - -   later 0 0 
68 + 580     -   later 0   
80 - - - - -   later 0 0 
82 + 340 - - -   later 0 0 
85 + 120 - - + 1 later 0 0 
87 + 610 - - -   later 0 0 
97 + 500     -   later 0   
                     
Neurosyphilis (n=3) 36 + 290     + 32 immediate 0   
56 - -     + 64 later 0   
96 + 660     + 8 later 0   
 * mucocutaneous oral lesion 
§ 
Test only performed when clinically indicated 
Ψ Patient with a one-week history of multiple non-tender genital ulcers thought to be atypical genital herpes and treated with acyclovir. Convalescent syphilis serology and PCR for herpes simplex virus types one and two were negative. 
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Appendix 7: Sample collection schedule for clinical study of treatment kinetics  
 
Day Time point Samples taken 
1 (in the GU 
medicine clinic) 
 
 
 
 
 
 
 
 
 
1a 
 
 
 
 
 
 
 
1b  
(pre-treatment) Ulcer snostrip (if primary disease) 
Blood: 1x 6ml rust/red top tube for syphilis 
serology (EIA, RPR, TPPA), 1x 4ml gold top 
tube LFTs, 1x 4ml EDTA (purple top), 1x3ml 
Tempus™ sample (blue tube) blood sample. 
Pregnancy testing for female patients of child-
bearing potential. 
 
Intravenous Cannula inserted. 
2 
 
Treatment 
 
 
Patient administered antibiotic selected by 
treating physician by nursing team at GU 
Medicine clinic. 
1 (inpatient) 
 
 
 
 
3   
 
2 hours post-treatment 2ml EDTA blood sample; 3ml Tempus™ 
sample +/- ulcer sample 
4-9    
 
4-hourly sampling 
(total 6 samples)   
i.e 00:00, 04:00 08:00, 
12:00, 16:00, 20:00  
2ml EDTA blood sample; 3ml Tempus™ 
sample +/- ulcer sample 
2 (inpatient) 10-14 
 
 
4-hourly sampling 
(total 5 samples) 
i.e. 00:00, 08:00, 
12:00, 16:00, 20:00 
2ml EDTA blood sample; 3ml Tempus™ 
sample +/- ulcer sample 
 
3 (inpatient) 
 
 
15-18 6-hourly sampling 
(total 4 samples) 
i.e. 00:00, 06:00, 
12:00, 18:00 
2ml EDTA blood sample; 3mL Tempus™ 
sample +/- ulcer sample 
 
4-7 (outpatient) 19-27 12 hourly sampling (8 
samples) 
i.e. 08:00 and 20:00 
2ml EDTA blood sample; 3mL Tempus™ 
sample +/- ulcer sample 
 
 
*The amount to blood taken for the study will not exceed 125ml. 
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Appendix 8: Publications relating to the thesis 
 
For copyright reasons, the publications relating to this thesis have been removed. They can be 
found at:  http://sti.bmj.com/ 
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